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 Much attention has been given to the molecular and cellular pathways linking 
inflammation with cancer and the local tumor environment to identify new target molecules 
that could lead to improved diagnosis and treatment. Among the many molecular players 
involved in the complex response, central to the induction of inflammation is intercellular 
adhesion molecule (ICAM)-1, which is of particular interest for its highly sensitive and localized 
expression in response to inflammatory signals. ICAM-1, which has been implicated to play a 
critical role in tumor progression in various types of cancer, has also been linked to cancer 
metastases, where ICAM-1 facilitates the spread of metastatic cancer cells to secondary sites. 
This unique expression profile of ICAM-1 throughout solid tumor microenvironment makes 
ICAM-1 an intriguing molecular target, which holds great potential as an important diagnostic 
and therapeutic tool. 
 Herein, we have engineered the ligand binding domain, or the inserted (I) domain of a 
leukocyte integrin, to exhibit a wide range of monovalent affinities to the natural ligand, ICAM-
1. Using the resulting I domain variants, we have created drug and gene delivery nanoparticles, 
as well as targeted immunotherapeutics that have the ability to bind and migrate to 
inflammatory sites prevalent in tumors and the associated microenvironment. Through the 
delivery of diagnostic agents, chemotherapeutics, and immunotherapeutics, the following 
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chapters demonstrate that the affinity enhancements achieved by directed evolution bring the 
affinity of I domains into the range optimal for numerous applications. 
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CHAPTER 1 
 
INTRODUCTION 
 
Inflammation 
 
Inflammation is the body’s necessary response to harmful insult, in which a careful 
interplay between the immune system and damaged tissues mediate the healing process. The 
restoration is characterized by heat, pain, redness, and swelling, instigated by increased blood 
flow, accumulation of fluid, and release of chemicals such as histamine and bradykinin[1, 2]. 
This intricate process requires tight control over the various components of the immune system 
for achieving desired immune responses to eliminate the stimulus and heal in a timely 
manner[3]. Acute inflammation is a self-limiting transient response that usually results in 
controlled wound healing. Chronic inflammation, on the other hand, is a prolonged  response 
prompted by dysregulated immunomodulation[4]. Such persistent homeostatic imbalance is 
often associated with many chronic human conditions and diseases, including allergy, 
atherosclerosis, and neoplastic progression[5-9]. 
In response to tissue damage, a complex network of biochemical and molecular cues 
initiate a cellular response designed to heal the afflicted tissue, where activated leukocytes are 
directed from the venous system to sites of damage. Monocytes and neutrophils, in addition to 
tissue-resident macrophages, are the first recruited effectors to the site of tissue injury, guided 
by chemotactic factors[10]. Once activated, macrophages become the main providers of growth 
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factors and cytokines, which activate endothelial, epithelial and mesenchymal cells in the 
inflamed milieu[10-12]. 
Activated vascular endothelium neighboring the site of tissue injury upregulate their 
expression of adhesion molecules in order to further orchestrate recognition by the circulating 
inflammatory cells[3, 10]. Simultaneously, leukocyte integrins, serving as binding partners for 
various adhesion molecules, are also induced and activated on the surface of approaching 
immune cells to allow tight adhesion to target sites (Fig. 1.1). Coupled with integrin clustering 
on the plasma membrane of leukocytes for increased valency, integrin affinity modulation has 
been shown to play a critical role in chemokine-induced arrest under flow[13, 14]. Finally, 
leukocytes transmigrate through the endothelium, either through the paracellular or 
transcellular route, facilitated by various extracellular proteases, such as matrix 
metalloproteinases[15, 16].  
 
 
Inflammation and cancer 
 
The link between inflammation and cancer was first postulated by Virchow in the 19th 
century, when he discovered the presence of leukocytes in tumors. Since then, many studies 
have strengthened this hypothesis and recently, clear evidence showing the roles that 
inflammation plays in tumor progression has been demonstrated[17, 18]. Now it is generally 
accepted that an inflamed milieu is a critical component of tumor initiation and 
progression[18], dubbing cancer as “wounds that do not heal”. 
- 3 - 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: The inflammatory response of vascularized tissue.  
Irritated inflammatory tissue recruits leukocytes, such as neutrophils and 
monocyte/macrophages through activated endothelial cells, involving the steps of rolling, 
strengthening of adhesion, crawling, and paracellular/transcellular migration (diapedesis). 
Subsequently, migrated leukocytes secrete pro-inflammatory cytokines and chemokines that 
further activates the surrounding tissue to recruit more immune cells. (Illustration designed and 
rendered by Spencer Park) 
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In many cases, some form of chronic inflammation precedes tumor development. 
Initially, the inflammatory responses as these are a part of normal host defense. However, 
tumorigenic pathogens can sabotage host’s immune response and establish chronic 
inflammation, facilitating cancer development. Persistent Helicobacter pylori infection is 
associated with gastric cancer and mucosa-associated lymphoid tissue lymphoma[19], while 
infections with hepatitis B or C viruses increase the risk of hepatocellular carcinoma[17, 20].  
Conversely, by mirroring wounds, tumors can initiate inflammation. Once established, 
solid malignancies trigger an intrinsic inflammatory response that launches a pro-tumor 
microenvironment[21]. Tumors begin remodeling the neighboring stroma through secretion of 
chemokines/cytokines, recruitment of leukocytes, and initiation of angiogenesis[22, 23]. As a 
result of the transformation, tumor microenvironment is composed of innate and adaptive 
immune cells co-existing with tumor cells as well as stromal cells, including mesenchymal cells, 
endothelial cells, and fibroblasts[24]. During this development, malignancies demand 
increasingly higher blood supply. When the tumor’s metabolic needs are no longer met, the 
cells receiving insufficient levels of nutrients die, forming a necrotic core and releasing 
proinflammatory cytokines, such as IL-1[25]. The augmented inflammation promotes further 
angiogenesis and the resultant wave of immune cells provide the tumor with necessary 
cytokines and growth factors[17]. 
 
Intercellular adhesion molecule-1 in inflammation and cancer 
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Much attention has been given to the molecular and cellular pathways linking 
inflammation with cancer and the local tumor environment to identify new target molecules 
that could lead to improved diagnosis and treatment[9, 21]. Among the many molecular players 
involved in the complex response, central to the induction of inflammation is the transcription 
factor known as, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-B). 
Malignant epithelial cells manipulate NF-B, which controls various genes involved in 
inflammation, to be constitutively active. For example, in tumor-associated macrophages, 
activated NF-B causes polarization of the cells into a phenotype that suppresses cytotoxic T 
lymphocyte response, increases angiogenesis, and promotes tumor development (Fig. 1.2)[26].  
One of the genes induced by the activation of NF-B is intercellular adhesion molecule 
(ICAM)-1, which is of particular interest for its highly sensitive and localized expression in 
response to inflammatory signals. Intercellular adhesion molecule (ICAM)-1 is a transmembrane 
glycoprotein belonging to the immunoglobulin superfamily of adhesion molecules and is 
composed of five extracellular Immunoglobulin G-like domains. ICAM-1 is continuously 
expressed at low levels on various cell types including fibroblasts, endothelial cells, and some 
leukocytes but is profoundly inducible in inflammation[27, 28]. More specifically, inflammatory 
mediators, including lipopolysaccharide, IFN-, IL-1 and TNF have been shown to cause strong 
induction of ICAM-1 in a wide variety of tissues and greatly increase binding of leukocytes, 
facilitating the infiltration of damaged tissues[29]. 
In line with the increasing reports on the importance of inflammation in tumor 
progression, ICAM-1 has also been implicated to play a critical role in tumor progression in 
various types of cancer[30-36], where its over-expression has been correlated to poor 
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prognosis [35, 37-39]. In addition, the expression level of ICAM-1 has also been linked to cancer 
metastases, where ICAM-1 facilitates the spread of metastatic cancer cells to secondary sites 
[40-43]. Not only is ICAM-1 over-expressed on many carcinomas, it is also induced in the 
inflamed milieu in the vicinity of tumors[9, 44, 45]. This unique expression profile of ICAM-1 
throughout solid tumor microenvironment makes ICAM-1 an intriguing molecular target, which 
holds great potential as an important diagnostic tool for assessing the progression and 
prognosis of tumors. In therapy, using drug-delivery or immunotherapy methods targeted 
against ICAM-1 would bypass the efforts often required in identifying proper tumor antigens for 
each type of cancer.  
 
Lymphocyte function-associated antigen-1 
 
Integrins are members of a versatile family of noncovalently associated α/β heterodimeric 
cell surface receptors that stabilize cell-cell and cell-extracellular matrix adhesion during immune 
responses[46]. A type of leukocyte Integrin, αLβ2 or lymphocyte function associated antigen 
(LFA)-1, is constitutively expressed on all leukocytes and is the natural ligand for ICAM-1. 
Although originally identified using antibodies that inhibit T cell-mediated killing, LFA-1 is also 
critically important for other leukocyte functions, including adherence to endothelial cells, 
fibroblasts, and epithelial cells[47, 48]. In resting lymphocytes, the integrin remains in a low 
affinity state but it is rapidly synchronized to undergo dynamic conformational changes during 
lymphocyte activation, which greatly increases its binding affinity to ICAM-1 (Fig. 1.3). In addition 
to the affinity modification, avidity alteration through clustering in the membrane plays an  
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Figure 1.2: Pathways that connect inflammation and cancer. 
Various types of oncogene by mutation or infectious conditions augment the risk of developing 
cancer. Activation of transcription factors, mainly nuclear factor-B (NF-B), in tumor cells 
coordinate the production of inflammatory cytokines and chemokines, as well as certain 
adhesion molecules like ICAM-1. These factors recruit and activate various leukocytes leading to 
accumulation of inflammatory mediators and ultimately an inflammatory microenvironment. 
(Illustration designed and rendered by Spencer Park) 
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Figure 1.3:  LFA-1 and the physiological ligand, ICAM-1. 
Activated LFA-1 binds its physiological ligand, ICAM-1, through the top of the extended form. 
ICAM-1 is upregulated on inflamed endothelial cells. (Illustration designed and rendered by 
Spencer Park) 
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important role in regulating adhesiveness of LFA-1 to ICAM-1[49]. Regulation of LFA-1 activation 
is, therefore, pivotal for controlling leukocyte trafficking and immune responses in health and 
diseases. 
 
LFA-1 structure and affinity-tuning 
 
LFA-1 contains a von Willebrand factor-type A domain, the inserted (I) domain in the 
αL subunit[50], which is responsible in mediating the interaction between LFA-1 integrin and 
ICAM-1. The I domain has a Mg2+ ion coordinated at the metal ion-dependent adhesion site 
(MIDAS) located within the ligand-binding face[50, 51], explaining the Mg2+ requirement in 
lymphocyte adhesion. The affinity of the αL I domain for ICAM-1, during LFA-1 activation, is 
controlled by downward dislodgment of its C-terminal α7 helix by 10 Å, which causes allosteric 
restructuring of MIDAS into the ‘open’ conformation and increases the affinity for ICAM-1 by 
10,000-fold (Fig. 1.4)[52, 53]. As part of an integrin molecule, the ‘open’ conformation of MIDAS 
is stabilized when the linker region after the α7-helix interacts with the adjacent I-like domain of 
the β subunit to retain the α7-helix in the downward position. 
To stabilize the ‘open’ conformation in an isolated, standalone I domain unit, however, 
previous studies have introduced a pair of cysteines within αL I domain, essentially anchoring the 
α7 helix[50, 52]. Some other studies demonstrated that single point mutations, can lead to higher 
affinity of the I domains. When directed evolution, a method where random mutagenesis in 
protein of interest is coupled with functional screening, was first applied to αL I domain, hot spots 
for activation were identified. In this study, yeast surface display system was used to screen for  
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Figure 1.4: Global conformational rearrangements of integrin. 
Inactive integrin exists in a bent conformation with the headpiece folded over the tailpiece. 
Active integrin exhibits the switchblade-like extension and the separation of the two subunits ( 
and ) at the cytoplasmic and transmembrane domains. Ribbon diagrams were made using 
PyMOL (DeLano, W.L.). 
 
 
 
 
 
 
- 11 - 
 
high affinity I domains using conformation specific antibodies and ICAM-1 for both structural and 
functional analysis. From a yeast library of I domains containing random mutations, select 
mutations exhibited affinities to ICAM-1 that was up to 200,000-fold higher than the wild-
type[54]. Without a priori structural knowledge of I domain, which undergoes complex allosteric 
changes, this study isolated I domain mutants with varying affinities to ICAM-1. The discovered 
affinities ranged from 1500 M to 6 nM, a wide range that allows screening of the mutants in 
different therapeutic methods of different disease settings to allow for optimal therapeutic index. 
 
 
Inflammation-targeted chemotherapeutic delivery 
 
The utmost ambition in chemotherapeutic delivery is to differentially deliver the drug to 
the site of tumor growth and achieve necessary local concentrations for effective therapeutic 
index. In this endeavor, utilizing nanoparticles is advantageous over the conventional methods 
of either delivering drugs directly or as molecular conjugates. Nanoparticles can protect the 
therapeutics in their active form from chemical and enzymatic degradation, enhance the 
pharmacokinetics, bioavailability, and biodistribution, and circumventing the need for chemical 
modification of therapeutic agents, which often leads to reduced potency and stability [55, 56].  
Most of these delivery vehicles are composed of lipids, polymers, or proteins that have 
the ability to encapsulate or associate with various therapeutics, including small molecule 
drugs, siRNAs, and DNA. One of the first drug-carrier-based therapeutics to be approved by the 
Food and Drug Administration for clinical use was Doxil in treating ovarian cancer and multiple 
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myeloma[57]. However, traditional passive distribution methods that are utilized by Doxil face 
difficulties in achieving high local concentration in tumors [58]. Though initially they are able to 
accumulate in tumor vicinity due to the leaky vasculature that surrounds tumors through a 
mechanism called enhanced permeation and retention (EPR) effect, they are quickly forced 
back into circulation by the high interstitial fluid pressure and dysfunctional lymphatic vessels 
present in tumor microenvironment [59-63]. Since drug carriers are designed for slow release 
of payloads, they often are not able to release sufficient amount of drugs during the short span 
of time in tumor vicinity before they are forced back into circulation.  
To overcome such physiological barriers, local applications of hyperthermia [64], 
photosensitization [65], and ultrasound [66] have been used to increase the permeability of 
tumor vessels. Alternatively, new types of nanoparticles to address such problems have also 
been engineered, including immunotargeting or site-directed carriers, many of which are 
specific to ligand/receptor interactions[56]. Active targeting methods, as such, allow the 
particles to be taken up by target cells after escaping circulation. This allows the accumulation 
of therapeutics at the site of disease to correlate with the presence of target antigens, thereby 
significantly minimizing the required effective dosage, and the associated cytotoxicity and 
unwanted side effects.  
Active targeting requires identification and targeting of tumor antigens, however, which 
is difficult to achieve. Not only is there a limited number of known tumor antigens, tumors are 
genetically unstable, causing them to be heterogeneous in their antigen expression. Due to the 
highly inconsistent nature of these antigens, specific delivery to tumors via active targeting has 
proven to be limited in efficacy. We believe that by shifting from this mainstream practice and  
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Figure 1.5: Targeted payload delivery to inflamed tumor microenvironment.  
The primary tumor microenvironment consists of tumor cells surrounded by normal epithelial 
cells, endothelial cells, and various immune cells. Despite the presence of heterogeneous cells, 
the common expression of inflammation markers, such as ICAM-1, makes targeting 
inflammation for payload delivery efficient. 
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relying more on other features of tumor microenvironment, such as the presence of 
inflammation, will help to circumvent such hurdles (Fig. 1.5).  
Drug carriers possessing the ability to target inflammation markers can be directed to 
the tumor stromal constituents, including the vasculature [67, 68] and/or tumor-associated 
macrophages[69]. Because the expression levels of cell adhesion molecules such as ICAM-1 and 
VCAM1 are highly upregulated at the sites of inflammation, they have been extensively  
targeted for payload delivery[70-72]. Moreover, multimeric clustering of these molecules 
promotes rapid endocytosis, allowing delivery systems to reach into the cytosol of target cells 
quickly, an important trait for delivery systems[73]. Therefore, it can be speculated that drug 
carriers designed to target the pivotal inflammatory signaling would be broadly effective in 
eradicating not only carcinoma cells expressing inflammatory markers but also those lacking by 
subverting the tumor stromal cells. 
 
Development of safe immunotherapy against solid tumors 
 
 In the recent years, the use of engineered T cells directed against specific antigens has 
demonstrated great potential in HIV and cancer therapy. Along with immune checkpoint 
blockade[74], this approach has triggered a paradigm shift in cancer immunotherapy. The first 
reported use of adoptive cellular therapy for tumor allografts was more than 60 years ago[75] 
but the results of the early trials using allogeneic or autologous lymphocytes were not 
promising. In 1989 and 1990, the concept of introducing genetic materials encoding for an 
antibody into a T cell hybridoma was first described[76, 77]. This was quickly followed by 
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studies demonstrating that a single polypeptide chain is sufficient to mimic the signaling 
capacity of the T cell receptor (TCR)[78-80]. Together, above studies verified the possibility of 
redirecting T cells to an antigen of choice independent of MHC restrictions and gave birth to the 
concept of chimeric antigen receptors (CARs). 
A chimeric antigen receptor is made up of an antigen recognition domain and the TCR 
signaling domain. The antigen recognition domain is usually a single chain variable fragment 
(scFv) adopted from an antibody against the antigen of interest. Most of the currently identified 
and targeted tumor antigens are self-antigens that are aberrantly expressed during malignancy. 
The affinity of TCRs for these antigens is considerably lower than affinity for viral antigens, 
revealing the weight of central tolerance on T cell repertoire to self-antigens[81]. In contrast, 
scFvs obtained through powerful screening methods, such as phage display, exhibit much 
higher affinities[82].  
The signaling machinery of CARs has evolved significantly from the first generation 
configuration of having only the CD3ζ signaling domain[83]. The first-generation CAR trials in 
cancer patients proved disappointing. It is predicted that the first-generation CARs became 
anergic without the costimulation input[84, 85]. Since then, in an effort to boost T cell 
persistence/proliferation, several costimulatory endodomains were tested. Second-generation 
CARs included a costimulatory signaling domain such as CD28 or 4-1BB [86, 87], and third-
generation CARs included a combination of costimulatory endodomains in addition to CD3ζ 
[88]. Many trials are currently ongoing to test second- and third-generation CARs. 
 The most successful CAR clinical trials have been against hematological cancers. 
Chemotherapy-refractory leukemia and lymphoma patients receiving CD19-specific CAR T cells 
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have shown especially promising results[89-92], where the patients exhibited remissions lasting 
more than two years[89]. In these studies, low doses of T cells demonstrated explosive in vivo 
expansion and efficient killing of CD19+ B cells, including aplasia of normal B cells.  
Unfortunately, the clinical results for CAR-T cells targeting solid cancers have been much 
less encouraging. The two most favorable trials targeted sarcoma using ErbB2 CAR, where 4 of 
17 patients showed stable disease[93], and neuroblastoma using GD2 CAR, where 3 of 11 
patients showed complete remissions[94]. The reason for CAR T cells under-performing in solid 
tumor models is thought to be multifactorial. First, CAR T cells must efficiently gather at the 
tumor site despite potential incompatibility between chemokine receptors present on T cell 
surface and chemokines secreted by tumors[95]. Second, CAR T cells must infiltrate physical 
barriers posed by tumor stroma and interact with tumor cells in spite of possible antigen loss or 
heterogeneity. Third, CAR T cells must overcome hypoxia, oxidative stress, lack of nutrients, 
acidosis, and immune-suppression[96, 97]. The exciting success of CAR therapy in hematologic 
malignancies is fueling the application of CARs in solid tumors. However, a more complete 
grasp over the major hurdles seen in solid tumors will be necessary to optimize CAR 
engineering. 
As with most cancer therapies, there is an emerging set of toxicities associated with 
CAR-T cell therapies. In the case of CD19 CAR-T cells, these toxicities include B cell aplasia, 
tumor lysis syndrome (TLS), and cytokine release syndrome (CRS). Intravenous immunoglobulin 
can be used to replace quantitative antibody deficiency. TLS has been managed successfully by 
standard supportive therapy, including hydration, alkalinization, allopurinol, and 
rasburicase[98]. In patients with B cell malignancies, CRS occurs at the time of peak levels of 
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CAR T cells in blood and bone marrow. Corticosteroids and cytokine blockade are currently 
being evaluated for patients with CLL and ALL.  
In treating solid tumors, on-target off-tumor toxicity is the major problem as most solid 
tumor antigens are not exclusively present on tumors. T cells expressing a CAR specific for 
carbonic anhydrase IX, an antigen present on the surface of clear cell renal cell carcinoma, 
caused an unexpected serious hepatic toxicity in several patients[99]. This is likely due to 
carbonic anhydrase IX expression in the biliary tract. This study indicates that CAR targets must 
be carefully chosen to avoid such adverse effects, or that on-target off-tumor toxicity must be 
mitigated through additional safety features, such as suicide switches under the control of an 
inducible promoter[100] or transient expression systems[101]. 
 
 
Dissertation outline 
 
 In this dissertation, I demonstrate the application of various LFA-1 I domain mutants 
exhibiting wide range of affinities toward its ligand, ICAM-1, for targeting tumor-associated 
inflammation. Through the delivery of diagnostic agents, chemotherapeutics, as well as 
immunotherapeutics, the following chapters demonstrate that the affinity enhancements 
achieved by directed evolution bring the affinity of I domains into the range optimal for 
numerous applications.  
In the first chapters, I used amphiphilic polymeric nanoparticles to encapsulate water-
insoluble chemotherapeutic and anti-inflammatory drugs in the hydrophobic core, while 
functionalizing the surface with LFA-1 I domain. The I domain mutants displaying different 
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degrees of affinity towards ICAM-1 were first screened in an in vitro setting to determine the 
most competent targeting agent.  
In chemotherapy, the major obstacle lies in delivering sufficient amount of drugs to 
tumors to have desired effects, thereby reducing the drugs concentrations in healthy tissues. 
Thus, after observing the potent ICAM-1-specific drug delivery and killing by nanoparticles 
functionalized with the highest affinity I domain mutant, we carried out the subsequent in vivo 
mouse studies with the same formulation. I found that by being directed by the high affinity I 
domain, nanoparticles preferentially accumulated in inflamed mouse stromal cells that 
upregulated the expression of ICAM-1. Though the specific cytotoxic effect was enhanced in the 
tumor model expressing a high level of ICAM-1, ICAM-1- tumor growth was also arrested due to 
the toxicity on the tumor-supporting cells. The associated systemic toxicity with this drug 
delivery method was determined to be low and transient. 
To demonstrate the versatile applicability of LFA-1 I domain in cancer therapy, we 
replaced the scFv region of chimeric antigen receptors with different I domain mutants to be 
applied in immunotherapy. Since target-mediated toxicity is a major concern in engineering 
CAR T cells for solid tumors, we utilized the various I domain mutants to discriminate tumors 
overexpressing ICAM-1 from normal tissues. High affinity CAR T cells recognized ICAM-1 
expressed at any level, including normal cells, causing systemic toxicity in host and ultimately 
leading to death. Affinity-tuned CAR T cells exhibited robust anti-tumor lysis but excluded 
normal tissues. The use of affinity-tuned CAR T cells endows potent CAR T cells with a safe 
strategy to discriminate targets widely overexpressed on solid tumors 
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CHAPTER 2 
 
SELF-ASSEMBLED NANOPLATFORM FOR TARGETED DELIVERY OF CHEMOTHERAPY AGENTS VIA 
AFFINITY-REGULATED MOLECULAR INTERACTIONS 
 
This chapter was originally published in Biomaterials (Park, S., Kang, S., Veach, A.J., Vedvyas, Y., Zarnegar, R., Kim, 
J.Y., Jin, M.M. Biomaterials. 2010;31(30):7766-75. ©2010 Elsevier.), and is reprinted with permission. The following 
is the detailed contribution of authors: S.P., R.Z., M.M.J., and K.J.Y. designed research, performed research, and 
wrote the paper; S.K., A.V., and Y.V., performed research. 
 
Summary 
 
Site-specific delivery of drugs while minimizing unwanted distribution has been one of 
the pursued goals in cancer therapy. In this endeavor, we have developed targeted polymeric 
nanoparticles called amphiphilic urethane acrylate nonionomer (UAN) for encapsulation of 
diverse water-insoluble drugs and diagnostic agents, as well as for simple and reproducible 
surface conjugation of targeting ligands. Using monoclonal antibodies or lymphocyte function-
associated antigen-1 (LFA-1) I domain engineered for varying affinities to intercellular adhesion 
molecule (ICAM)-1, we were able to deliver UAN nanoparticles to human cancer cells with the 
efficiency dependent on the strength of the molecular interactions and the degree of ICAM-1 
expression on cell surface. Compared to non-specific uptake of free drugs, targeted delivery of 
UAN nanoparticles carrying equal amount of drugs produced more potent cytotoxicity. Notably, 
without the targeting ligands attached, UAN nanoparticles were largely precluded from non-
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specific uptake by the cells, resulting in much lower toxicity. The versatility of our UAN 
nanoparticles in both payload encapsulation and presentation of targeting ligands may facilitate 
developing a robust platform for evaluating various combinations of cancer drugs and 
molecular interactions toward developing effective cancer therapy formulations. 
 
Introduction 
 
Nanoparticles are emerging as a powerful platform for delivery of imaging[1] and 
therapeutic entities[2], particularly due to their potential applications in cancer therapy for 
early detection, enhanced therapeutic potency, and reduced side effects[3]. For example, 
microspheres, liposomes, nanoshells, dendrimers, and biodegradable polymers have been 
utilized as specific drug delivery systems[4]. Compared to the conventional methods of 
delivering therapeutic agents directly via intravenous or enteral routes, or as molecular 
conjugates, nanoparticle-mediated delivery may protect the therapeutic agents from chemical 
and enzymatic degradation and circumvent the need for chemical modification of therapeutic 
agents, which often leads to reduced potency and stability of drugs[5, 6]. Yet, a successful 
targeted delivery of nanoparticles needs to address the challenges in delivering hydrophobic 
payloads, controlling drug release, and accomplishing specific delivery while minimizing adverse 
immune response[7, 8].  
Recently, polymeric nanoparticles have been reported to exhibit characteristics of 
sustained release, effective solubilization of hydrophobic drugs, and reduced interactions with 
the reticuloendothelial system[6, 9, 10]. In order to achieve selective targeting by 
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nanoparticles, targeting ligands are often attached to the surface of the particles. The high 
surface-to volume ratio in these nanoparticles increases the surface density of ligands, leading 
to a multivalent, high affinity binding effect[11]. Specific targeting is additionally improved by 
the enhanced permeation and retention effect in tumor environments due to a leaky 
vasculature structure, allowing appropriately sized nanoparticles to extravasate[12]. 
Nanoparticles of certain size range (10-100 nm) have been shown to accumulate more readily 
in tumors through the retention effect compared to the larger ones, making them optimal for 
tumor penetration. 
To take advantage of these unique characteristics of polymeric nanoparticles, we have 
developed a versatile nanoparticle platform using amphiphilic urethane acrylate nonionomer 
(UAN)[13] with two functional layers. The hydrophilic outer shell is coated with a high density 
of Nickel-nitrilotriacetic acid (Ni-NTA) for simple conjugation of tumor-specific targeting 
molecules[14] and the hydrophobic core has a large capacity for water-insoluble chemotherapy 
drugs and imaging agents, where the encapsulation process occurs through the diffusion of 
hydrophobic molecules from water into the hydrophobic core[14, 15]. Through this approach, 
we demonstrate efficient encapsulation of water-insoluble fluorescent dyes, 9,10-
diphenylanthracene (DPA) and fluorescein isothiocyanate (FITC), and cytotoxic drugs, such as 
camptothecin, a topoisomerase inhibitor[16], and celastrol, a proteasome inhibitor[17]. 
Some of the current approaches in targeting tumors include ligands specific to Her2[18], 
transferrin receptor[19], epidermal growth factor receptor[20], folate receptor[21], integrin 
αVβ3[22], hyaluronan receptor[23], and chondroitin sulfate[24]. As the target molecule in the 
present study, we have chosen intercellular adhesion molecule (ICAM)-1. ICAM-1 is present in 
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low concentrations in the membranes of endothelial cells, and epithelial cells, and a subset of 
immune cells but is greatly up-regulated in response to inflammatory signals[25, 26]. In 
addition, constitutive over-expression of ICAM-1 has also been found in many carcinomas, such 
as breast, colon, non-small cell lung, renal-cell, pancreas, and gastric carcinomas compared to 
the respective normal epithelial cells[27-32] as well as in the tumor microenvironments, 
wherein an inflammatory milieu promotes angiogenesis and tumor growth[33]. 
Though most molecular targeting approaches have been based on antibodies[34] and 
small peptides[35], herein, we demonstrate ICAM-1 targeting with a native ligand, called the 
inserted (I) domain derived from lymphocyte function-associated antigen (LFA)-1. LFA-1 is a 
member of the integrin family, expressed on all leukocytes[36], that mediates leukocyte 
adhesion to endothelial cells and transmigration into inflamed tissues[37]. We used the I 
domains that have previously been engineered by various activating mutations (F292A, F292G, 
F265S/F292G) to increase the affinity to ICAM-1 in a step-wise manner[38]. Using ICAM-1 
expressing HeLa cells[39] as a model cancer cell line, we demonstrate specific delivery of UAN 
encapsulating hydrophobic dyes and therapeutic agents to the cells, in a manner dependent on 
the affinity between the LFA-1 I domains and ICAM-1, as well as the expression level of ICAM-1. 
 
Experimental Procedures 
 
Synthesis and characterization of NTA-coupled UAN nanoparticles 
The synthesis of UAN was previously described[40]. In brief, glycerol propoxylate (n∼5, 
MW∼1000, Sigma Aldrich) was mixed with toluene diisocyanate (TDI, Sigma Aldrich) to react 
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the hydroxyl groups of glycerol propoxylate and the isocyanate (-N=C=O) groups of TDI (Fig. 
2.1A). The remaining isocyanate groups in TDI were reacted with the hydroxyl groups of 2-
hydroxyethyl methacrylate (2-HEMA, n∼34, Sigma Aldrich) and polyethylene glycol (PEG, MW = 
1500, Sigma Aldrich). The final product, urethane acrylate nonionomer, consisted of a 1:3:2:1 
molar ratio of glycerol propoxylate:TDI:HEMA:PEG. 50 mg of the UAN monomers were then 
cross-linked by the reaction between the vinyl groups (-CH=CH2) of HEMA. This polymerization 
was accomplished by 2 mg of azobisisobutyronitrile (AIBN, Sigma Aldrich), which creates free 
radical initiators when heated. The cross-linking step was carried out in 10 ml of dimethyl 
sulfoxide (DMSO, Sigma Aldrich) at 65°C overnight with vigorous stirring (Fig. 1B). The average 
molecular weight of the synthesized UAN chains was 6,700 (MALDI Micro MX, Waters) with a 
polydispersity of 2.0 measured via ambient temperature gel permeation chromatography (GPC, 
Waters). To create the NTA moiety on the hydroxyl end of the PEG groups in polymerized UAN, 
10 mg of Nα,Nα-Bis(carboxymethyl)-L-lysine hydrate (NTA analog, Sigma Aldrich) in 0.1 ml 
DMSO was mixed with 6.4 mg of TDI (molar ratio of NTA to TDI is 1:1) for 2.5 hours at room 
temperature to prepare NCO-terminated NTA-TDI complexes. Then NTA-TDI was mixed with 50 
mg of cross-linked UAN overnight at room temperature to covalently link NCO of NTA-TDI to OH 
groups of UAN chains. In order to form nanoparticles from these monomers, the UAN chains 
dissolved in DMSO were diluted in distilled water (dH2O) at a volume ratio of 1:10 
(DMSO:dH2O). The payloads such as FITC, camptothecin, and celastrol were added to UAN 
chains in DMSO at 0-20% of UAN weight prior to dilution with water. 
Dynamic light scattering (DLS, Malvern Instruments) was used to measure the average 
size of the UAN nanoparticles after synthesis, after NTA conjugation, and after payload  
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Figure 2.1: Synthesis and characterization of UAN.  
(A) UAN monomer is synthesized by covalently linking 2-HEMA, PEG, and glycerol propoxylate 
at 2:1:1 M ratio. (B) NTA-UAN is formed by cross-linking UAN monomers with AIBN and 
conjugation of NTA to PEG. NTA-UAN forms nanoparticles when suspended in aqueous 
solution. (C) TEM images of UAN nanoparticles after staining with uranyl acetate. Scale bar is 
shown. (D) The function and specificity of Ni-NTA on UAN nanoparticles were confirmed by 
their binding to a His-peptide column. (E–F) The release kinetics of hydrophobic dyes and drugs 
from UAN were inferred by measuring the rate of escape through dialysis tubes without (E) or 
with (F) UAN. The fit of the first-order kinetics to the data is shown as a line. (G) The delay in 
the rate of escape (τ_UAN-τ) of the payloads (HPTS, FITC, celastrol, CPT) is plotted against their 
respective solubility values in water on a semi-log plot. 
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encapsulation. Transmission electron microscopy (TEM; FEI Tecnai™) images of the UAN 
particles were taken after staining with 1% uranyl acetate. 5 μl of the sample was placed on a 
glow-discharge grid for two minutes, after which excess solution was removed with filter paper. 
5 μl of 1% uranyl acetate was then placed on the grid for one minute and removed with filter 
paper. Images were taken after air-drying the grid for 30 minutes. 
 
His-peptide column and Ni-NTA functionality test 
His-peptide column was made by covalently attaching 2 mg of His-tag peptide (NH2-Cys-
Gly4-Trp-Ser-His6-COOH; subscripts denote the number of repeats) to 1 ml of aldehyde-
activated agarose resin (AminoLink Coupling Resin and Kit, Pierce). The Schiff base formed 
between the amine and aldehyde groups was then reduced by cyanoborohydride according to 
the manufacturer's protocol. 
 
‘Escape’ Kinetics Assay 
The release kinetics of the payloads encapsulated in UAN were indirectly measured 
using dialysis tubes. A highly water-soluble dye, 8-Hydroxypyrene-1,3,6-trisulfonic acid 
trisodium salt (HPTS, Anaspec) was used as a comparison with hydrophobic agents such as FITC 
(Pierce), celastrol (Cayman Chemical), and camptothecin (MP Biomedicals) to demonstrate 
UAN's ability to delay the ‘escape’ or the rate of diffusion of hydrophobic molecules through 
dialysis tubes. 1 ml of each UAN(payload) sample was placed in separate dialysis tubes (MWCO 
7,000 Da, Fisher) and subsequently placed in separate 2 liter water-baths with stirring. After 
overnight dialysis, the concentrations of the payloads encapsulated within UAN were measured 
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and the samples were subsequently placed in separate fresh dialysis tubes. 2 μl of each of the 
samples was taken out from the dialysis tubes and the absorbance levels were measured at 
different time points using a spectrophotometer (Nanodrop™ 2000) set at appropriate wave-
lengths (HPTS: λmax = 454 nm, FITC: λmax = 495 nm, celastrol: λmax = 424 nm, camptothecin: 
λmax = 365 nm). Since DPA (Sigma Aldrich) was completely water-insoluble, DPA precipitated 
out of solution did not diffuse through the dialysis membrane. Therefore, UAN(DPA) was placed 
in a 1.7 ml microcentrifuge tube, and the supernatant after removing the DPA pellet that was 
released from UAN was measured for absorbance (λmax = 413 nm). The extinction coefficient 
and water solubility of each of the molecules are as follows: HPTS: 20,800 M-1cm-1 and highly 
water soluble, FITC: 70,000 M-1cm-1 and 100 μg/ml, celastrol: 10,063 M-1cm-1 and 2.33 μg/ml, 
camptothecin: 42,282 M-1cm-1 and 1 μg/ml, and DPA: 14,000 M-1cm-1 and water-insoluble. The 
same procedure was carried out to evaluate the escape kinetics of free materials with the initial 
concentrations of the payloads set to be equal to those encapsulated in UAN. The percent 
escape was plotted as 100% [C0-C(t)]/C0, where C(t) and C0 refer to the measured payload 
concentration inside the dialysis tube at time = t and at time = 0 h, respectively. The rate of 
escape from dialysis tubes (τ) was then calculated by assuming the first order diffusion model, 
C(t) = C0 exp(-t/τ) and curve-fitting the resulting equation, 100% [1- exp(-t/τ)], to the percent 
escape data. 
 
Production of I domains, protein A, and R6.5 antibody 
LFA-1 I domains and immunoglobulin G-binding recombinant protein A (17 kDa 
fragment) with a His tag at the C-terminal were produced in Escherichia coli BL21(DE3) 
- 33 - 
 
(Invitrogen) using pET20b and pET28a vectors, respectively. To produce protein A, a 1 liter 
bacteria culture with OD600 of 0.4-0.5 was induced with 1 mM isopropyl-b-D-thiogalactoside 
(IPTG, Gold Biotechnology) for 4 hours, after which it was centrifuged (3000 rpm, 4°C, 10 
minutes) to pellet the cells. The soluble fraction of protein A was extracted by sonication and 
was purified using a Ni-NTA column (Novagen). Elutions from the column were further purified 
by size exclusion in a liquid chromatography column (Akta, GE Healthcare). Recombinant LFA-1 I 
domains (Asn-129 to Tyr-307) were produced as described previously[38]. Briefly, after protein 
induction, inclusion bodies were resuspended in 10 ml of the washing buffer (50 mM Tris (pH 
8.0), 23% w/v sucrose, 0.5% w/v Triton X-100, 1 mM ethylenediaminetetraacetic acid (EDTA)), 
sonicated, and centrifuged again to wash the inclusion body. This process was repeated three 
times. Then, the inclusion bodies were solubilized with 20 ml of the solubilization buffer (50 
mM Tris (pH 8.0), 6 M Guanidine-HCl) for 1.5 hours at 4°C with stirring. This solution was 
diluted with 2 liter of refolding buffer (50 mM Tris (pH 8.0), 10% glycerol, 1 mM MgCl2) and 
stirred slowly at 4°C overnight to initiate protein refolding. Finally, the refolded solution was 
concentrated down to 1-5 ml by centrifugation (Amicon 5 kDa MWCO Millipore), filtered 
through 0.45 μm, and purified by gel filtration chromatography. Monoclonal antibody (mAb) 
R6.5 was produced from hybridoma (ATCC), and purified by a Protein A column (Pierce) 
followed by size exclusion. 
 
Cell culture and labeling with UAN 
HeLa cells were grown in Advanced DMEM (Gibco) containing 10% fetal bovine serum 
(FBS) (Atlanta Biologicals) and 2mM L-glutamine (GlutaMAX™, Gibco) at 37°C in a 5% CO2 
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humidified incubator. HeLa cells in 96 well plates (∼90 % confluency) were washed twice with 
100 μl of the labeling buffer (phosphate buffer saline (PBS), pH 7.4, 5% bovine serum albumin 
(BSA), 5 mM MgCl2) and incubated with UAN (250 μg/ml) conjugated to I domain in 100 μl of 
labeling buffer at room temperature for 30 minutes. UAN(payload) nanoparticles were kept in a 
dialysis tube (MWCO 7,000 Da, Fisher) until they were used for cell labeling, with a minimum 
dialysis time of 48 hours to remove unencapsulated payloads. The unbound UAN particles were 
aspirated out and the cells were washed three times with the labeling buffer. The cells were 
then washed with the culture media and kept at 37°C, while being observed at different time 
points. Human breast adenocarcinomas (MDA-MB-231) were cultured in αMEM containing 10% 
FBS and 2mM L-glutamine, human thyroid cancer cell line (KTC-1)[41] in RPMI 1640 with 10% 
FBS and 2mM L-glutamine, and human microvascular endothelial cell (HMEC)-1 in MCDB 131 
media (Gibco) containing 10% FBS, 2mM L-glutamine, 10 ng/ml human epidermal growth 
factor, 1 μg/ml hydrocortisone, and 1% penicillin-streptomycin at 37°C in a 5% CO2 humidified 
incubator. Human acute monocytic leukemia cell line, THP-1 (ATCC), were cultured in RPMI 
1640 media with 10% fetal bovine serum, and 0.05 mM 2-mercaptoethanol at 37°C in a 5% CO2 
humidified incubator. In order to induce upregulation of ICAM-1, the cells were treated with 1 
μg/ml of lipopolysaccharide (LPS) in the appropriate culture media for 24 hours. 
 
Immunofluorescence Flow Cytometry 
HeLa, KTC-1, MDA-MB-231, and HMEC-1 cells (∼200,000 cells per labeling) were 
trypsinized and washed with the labeling buffer. Since THP-1 is a suspension cell line, it was 
centrifuged (700 rpm, 4°C) and washed with the labeling buffer. 250 μg/ml of UAN coated with I 
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domain and containing FITC (I domain-UAN(FITC)) in 100 μl was added to the cells. After 15 
minutes of incubation, cells were washed and re-suspended in 100 μl of the labeling buffer for 
flow cytometry (COULTER® EPICS® XL-MCL™ Flow Cytometer, Beckman Coulter). In evaluating 
the expression level of ICAM-1 in different cell lines, cells were labeled with 10 μg/ml of mAb 
R6.5 or LB2 (Santa Cruz Biotech), washed, and subsequently labeled with goat-anti-mouse-PE 
secondary antibody (Santa Cruz Biotech). 
 
Quantification of Cell Viability 
To quantify the number of viable cells after drug delivery, cells were fixed with 10% 
formalin for 5 minutes and stained with 0.05% crystal violet (Fisher Scientific) in distilled water 
for 30 minutes. After washing out the dye outside of the cells, methanol was added to release 
the crystal violet from the cells, which was quantified by detecting the absorbance level at 540 
nm. 
 
Statistical Analysis 
Data were expressed as mean ± standard deviation of at least triplicate samples. One-
way ANOVA was performed on the four groups of HeLa cells, each treated with UAN(drug) 
conjugated to different I domain mutants (WT, F292A, F292G, F265S/F292G). The means of the 
number of viable cells from each of the groups were compared. Post hoc Tukey's HSD test was 
carried out in order to assess which groups significantly differed from others. All of the 
statistical analyses were performed using GraphPad Prism5 (GraphPad Software). 
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Results 
 
Synthesis and characterization of targeted UAN nanoparticles 
When NTA-coupled UAN (NTA-UAN) dissolved in DMSO is diluted in water, 
polypropylene oxide-based segments associate with each other to form micelle-like 
nanoparticles with hydrophobic interior. Being covalently bound to the -OH groups of 
hydrophilic polyethylene oxide, NTA groups are more likely to be exposed on the surface of the 
UAN nanoparticles (as depicted in Fig. 2.1B). Similar to the surfactant micelles, UAN chains can 
absorb small hydrophobic payloads within their hydrophobic core. Thus, the hydrophobic 
agents can be added to NTA-UAN in DMSO (FITC, celastrol, camptothecin) or in water after 
dilution (DPA), which would cause the agents to be encapsulated in the core of the 
nanoparticles through hydrophobic interactions. Dynamic light scattering was used to measure 
the size distribution (hydrodynamic radius) of the following formulations: bare UAN (32.6 nm ± 
2.7), NTA-UAN (42.98 nm ± 4.12), and NTA-UAN after encapsulation of various hydrophobic 
agents (NTA-UAN(DPA): 47.72 nm ± 5.56, NTAUAN(FITC): 44.29 nm ± 2.19, NTA-
UAN(camptothecin): 52.22 nm ± 5.3, NTAUAN(celastrol): 43.7 nm ± 1.82). TEM images revealed 
that bare UAN nanoparticles were spherical, uniformly sized, and well dispersed (Fig. 2.1C). 
The presence of NTA on the surface of UAN was studied using a His-peptide column (Fig. 
2.1D). NTA-UAN nanoparticles were first charged with nickel ions by incubation with 10 mM 
NiCl2 in PBS (pH7.4) and loaded to the His-peptide column, after which the amount of flow 
through and samples eluted with 50 mM EDTA were determined by the absorbance levels at 
280 nm. Approximately 90% of NTA-UAN nanoparticles were bound to the column, and eluted 
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entirely with 50 mM EDTA. On the other hand, NTA-UAN pretreated with EDTA to remove 
nickel ions from UAN nanoparticles did not bind to the His-peptide column, indicating the 
binding of NTA-UAN nanoparticles to the column was solely dependent on Ni-NTA interaction 
with His-peptide. 
The amounts of the payloads encapsulated in 1 mg of NTA-UAN nanoparticles after 
overnight dialysis were 110 μg of FITC, 87.8 μg of celastrol, 4 μg of DPA, and 28.6 μg of 
camptothecin. To study the release kinetics of the payloads from UAN nanoparticles, we 
measured the rate of diffusion or the escape rate of the payloads through a dialysis membrane 
with the appropriate molecular weight cutoff to contain UAN nanoparticles but allow free 
payloads to diffuse through. We found that the time constants (τ) for the first-order escape 
kinetics of the payloads from dialysis tubes without UAN were in correlation with their 
hydrophobicity: the 95% confidence interval for τ values of HPTS, FITC, celastrol, and 
camptothecin were, respectively, 3.9 ± 0.7, 9.4 ± 2.6, 27.5 ± 7.0, 30.3 ± 9.9 hours (Fig. 2.1E). The 
rate of escape of the payloads after encapsulation into UAN (τ_UAN) was delayed in proportion 
to the payloads’ hydrophobicity: the τ_UAN values of HPTS, FITC, celastrol, and camptothecin 
were, respectively, 6.1 ± 2.3, 47.7 ± 27.0, 203.7 ± 115.5, 134.4 ± 61.8 hours (Fig. 2.1F, G). The 
release rate of DPA from UAN was measured at 757.1 ± 417.4 hour. 
 
Affinity Dependent Cell Labeling Assay 
LFA-1 I domain exhibits multiple conformations that are linked to differential affinity to 
ICAM-1 (Fig. 2.2A, B). Using a directed evolution approach, we have previously isolated a 
number of point mutations that led to an increase in the affinity of the I domain to ICAM-1 [38].  
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Figure 2.2: LFA-1 I domains engineered for high affinity for targeting ICAM-1. 
(A) Structural diagrams of low (inactive) and high affinity (active) conformations of LFA-1 I 
domains. Structurally conserved regions between the two states are in light gray, while the 
regions that differ more than 1 Å in their Cα positions are in dark gray (inactive) and in medium 
gray (active). The metal ions in the metal ion-dependent adhesion site are shown as spheres. 
(B) The structure of the I domain in complex with ICAM-1 domain 1 (D1). Allosteric activation 
sites found in our previous study[38] are displayed in spheres along the peptide backbone. The 
metal ion and three oxygen atoms of water molecules are depicted as spheres, while the 
residues that coordinate to the metal ion are drawn with the sticks. (A) and (B) are adapted 
from Fig. 5 of Hu, X., et al[42]. (C) Schematic of ICAM-1 domains. Domain 1 binds to LFA-1 I 
domain. The mAbs LB2 and R6.5 bind domain 1 and domain 2, respectively. (D) Surface plasmon 
resonance data for binding of I domains (100 μM of WT (wild-type) and F292A and 1 μM of 
F265S, F292G, and F265S/F292G) to ICAM-1 immobilized (adapted from Fig. 2 of Jin et al[38]). 
Compared to the wild-type, each mutation of I domain (F292A, F265S, F292G, F265S/F292G) 
increases the binding affinity of I domain to ICAM-1 in a step-wise manner. The numbers in 
parentheses denote the equilibrium dissociation constants, KD. 
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The equilibrium dissociation constants (KD) for WT, F292A, F292G, and F265S/F292G were 
determined, respectively, to be 1500 ± 200 μM, 20 ± 0.8 μM, 0.119 ± 0.017 μM, and 0.006 ± 
0.0002 μM. (Fig. 2.2D). Compared to the more commonly used targeting approaches based on 
antibodies or short peptides, the I domain is a native, small (∼20 kDa), and highly specific ligand 
to the ICAM family molecules, and can be produced in bacteria in a large-scale. The I domain 
was produced with a His-tag for non-covalent conjugation to NTA-UAN nanoparticles. To 
estimate a maximum coating capacity of UAN, LFA-1 I domain was added in excess to UAN-NTA, 
after which the unbound I domain was removed by gel filtration. By the Lowry method (DC 
Protein Assay Kit, BioRad), the maximum capacity of UAN in binding the I 
domain was determined to be ∼100 μg of I domain/mg of UAN. In order to obviate the need for 
removing unbound proteins, the weight ratio of I domain to UAN for conjugation was used at 
1:25 throughout this study. This corresponds to a molar ratio of 136:1 (I domain :UAN 
nanoparticle), given the molecular weight of the I domain of ∼20 kDa, the measured value of 
UAN density of 1 mg/ml, and the molecular weight of 68 MDa estimated for UAN with a 60 nm 
diameter. 
To determine how the nature of different I domain mutants coating UAN would 
influence their interactions with ICAM-1, we examined the binding and uptake of nanoparticles 
by living cells. Cervical cancer cells (HeLa) were used as a model for the study, representing a 
group of cancer cells expressing high levels of ICAM-1. HeLa cells were labeled with I domain-
UAN(FITC), washed with the culture media, and maintained at 37°C, while being observed at 
different time points (images were taken 2 hours after incubation) (Fig. 2.3A). The fluorescence 
intensity exhibited by the cells reflected LFA-1 I domain/ICAM-1 affinity dependent labeling:  
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Figure 2.3: Affinity- and expression-dependent delivery of I domain-UAN(FITC) to ICAM-1 
expressing cells.  
(A) UAN nanoparticles encapsulating FITC and conjugated to different I domains were delivered 
to HeLa and MDA-MB-231 cells. (B) Immunofluorescence flow cytometry measurement of the 
delivery into HeLa of UAN(FITC) with no I domain, WT, or I domain variants (n = 3). (C) The 
levels of ICAM-1 expression in HeLa, MDA-MB-231, and KTC-1 cells were measured by mAb 
R6.5 (open histogram) or with secondary antibody alone as a control (filled histogram). (D) 
Immunofluorescence flow cytometry measurements of F265S/F292G-UAN(FITC) binding to 
HeLa, MDA-MB-231, and KTC-1 cells. 
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while F292A-UAN(FITC) showed only slightly higher cell labeling than the wild-type, F292G-UAN 
and F265S/F292G-UAN led to greatly enhanced fluorescence. The observed affinity dependent 
binding of UAN(FITC) was confirmed in a separate experiment, in which trypsinized HeLa cells 
were labeled with I domain-UAN(FITC) and the fluorescence intensity was measured by flow 
cytometry (Fig. 2.3B). 
In order to examine if the expression level of surface antigen influences the efficiency of 
nanoparticle delivery, the level of I domain-UAN(FITC) binding to HeLa cells was compared to 
the association with other cancer cell lines, KTC-1 and MDA-MB-231, which express high and  
low levels of ICAM-1, respectively (Fig. 2.3C). As expected, the levels of I domain-UAN(FITC) 
binding to KTC-1 and MDA-MB-231 were in good correlation with the levels of ICAM-1 
expression (Fig. 2.3D). The dependence of UAN targeting on the levels of antigen expression will 
be an important facet in achieving preferential delivery into cells over-expressing tumor-specific 
antigens. 
 
Affinity Dependent Cellular Cytotoxicity Assay 
We examined the cellular cytotoxicity effects of UAN nanoparticles encapsulating 
celastrol, a quinone methide triterpene derived from the Chinese plant Tripterygium 
wilfordii[17, 43], which is known to inhibit the function of proteasomes[43]. Celastrol has been 
shown to inhibit the proliferation of a variety of tumor cells, including those of leukemia, 
gliomas, prostate cancer[44], and melanomas[45]. After incubation with the UAN conjugated to 
I domains of different affinity (WT, F292A, F292G, F265S/F292G) for 30 minutes, HeLa cells 
were washed and maintained in culture media for 24 hours before assaying for cell viability.  
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Figure 2.4: Affinity dependent cytotoxicity by I domain-UAN(celastrol or CPT).  
I domain-UAN nanoparticles encapsulating celastrol (A, B) or CPT (C) were delivered to HeLa 
cells. The cells treated with celastrol were stained with crystal violet for better visualization. 
Cell viability was then quantified by measuring the amount of crystal violet after cell lysis and 
shown as bar graphs (D–F), normalized to the levels with WT-UAN (n = 3). (G) The percentage of 
viable cells after HeLa cells treated with UAN(celastrol or CPT) was plotted as a function of I 
domain affinity to ICAM-1 (n = 8). Values were normalized to that of the wild-type. The 
significance of the differences in cell viability due to I domain-UAN was analyzed by one-way 
ANOVA and Tukey’s HSD post hoc test statistics. 
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UAN encapsulating high (125 μM) and low (20 μM) concentrations of celastrol caused I domain 
affinity dependent cytotoxicity to cells (Fig. 2.4). In the case of UAN encapsulating 20 μM 
celastrol, more than 80% cell death was detected with F292G-UAN and F265S/F292G-UAN, and 
a much lower cytotoxic effect with WT-UAN and F292AUAN (Fig. 2.4A, D). Though a similar 
pattern was detected with UAN encapsulating 125 μM celastrol, a significant number of cells 
had died and lifted off from the culture flask when targeted with WT-UAN as well (Fig. 2.4B, E). 
Monomeric interaction between the wild-type I domain and ICAM-1 is low (1500 ± 200 
μM)[46], but the high density of I domains attached to UAN would have increased the effective 
affinity to ICAM-1 via multivalency or avidity effect, resulting in a sufficient amount of celastrol 
delivered into the cells. The discrepancy between the minimal cell labeling by WT-UAN(FITC) 
and the significant cell death caused by WT-UAN(celastrol) can be attributed to the higher 
sensitivity with which cellular cytotoxicity can be detected compared to the sensitivity of our 
imaging system in detecting fluorescence. To further explore the efficacy of these nanoparticles 
in delivering chemotherapeutic agents, we replaced celastrol with camptothecin. Camptothecin 
loaded at 2 μM produced cytotoxic effect comparable to celastrol loaded at 20 μM, producing a 
potent cell death when targeted by F265S/F292G and negligible cytotoxicity with the wild-type I 
domain (Fig. 2.4C, F). Cytotoxicity caused by UAN(camptothecin/celastrol) conjugated to 
different I domains indicated that the differences in the cell viability were in fact due to the 
different affinities to ICAM-1 (Fig. 2.4G; p<0.0001, one-way ANOVA). Cell viability due to WT-
UAN vs. F292G-UAN and WT-UAN vs. F265S/F292G-UAN was also significantly different 
(p<0.001 by Tukey's HSD Post Hoc Test). The observed cell death was not due to the UAN  
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Figure 2.5: Comparison of cytotoxicity due to free celastrol, UAN(celastrol) without targeting, 
and F265S/F292G-UAN(celastrol).  
(A) Cytotoxicity of HeLa due to the treatment with celastrol, UAN(celastrol), or F265S/F292G-
UAN(celastrol) was analyzed. HeLa cells were stained with a crystal violet for better 
visualization (images were taken 28 h after the treatment) and subsequently lysed for 
quantification of cell viability. Each condition contained 100 μM of celastrol. (B) The measured 
cell viability was shown in bar graphs, normalized to that of ‘No I domain Control’ (n = 3). 
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polymer, as the F265S/F292G-UAN without drug encapsulation at up to 500 μg/ml led to 
negligible cytotoxic effect (data not shown). 
 
Free celastrol vs. UAN(celastrol) 
In order to demonstrate that targeted delivery of drugs carried by UAN is more potent 
than non-specific uptake of free drugs, we treated HeLa cells with UAN(celastrol) with no I 
domain, F265S/F292G-UAN(celastrol), and celastrol alone, each with 100 μM of celastrol (Fig. 
2.5). After 30 minutes of incubation, cells were washed with the culture media and kept at 37°C 
for 28 hours. The percent cell viability was measured using the crystal violet assay. Though 
celastrol alone was able to cause substantial amount of cell death (78%), F265S/F292G- 
UAN(celastrol) induced significantly higher cytotoxicity (∼90%) (Fig. 2.5B). Notably, 
UAN(celastrol) without the I domain caused negligible amount of cell death, providing strong 
evidence that cytotoxicity induced by F265S/F292G-UAN was due to the specific uptake of 
UAN(celastrol) into the cells. Additionally, UAN nanoparticles were effectively precluded from 
non-specific uptake by the cells, and the cytotoxicity caused by celastrol diffusing out of UAN 
during the 30 min incubation was insignificant. 
 
Exploiting the Versatility of UAN Nanoparticle Platform 
The versatility of our nanoparticle platform comes not only from its ability to 
encapsulate many different naturally available hydrophobic therapeutic and contrasting agents, 
but also from the fact that it can be conjugated to any targeting molecules with a His-tag. To 
demonstrate such versatility, we used a recombinant His-tagged protein A as the linker  
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Figure 2.6: Antibody-mediated targeting of ICAM-1.  
(A) In order to demonstrate the versatility of UAN platform, UAN nanoparticles were 
encapsulated with DPA or CPT, while the surface of UAN was coated with four different 
combinations of protein A and mAb R6.5. HeLa cells were imaged 2 h after incubation with 
UAN(DPA) and 28 h with UAN(CPT). (B) The bar graphs were normalized to that of no protein A 
and no R6.5 control (‘−/−’, n = 3). 
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between our nanoparticle and R6.5, a mAb against ICAM-1. We also encapsulated a different 
dye, DPA, for cell labeling, and camptothecin for cellular cytotoxicity assay (Fig. 2.6). For 
encapsulation of DPA, a ‘soaking’ method [15] of pre-formulated particles was used. DPA was 
dissolved in dichloromethane at 25 mg/ml and 25 μl of this DPA solution was added to UAN 
nanoparticles (500 μg/ml) in 10 ml water. The mixture was stirred for 24 hours to evaporate off 
dichloromethane, during which DPA was encapsulated into the core of UAN. Unencapsulated 
DPA was precipitated out of solution and removed by a 0.2 μm filter. Protein A was conjugated 
to NTA-UAN nanoparticle at a weight ratio of 1:25 (protein A:UAN) for 30 minutes at 4°C, which 
was subsequently incubated with R6.5 at a molar ratio of 1:1 (R6.5:protein A) under the same 
conditions. Three additional conditions were included as control samples: bare NTA-UAN 
particles, NTA-UAN mixed with R6.5, and NTA-UAN with protein A. These conditions showed no 
detectable labeling or cytotoxicity. Only with both protein A and R6.5 conjugated onto the 
surface of UAN nanoparticles, an efficient delivery was observed resulting in effective cell 
labeling and cell death. Cell viability was quantified using the crystal violet assay, which showed 
an approximately 80% decrease in the number of viable cells. 
 
I domain-UAN Shows Minimal Binding to Cells Expressing Basal Levels of ICAM-1 
ICAM-1 is ubiquitously present in lymphocytes, macrophages, and endothelial cells at 
low levels but is greatly upregulated under inflammatory conditions. To examine the possibility 
of UAN nanoparticle in targeting normal cells with low levels of ICAM-1, we used endothelial 
(HMEC-1) and monocytic (THP-1) cell lines, and measured the delivery efficiency of UAN into 
the cells with and without the treatment with LPS, a potent inducer of inflammation and ICAM-  
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Figure 2.7: Minimal binding of I domain-UAN to cells with basal expression of ICAM-1.  
(A) Immunofluorescence flow cytometry measurement of mAb LB2 binding to HMEC-1 and 
THP-1 cells with (black open) or without (gray open) LPS treatment, or without labeling (filled 
histograms) to show the induction of ICAM-1 expression level. (B, C) Immunofluorescence flow 
cytometry measurement of F265S/F292G-UAN(FITC) (black open) binding to HMEC-1 and THP-1 
cells with or without LPS treatment. UAN(FITC) without the I domain (gray open histograms) 
was used to measure non-specific binding to cells. Cells without labeling is shown in filled 
histograms. (D) Immunofluorescence flow cytometry results expressed as a bar graph. 
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1 expression (Fig. 2.7). The increase in ICAM-1 expression in HMEC-1 and THP-1 cells after 24 
hours of LPS treatment was confirmed by immunofluorescence flow cytometry with the mAb, 
LB2 (Fig. 2.7A). When these cells were labeled with F265S/F292G-UAN prior to LPS induction, 
little binding was measured (Fig. 2.7B). However, with LPS treatment, a 4-5 fold increase in the 
levels of UAN binding was observed (Fig. 2.7B, C), implying a requirement for a threshold or 
minimum concentration of ICAM-1 on cell surface to be targeted by a sufficient dose of UAN 
nanoparticles to produce cytotoxic effects. 
 
Discussion 
 
The delivery of drugs to the target cells and tissues with minimal distribution into 
unwanted targets will be critical in maximizing payload concentration at the sites of interest 
while preventing side effects. Thus far, no molecular target has been identified that is present 
only in tumors. Enhancing the specificity of drug carriers by controlling the affinity and avidity 
of molecular interactions will, therefore, aid to minimize binding to normal cells with basal 
levels of the molecular target. In this study, we have demonstrated that UAN nanoparticles are 
highly versatile and robust in terms of the methods used for conjugation, selection of optimal 
surface density of targeting molecules, and encapsulation of hydrophobic imaging and 
therapeutic agents. Using LFA-1 I domain mutants as tools to validate our UAN platform, we 
demonstrated affinity dependent delivery of both therapeutic and diagnostic agents to ICAM-1 
expressing HeLa cells. We have also found that the level of ICAM-1 on the surface of target cells 
contributed to a great degree in specific binding of UAN nanoparticles. This finding is evidenced 
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by the fact that despite ubiquitous expression of ICAM-1 in many different types of cells such as 
endothelium, epithelium, and a subset of leukocytes, our UAN nanoparticles exhibited little 
binding to them under resting conditions, and significant binding to endothelium and 
leukocytes only after induction of ICAM-1 by inflammatory molecules. ICAM-1 expression 
dependent delivery of UAN was also seen with two other cancer cell lines, KTC-1 and MDA-MB-
231, which demonstrated a correlation between the level of UAN binding and ICAM-1 
expression. 
A large proportion of chemotherapeutic drugs are derived from plants[47] and contain 
hydrophobic aromatic groups and a chain of hydrocarbon, making them water insoluble[6]. 
Though much work has been done to modify these drugs to yield better analogues for solubility 
and bioavailability, these efforts have often resulted in drugs with reduced potency or 
stability[6]. Studies have shown, however, that chemotherapeutic drugs in their native forms 
can be encapsulated in the hydrophobic core of polymeric nanoparticles and protected from 
degradation, leading to an increased potency[5, 48]. The ability of UAN nanoparticles to retain 
hydrophobic materials was confirmed in the release kinetics study, which showed an increase in 
retention in correlation with their degree of hydrophobicity. Although the exact mechanism by 
which the payloads diffuse out of UAN after internalization into the cells is uncertain, the rate 
of diffusion may change once the UAN nanoparticles are exposed to a lower pH and lipid 
components in the endosomes. 
Due to the presence of Ni-NTA, the versatility of UAN extends to its ability to be linked 
to any molecule with a His-tag, expanding the repertoire of targeting molecules that can be 
utilized. Recombinant engineering of His-tagged proteins is a common practice in molecular 
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biology and these proteins can be produced in a variety of expression systems. Thus, a large 
library of recombinant His-tagged proteins is available for immobilization onto our 
nanoparticles[14]. Rather than applying different surface chemistry for conjugation of different 
targeting molecules, Ni-NTA/His-tag interaction provides a universal and reproducible 
conjugation process. This non-covalent but high affinity conjugation method obviates the 
problems associated with the conjugation via chemical activation (e.g., carbodiimide), such as 
the lack of control over the degree of conjugation and orientation of the molecules, and 
frequent aggregation of nanoparticles and proteins. By using a ratio of proteins to nanoparticle 
that does not fully saturate the NTA moieties on UAN while ensuring a coating density 
sufficiently high for tight binding, we eliminated the purification step of removing unbound 
proteins from the final formulation of UAN nanoparticles. The fact that encapsulation of drugs 
and conjugation of targeting molecules to UAN nanoparticles do not require any chemical 
conjugation and special purification methods will be of significant advantage in the potential 
therapeutic use of UAN in clinics. 
An important facet of targeted delivery of nanoparticles is the prospect of achieving 
specific and more potent treatment than the conventional therapy methods. Here, we have 
demonstrated that UAN encapsulating celastrol was much more potent than celastrol alone, 
which is currently being evaluated in preclinical studies for cancer therapy[45], and that UAN 
itself causes no toxicity. Furthermore, UAN(celastrol) without the I domain was shown to cause 
much less cytotoxicity, indicating that non-specific uptake of UAN nanoparticles by the cells was 
much lower than that of free drugs. This characteristic will be of significant importance since 
the administration of chemotherapeutic drugs alone lack specificity and cause significant 
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damage to non-cancerous tissues, leading to serious, unwanted side effects in bone marrow, 
gut epithelial cells, reticuloendothelial system, and hair loss. Owing to the ability to encapsulate 
hydrophobic materials and achieve consistent surface modification via the Ni-NTA/His-tag 
interaction as presented, UAN provides a promising platform for effective drug delivery in 
numerous disease models. 
 
Conclusion 
 
In this study, we have demonstrated that UAN nanoparticles possess ideal properties to 
achieve effective encapsulation of hydrophobic agents as well as specific delivery of imaging 
and cytotoxic agents to the target cells in a manner dependent on the levels of target receptor 
expression. The versatility of UAN nanoparticles allows for reproducible and controlled 
conjugation of targeting ligands via the Ni-NTA/His-tag interaction for specific targeting of 
diverse disease markers, while facilitating encapsulation of various hydrophobic materials in the 
core. Though we only demonstrated this ability using DPA, FITC, camptothecin and celastrol, 
the encapsulation method should be applicable to a wide array of hydrophobic materials. A 
drug carrier system targeting molecules over-expressed in tumor or inflammation, such as 
ICAM-1, can be effective in not only targeting tumors overexpressing ICAM-1 but also tumor 
microenvironments, which have been shown to display characteristics of inflammation sites[49-
51]. Finally, the use of physiological ligands such as LFA-1 I domain used in this study may be 
superior to antibodies or short peptides in ensuring target specificity and preventing adverse 
immune responses associated with foreign antigens. 
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CHAPTER 3 
 
Tumor suppression via paclitaxel-loaded drug carriers that target inflammation marker 
upregulated in tumor vasculature and macrophages 
 
This chapter was originally published in Biomaterials (Park, S., Kang, S., Chen, X., Kim, E.J., Kim, J., Kim, N., Kim, J.Y., 
Jin, M.M. Biomaterials. 2013;34(2):598-605. ©2013 Elsevier.), and is reprinted with permission. The following is 
the detailed contribution of authors: S.P., M.M.J., and K.J.Y. designed research, performed research, and wrote the 
paper; S.K., X.C., E.J.K., J.K., and N.K. performed research. 
 
Summary 
 
Clinically approved chemotherapeutic nanoparticles may provide advantages over free 
drugs by achieving slower clearance and preferential accumulation in tumors. However, the 
lack of leaky vasculatures can create barriers to the permeation of ~100 nm-sized nanoparticles 
in solid tumors. We hypothesized that nanoparticles designed to target both tumor and tumor 
stroma would penetrate deeper into the tumors. To construct such comprehensive drug 
carriers, we utilized cross-linked amphiphilic polymer nanoparticles and functionalized them to 
target ICAM-1, a biomarker prevalent in various tumors and inflamed tumor stroma. The 
targeting moiety was derived from the modular domain present in L integrin, which was 
engineered for high affinity and cross-reactivity with human and murine ICAM-1. ICAM-1-
selective delivery of paclitaxel produced potent tumor suppression of not only ICAM-1-positive 
cervical cancer cells but also ICAM-1-negative tumors, presumably by causing cytotoxicity in 
tumor-associated endothelium (CD31+) and macrophages (CD68+) over-expressing ICAM-1. 
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Contrary to the strategies of targeting only the tumor or specific tumor stromal constituents, 
we present a strategy in delivering therapeutics to the major cellular components of solid 
tumors. Drug carriers against inflammation-biomarkers may be effective against many different 
types of tumors, while being less susceptible to the highly mutable nature of tumor markers. 
 
Introduction 
 
Achieving site-specific delivery of drug carriers, while minimizing unwanted distribution, 
has been one of the pursued goals in cancer therapy. Current drug carriers of ~100 nm in size 
can be selectively delivered into tumors through the enhanced permeability and retention 
(EPR) effect[1]. Several different nanoparticles employing the EPR effect have been approved 
for clinical use, e.g., Doxil and Abraxane. Tumor killing by non-molecularly targeted carriers may 
be accomplished via slow release of drugs within the tumor interstitial space or from the 
release of drugs inside cells after non-specific uptake[2]. However, current drug delivery 
systems fall short on achieving adequate concentrations of drugs in tumor cells in hypoxic 
regions as well as in malignancies that lack leaky vasculature, promoting the development of 
drug-resistance[3]. 
Much of the limitations of non-targeted nanoparticle-based drug carriers come from the 
fact that (i) leaky pores in tumor vessels are often sparsely distributed and some tumors 
completely lack well-perfused vasculatures, leading to heterogeneous or limited dissemination 
of nanoparticles[1, 4], (ii) increased interstitial pressure within tumors tends to rapidly clear 
nanoparticles distributed outside of cells, and (iii) surface modifications of drug carriers to 
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reduce non-specific uptake by phagocytic cells and opsonization also disfavor the uptake of 
nanoparticles by tumors[2, 5, 6]. 
To overcome such physiological barriers, local applications of hyperthermia[7], 
photosensitization[8], and ultrasound[9] have been used to increase the permeability of tumor 
vessels and thus, the penetration of drug carriers throughout the tumor. Alternatively, new 
types of nanoparticles to address the aforementioned problems have also been engineered. For 
example, drug carriers possessing the ability to target tumor stromal constituents, including the 
vasculature[10, 11] and/or tumor-associated macrophages[12], have shown promising results. 
Similarly, we have previously found that a molecule called intercellular adhesion molecule 
(ICAM)-1 was highly induced in endothelial cells within and in the vicinity of tumors[13]. ICAM-1 
is a cell adhesion molecule normally expressed at low levels in a variety of cell types but over-
expressed in inflammation and neoplastic conditions, likely due to the activation of the 
transcriptional factor, NF-B. ICAM-1 is upregulated in many carcinomas including breast, 
colon, non-small cell lung, and gastric tumors[14-19], where the overexpression of ICAM-1 is 
correlated with tumor progression, metastatic capability, and poor prognosis[20-22]. 
Upregulation of ICAM-1 within the tumor stroma is, therefore, consistent with the increasing 
reports on the implication of inflammation in tumor initiation, progression, and metastasis[23, 
24]. More importantly, it can be speculated that drug carriers designed to target ICAM-1 would 
be broadly effective in eradicating not only carcinoma cells expressing ICAM-1 but also those 
lacking ICAM-1 by killing the tumor stromal cells that are critical to tumor growth and 
metastasis. The delivery of drugs against multi-cellular components comprising tumors may 
also be less susceptible to the development of drug-resistance. 
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In order to create ICAM-1-specific drug carriers, we used a modular domain called the 
inserted (I) domain derived from the integrin, leukocyte function associated antigen-1 (LFA-1; 
also known as L2 or CD11a/CD18), where the I domain is the only region that provides 
molecular contact with ICAM-1. The I domain in its native sequence, separated from LFA-1, 
exhibits a low level of binding to ICAM-1, and was therefore engineered for high affinity and 
cross-reactivity with human and murine ICAM-1[25-27]. LFA-1 I domain’s reaction with murine 
ICAM-1 is an important property that permits selectivity studies of drug carriers against both 
the ICAM-1-expressing human tumors and the inflamed murine tumor microenvironment in 
mouse models of human cancer. At the same time, this feature enables us to analyze the 
unintended delivery to the low, yet widespread, expression of ICAM-1 in many different cellular 
types. As a drug carrier, we employed nanoparticles synthesized with cross-linked amphiphilic 
copolymer, providing a hydrophobic core for encapsulation of hydrophobic molecules and 
hydrophilic corona for stability in vivo as well as facile conjugation with targeting moieties[28]. 
Drug carriers designed to target markers prevalent in carcinomas and inflamed tumor 
microenvironment may prove effective against many different types of cancers. 
 
Experimental Procedures 
 
Production of high-affinity LFA-1 I domain 
Recombinant LFA-1 I domain with a His-tag at the N-terminal was produced in 
BL21(DE3) Escherichia coli cells (Invitrogen) as described previously[26]. Briefly, after protein 
induction with 1 mM IPTG (isopropyl--D-thiogalactoside), E. coli cells were resuspended in 10 
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ml of the washing buffer (50 mM Tris (pH 8.0), 23% w/v sucrose, 0.5% w/v Triton X-100, 1 mM 
ethylenediaminetetraacetic acid (EDTA)), sonicated, and centrifuged again to purify the 
inclusion body. The inclusion bodies were solubilized with 20 ml of the solubilization buffer (50 
mM Tris (pH 8.0), 6 M Guanidine-HCl) for 1.5 h at 4°C with stirring, after which the solution was 
diluted with 2 l of refolding buffer (50 mM Tris (pH 8.0), 10% glycerol, 1 mM MgCl2) and stirred 
slowly at 4°C overnight for the refolding process. Finally, the protein was concentrated down to 
1-5 ml (Amicon 3 kDa MWCO Millipore), filtered through a 0.45 mm filter (Nalgene), and 
purified by gel filtration chromatography (Superdex-75, GE Healthcare Life Sciences 
ÄKTApurifierTM). 
 
Preparation of I domain-coated urethane acrylate nonionomer (UAN) nanoplatforms 
The synthesis of cross-linked UAN bound to nickel-nitriloacetic acid (NTA-UAN) was 
previously described[29]. In brief, UAN consists of 1:3:2:1 molar ratio of glycerol 
propoxylate:toluene diisocyanate:2-hydroxyethyl methacrylate (HEMA):-polyethylene glycol 
(PEG). 50 mg of the UAN monomers were cross-linked by the reaction between the vinyl groups 
of HEMA in 10 ml of dimethyl sulfoxide (DMSO, Sigma Aldrich) at 65°C overnight with vigorous 
stirring, catalyzed by 2 mg of azobisisobutyronitrile (AIBN, Sigma Aldrich). The average 
molecular weight of the resulting UAN chains was 6700 Da (measured by mass spectrometer 
(MALDI Micro MX, Waters)) with a polydispersity of 2.0 (measured via ambient temperature gel 
permeation chromatography (GPC, Waters)). To incorporate the NTA moiety on the hydroxyl 
end of the PEG groups in polymerized UAN, 10 mg of N,N-Bis(carboxymethyl)-L-lysine 
hydrate (NTA analog, Sigma Aldrich) in 0.1 ml DMSO was mixed with 6.4 mg of TDI (molar ratio 
- 62 - 
 
of NTA to TDI was 1:1) for 2.5 h at room temperature to prepare NCO-terminated NTA-TDI 
complexes. Then the NTA-TDI solution was added to 5 ml of DMSO containing 50 mg of cross-
linked UAN and mixed overnight at room temperature to covalently link NCO of NTA-TDI to OH 
groups of UAN chains. In order to form nanoparticles, the cross-linked UAN chains dissolved in 
DMSO were diluted in HEPES buffer saline (HBS) at a volume ratio of 1:100 (DMSO:HBS). 
Previously, the size distribution (hydrodynamic radius) of NTA-UAN formulations 
encapsulating various hydrophobic agents was determined to be ~45-60 nm using dynamic light 
scattering (Malvern Instruments)[29]. In addition, transmission electron microscopy images 
revealed that bare UAN nanoparticles were spherical, uniformly sized, and well dispersed[29]. 
The payloads such as DiO (Invitrogen), DiR (Invitrogen), and Paclitaxel (PTX) (Sigma) were added 
to UAN chains in DMSO at 0-20% of UAN weight prior to dilution with HBS. The NTA moiety of 
UAN was charged with 10 mM NiCl2 for 30 min at RT. Excess payloads, NiCl2, and DMSO were 
removed via dialysis and subsequent concentration of the solution down to appropriate 
volume. Ni-NTA-UAN was then incubated with I domain at a weight ratio of 25:1 (Ni-NTA-UAN:I 
domain) at 4°C for 30 min to form I domain-coated cross-linked UAN (Id-UAN) before being 
used in subsequent experiments. 
 
EC50 analyses 
HeLa cells cultured in a 24-well plate were treated with 300 ml of the labeling buffer (pH 
7.4 PBS, 1% (w/v) BSA, 1 mM MgCl2) containing varying concentrations of UAN(PTX) (non-
targeted cross-linked UAN carrying PTX), Id-UAN(PTX) (I domain-bound UAN(PTX)), or PTX. The 
amount of PTX ranged from 0.1% to 17% of UAN (w/w). Ten minutes after the treatment, cells 
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were washed twice with the labeling buffer and resuspended in 300 ml of the culture media 
without FBS for 72 h. Cell viability was then measured by directly counting cells on a 
hemocytometer. Cells labeled with trypan blue were excluded in cell counting. 
 
Developing subcutaneous lipopolysaccharde (LPS) mouse model 
100 ml of LPS (1 mg/ml in PBS) and PBS were bilaterally injected into the lower flanks of 
7-week-old female severe combined immunodeficiency (SCID) mice. All animal experiments 
were conducted in compliance with the regulations defined by the Institutional Laboratory 
Animal Use and Care Committee of Cornell University. 
 
Developing subcutaneous tumor xenograft mouse model 
3x106 human cervical cancer HeLa cells and human embryonic kidney 293T cells mixed 
with Matrigel (BD) in equal volume (150 ml each) were injected bilaterally into front lower flank 
areas of 7-week-old female SCID mice. Once the tumor size reached approximately 100 mm3 (7-
10 days), mice were used for subsequent treatments. 
 
Near-IR optical imaging of mice 
Ex vivo imaging was performed 18-24 h after retro-orbital injection of UAN(DiR) or Id-
UAN(DiR) using an NIR camera (Luca, Andor Technology). Each injection consisted of 200 mg of 
UAN. Image analysis was performed using Matlab R2007a (MathWorks) and ImageJ (NIH). 
 
Tumor cytotoxicity assay 
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Mice were randomized into three groups (n = 10 each) for the following treatments 
given every 3 days for a total of three interventions: retro-orbital intravenous (i.v.) injection of 
HBS as a control, i.v. injection of 200 mg (UAN weight) of UAN(PTX), or i.v. injection of 200 mg 
(UAN weight) of Id-UAN(PTX). Tumor size was measured daily, while the blood collection from 
tail-vein (~200 l) and body weight measurement for the toxicity assays were carried out on the 
days of injection. 
 
Liver toxicity assay 
Blood samples from tail-vein collected in capillary tubes were snap-frozen in liquid 
nitrogen and kept at -80°C until being analyzed for the activity levels of aspartate transaminase 
(AST) and alanine transaminase (ALT) according to the manufacturer’s protocol (BioVision). 
 
Flow cytometry and immunofluorescence analysis of ex vivo tissues 
Tissues from tumors and other organs were collected from tumor bearing mice with or 
without in vivo injections of Id-UAN(DiO) or UAN(DiO). Harvested tissues were diced and 
digested with collagenase A (1 mg/ml) for 8 h before being strained. Collected cells were 
washed once with labeling buffer and incubated for 30 min using rat anti-mouse CD31 
monoclonal antibody (mAb) (MEC13.3, BD), rat anti-mouse CD68 mAb (FA-11, BioLegend), 
rabbit anti-murine ICAM-1 polyclonal antibody (M-19, SantaCruz), rabbit anti-human ICAM-1 
mAb (LB-2, SantaCruz). After labeling with primary antibodies, cells were washed with labeling 
buffer and incubated with anti-rat or anti-rabbit phycoerythrin (PE)-labeled secondary 
antibodies (Invitrogen). Subsequently, flow cytometry experiment was carried out to measure 
- 65 - 
 
the fluorescence intensity of DiO as well as the antibodies (Beckman Coulter EPICS XL-MC). The 
data were analyzed using FlowJo (Tree Star). 
 
Statistical analysis 
Data were expressed as mean ± standard deviation of at least triplicate samples. Two-
way ANOVA and Bonferroni post hoc test were carried out in order to assess which groups 
significantly differed from others. All of the statistical analyses were performed using GraphPad 
Prism 5 (Graphpad Software). 
 
Results 
 
Biodistribution, selectivity, and toxicity of drug carriers 
Prior to testing the efficacy of ICAM-1-specific nanoparticles in eradicating tumors, we 
first evaluated their biodistribution, selectivity to ICAM-1, and toxicity with or without surface 
conjugation with I domain. The engineered I domain we utilized in this study contains 
F265S/F292G mutations and binds human and murine ICAM-1 with high affinity (2 nM KD)[30]. 
Cross-linked UAN nanoparticles contain a core formed by polypropylene oxide networks, which 
can retain hydrophobic molecules at up to 20% w/w of UAN, and exhibit slower release kinetics 
with increasing hydrophobicity of payloads[29]. Almost irreversible retention of water-insoluble 
near-infrared dye, DiR, by cross-linked UAN suspended in an aqueous solution was exemplified 
by negligible partitioning of DiR into chloroform, while free DiR was almost entirely dissolved in 
chloroform (Fig. 3.1A). 
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Biodistribution of UAN(DiR) or Id-UAN(DiR) into the major organs and the sites of 
interest was quantified by near-infrared imaging of organs ex vivo. Two different mouse models 
were chosen to examine the difference in biodistribution caused by the presence of I domain 
on UAN: (1) untreated mice to assess the targeting of basal expression of ICAM-1 and (2) mice 
with subcutaneous injection of lipopolysaccharide (LPS) to examine the ability of Id-UAN to 
localize to the site of ICAM-1 over-expression. Major organs and the subcutaneous treatment 
sites were harvested 18 h post-injection of UAN particles for biodistribution analysis. In 
untreated mice, irrespective of the conjugation with I domain, liver and spleen accounted for 
66% of UAN nanoparticles that accumulated into major organs (Fig. 3.1B). Although at much 
lower levels, Id-UAN(DiR) showed a higher level of accumulation than UAN(DiR) in lungs and 
kidneys. Next, using a mouse model with subcutaneous bilateral injections of LPS and PBS (12 
h), we examined the influence of localized induction of ICAM-1 on nanoparticle distribution 
(Fig. 3.1C). Notably, the presence of I domain on the surface of UAN caused a 3-fold higher 
concentration at the LPS injection site compared to the PBS injection site. In contrast to Id-
UAN(DiR), UAN(DiR) accumulated significantly less into both LPS and PBS sites, displaying 
insignificant difference between the two regions. Although the overall pattern of 
biodistribution into the major organs in LPS mouse model was comparable to that of the 
untreated mice, the higher level of uptake was observed in the liver and spleen, likely caused by 
the LPS seeping into circulation and triggering a mild systemic inflammation. This would then 
enhance the phagocytic activity of immune cells and dilate the vessels, resulting in elevated 
accumulation into some of the major organs. 
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The high accumulation of the particles in the liver, however, raised a concern for 
possible systemic side effects. We carried out a liver toxicity assay by measuring the serum 
activity levels of aspartate transaminase (AST) and alanine transaminase (ALT), two enzymes 
that often serve as markers for liver damage (Fig. 3.1D). AST and ALT levels measured between 
0 and 48 h after LPS injection, used to artificially induce liver toxicity were gradually elevated, 
peaking at 24 h and dropping back to normal levels by 48 h. In contrast, ALT/AST levels after 
UAN(DiR) injection remained below the threshold for liver toxicity, and did not differ greatly 
from mice treated with PBS. 
 
Tumor targeting: tissue- and cell-level distribution analysis 
To confirm the selectivity of UAN conferred by the I domains toward ICAM-1 over-expressed in 
tumors or in inflamed tumor stroma, we used a mouse model harboring bilateral subcutaneous 
xenografts of ICAM-1-positive HeLa and ICAM-1-negative 293T tumors. When tumors grew to 
~100 mm3 in size, mice were intravenously injected with UAN nanoparticles and imaged at 24 h 
post-injection. Id-UAN(DiR) was found at both tumor sites, whose fluorescence levels were 
significantly higher than those in the tumors injected with UAN(DiR) (5.1-fold in HeLa and 2.1-
fold in 293T tumor) (Fig. 3.2A). Furthermore, 2.9-fold increase in accumulation into HeLa over 
293T was observed with Id-UAN(DiR), while comparable amounts were found in both tumors 
with UAN(DiR). 
We then examined if increased delivery of Id-UAN(DiR) into 293T tumor was from 
targeting of ICAM-1 induced in tumor stromal cells, such as vasculature endothelium and/or 
tumor-associated macrophages. To first confirm if 293T cells have induced ICAM-1 in the course 
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Figure 3.1: Biodistribution, selectivity, and toxicity of drug carriers.  
(A) Partitioning of DiR from chloroform into the hydrophobic core of UAN dispersed in PBS. 
0.05 mg of DiR was dissolved in 0.05 ml of DMSO or DMSO containing cross-linked UAN (1 mg) 
before being added to a liquid bilayer of PBS/chloroform (0.5 ml each) and shaken gently for 
4 h. (B) NIR imaging and quantification of UAN(DiR) and Id-UAN(DiR) dispersed throughout the 
major organs after intravenous injection at 24 h post-injection (n = 6; a.u. = arbitrary unit). (C) 
UAN(DiR) and Id-UAN(DiR) distribution at 24 h post-injection in LPS mouse model. 
Nanoparticles were injected 12 h after subcutaneous LPS/PBS injection (n = 4). (D) Liver toxicity 
of UAN(DiR) compared to LPS and PBS. Bar graphs represent serum activity levels of ALT and 
AST (n = 6) (Error bars are standard deviations (SD) *p < 0.05, ***p < 0.001; Two-way ANOVA 
test followed by Bonferroni post hoc test). 
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of tumor growth, we carried out immunofluorescence flow cytometry on the cells isolated from 
untreated HeLa and 293T tumors (Fig. 3.2B). From labeling of cells with antibodies against 
human or murine ICAM-1 (CD54), we found only murine ICAM-1 was induced in 293T tumors 
while both human and murine ICAM-1 were present in HeLa tumors, proving the lack of ICAM-1 
expression in 293T cells and upregulation of ICAM-1 in tumor stromal cells. Next, to test if 
CD31+ and CD68+ cells were the cellular types responsible for the presence of ICAM-1 in tumor 
stroma, we labeled the cells isolated from tumors with antibodies against ICAM-1 along with 
antibodies against either CD31 or CD68. Indeed, significantly higher percentage of tumor-
associated CD31+ and CD68+ cells exhibited over-expression of ICAM-1, while corresponding 
cellular types derived from skin and spleen were mostly negative for ICAM-1 expression 
(CD31/CD68 from skin; CD31 from spleen) or induced at lower levels (CD68 from spleen) (Fig. 
3.2C and D). 
Tumor-targeting nanoparticles that have escaped from circulation through leaky 
vasculature would diffuse through the tumor interstitial space. Subsequent uptake of these 
particles is influenced by the intrinsic properties of particles (i.e., size, charge, shape) and the 
presence of active molecular targeting moieties. Therefore, some of the signals coming from 
the tumors and organs may be due to the particles being merely trapped in the extracellular or 
interstitial space. Since UAN nanoparticles are designed to deliver drugs directly into cells for 
effective cytotoxicity rather than through slow release within extracellular space, we carried 
out flow cytometry to quantify cellular uptake of UAN particles loaded with a hydrophobic 
green fluorescent dye, DiO (Fig. 3.2E). Similar to the tissue-level analysis, Id-UAN(DiO) was 
taken up by higher percentages of cells harvested from both tumors, with DiO+ cells in HeLa  
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Figure 3.2: Tumor targeting: tissue-/cell-level distribution analysis.  
(A) Major organs and tumors at 24 h post-injection of nanoparticles. Mice bearing bilateral 
HeLa and 293T tumors were injected with either UAN(DiR) or Id-UAN(DiR) (n = 8). (B) CD54 
induction in tumor stroma. Cells isolated from untreated HeLa/293T tumors were labeled with 
antibodies against human (hCD54) or murine ICAM-1 (mCD54). (C and D) Cells isolated from 
tumors (C: 293T, D: HeLa), skin, and spleen were dual-labeled for mCD54 and mCD68/mCD31 to 
identify cellular types expressing mCD54. Numbers indicate the percentage of gated 
populations of cells isolated from tumors. (E) Differentiating cellular uptake of UAN particles 
from those trapped in an extracellular space. Fluorescence of isolated cells from tumors was 
measured using flow cytometry (n = 4). Specificity of Id-UAN(DiO) against ICAM-1 is shown in 
pie charts. After injection of Id-UAN(DiO) or UAN(DiO), cells from tumors were isolated and 
labeled with antibodies against hCD54 or mCD54. (F) Mice carrying bilateral HeLa and 293T 
tumors were intravenously injected with Id-UAN(DiO) (orange), UAN(DiO) (green), or PBS 
(black) 24 h preceding the excision and cell isolation. The cellular components of tumors 
labeled with Id-UAN(DiO) vs. UAN(DiO) were identified via labeling for mCD31, or mCD68 (Error 
bars are SDs. *p < 0.05, ***p < 0.001; two-way ANOVA test followed by Bonferroni post hoc 
test.).  
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tumor being 2.0-fold higher compared to the DiO+ cells in 293T. Cellular uptake of Id-UAN 
nanoparticles in both tumors was specific to ICAM-1; 50-80% of DiO-positive cells were also 
positive for either human or murine ICAM-1 (Fig. 3.2E; shown in the pie charts). Cellular-level 
analysis, however, showed that larger amounts of nanoparticles were internalized by the 
tumors than the organs (e.g., liver and spleen) which is in contrast to the ex vivo imaging of the 
organs and tumors that showed higher levels in the organs. This discrepancy, therefore, should 
point to the possibility of the particles being present in the extracellular spaces of these organs, 
causing them to be removed during the process of isolating cells for flow cytometry. 
In order to quantify the percentage of tumor stromal cells that had internalized Id-
UAN(DiO) and UAN(DiO), HeLa and 293T tumors were excised and digested for another series 
of flow cytometry analyses, conducted at 24 h after the injection of Id- UAN(DiO) and 
UAN(DiO). Collected cells were labeled with antibodies against CD31 and CD68. We found that 
among DiO-positive cells that were analyzed, 35-60% of the cells were positive for CD31 or 
CD68, proving that Id-UAN(DiO) was indeed taken up by both the vasculature endothelium and 
macrophages, as the two major constituents in tumor stroma (Fig. 3.2F). 
 
Greatly enhanced EC50 via molecular interaction-guided drug delivery 
In an attempt to validate UAN as an effective drug delivery vehicle, we used paclitaxel, a 
water-insoluble chemotherapeutic drug. After encapsulation of PTX, we first examined the 
effectiveness of Id-UAN(PTX) in specifically attenuating the growth of ICAM-1-expressing cells in 
vitro (Fig. 3.3A). HeLa cells were exposed to either free paclitaxel, UAN(PTX), or Id-UAN(PTX) for 
only 10 min to model the transient exposure of drugs to a tumor in an in vivo system. Cells 
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were then cultured for 72 h prior to cell viability quantification. Compared to UAN(PTX), which 
would induce cell death through slow release of PTX or non-specific uptake, the attachment of 
the I domain to the particles drastically improved the cytotoxic effects (EC50 = 1 M by Id-
UAN(PTX) vs. 37.5 M by UAN(PTX)), highlighting the added advantage of active targeting for 
drug carriers such as UAN. Free PTX resulted in EC50 = 63 M, significantly higher than those 
reported in other studies with longer incubation times, indicating PTX was not efficiently taken 
up by the cells during the 10-min exposure. Possible cytotoxic effects induced by UAN particles 
themselves were also examined by treating the cells with only the carrier, Id-UAN, at different 
concentrations. The results demonstrated that empty vehicles on their own (EC50 = 4.4 mg/ml) 
would have minimal cell killing effect at the concentrations used in the subsequent in vivo 
experiments (200 g of UAN per mouse). The difference in cytotoxicity made by the presence 
of I domain on the surface of UAN was reexamined using the following PTX concentrations: 35, 
1, and 0.2 M (Fig. 3.3B). Although all other formulations were only marginally effective at PTX 
concentrations up to 35 M, Id-UAN(PTX) was able to confer ~50% specific cell death at 1 M. 
 
Molecular interaction-guided tumor attenuation and systemic toxicity in vivo 
After confirming selective delivery by the I domain, which targeted not only ICAM-1-
positive tumor cells but also the stromal cells over-expressing ICAM-1, we evaluated the 
therapeutic efficacy of paclitaxel-loaded UAN particles in HeLa and 293T tumor xenografts. 
When the tumors reached a size of ~100 mm3, mice were intravenously injected three times 
over 6 days with PBS, UAN(PTX), or Id-UAN(PTX). 3-4 days after the last injection, mice were 
sacrificed for further ex vivo analyses (Fig. 3.4A). Consistent with the tissue- and cellular-level  
- 73 - 
 
 
 
 
 
 
 
Figure 3.3: In vitro EC50 comparison between Id-UAN(PTX), UAN(PTX), and PTX.  
(A) HeLa cells subcultured in 24-well plates were treated for 10 min with varying concentrations 
of Id-UAN(PTX), UAN(PTX), PTX, or Id-UAN. At 72 h, cells were stained with trypan blue for 
differentiation of live/dead cells (n = 3). (B) Cell viability at select concentrations of PTX is 
shown in a bar graph (Error bars are SDs. *p < 0.05, ***p < 0.001; Two-way ANOVA test 
followed by Bonferroni post hoc test). 
 
 
 
 
 
- 74 - 
 
biodistribution of UAN particles (Fig. 3.2), Id-UAN(PTX) treatment resulted in significant 
inhibition of tumor growth in both HeLa and 293T tumors (Fig. 3.4B), while little inhibition was 
observed in mice treated with UAN(PTX) compared to the PBS control (Fig. 3.4C). The image of 
the tumors recapitulated the notable difference between the efficacy of Id-UAN(PTX) and 
UAN(PTX) in tumor suppression (Fig. 3.4D). In addition to the difference in tumor size, the 
tumors treated with UAN(PTX) appeared darker due to abundant vasculatures in these tumors. 
On the other hand, tumors from mice administered with Id-UAN(PTX) seemed to lack the dark-
red appearance, possibly due to the disruption of the tumor-associated vessels. Here, it needs 
to be reemphasized that the growth inhibition of 293T tumors by Id-UAN(PTX) should mainly 
come from the delivery of paclitaxel into the tumor stroma, presenting an evidence for tumor 
suppression achieved via drug carriers targeting the inflamed tumor microenvironment. To 
gauge the potential use of targeted UAN as drug carriers in clinics, we carried out a systemic 
toxicity assay associated with Id-UAN(PTX) by measuring the activity levels of ALT/AST enzymes 
in serum as well as the body weight of the mice (Fig. 3.4E and F). The ALT activity levels 
increased slightly 9-12 days after the first treatment but were below the levels indicative of 
liver toxicity (~56 mU/ml). Overall, no significant differences in ALT/AST levels and the rate of 
increase in body weight during the treatments were observed between the mice treated with 
UAN(PTX) and those treated with Id-UAN(PTX). Despite Id-UAN(PTX)’s cytotoxic effect on the 
tumors, the low to minimum levels of liver toxicity as well as the normal rate in body weight 
increase indicate that the particles were inert to non-specific interaction and were residing 
mostly in the extracellular space in the major organs. 
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Figure 3.4: Effects of Id-UAN(PTX) therapy on tumor growth in HeLa/293T xenografts and 
toxicity.  
(A) Timeline of tumor xenograft, nanoparticle injections, and ex vivo analysis is shown. (B) Mice 
bearing bilateral HeLa and 293T tumors were injected with either PBS, UAN(PTX), or Id-
UAN(PTX). Tumor size in each mouse was measured daily. The difference in tumor size due to 
the treatment with Id-UAN(PTX) vs. UAN(PTX) was statistically significant beginning on day 3 for 
293T and day 2 for HeLa (p < 0.001). (C) Change in tumor volume in mice receiving PBS. (D) 
Representative image of tumors excised from each group (scale bar, 5 mm). (E) Mean body 
weight of mice after each round of injections of UAN(PTX) or Id-UAN(PTX) on days 0, 3, 6, and 9. 
(F) Measurement of activity levels of ALT and AST in serum over the course of treatment. Blood 
was collected on days 0, 3, 6, and 9, prior to injection of nanoparticles (error bars are SDs). 
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Discussion 
 
Utilizing polymeric nanoparticles as drug carriers, here we report that molecular 
markers induced in pro-inflammatory tumor microenvironment may provide a therapeutic 
strategy that is applicable to the suppression of different types of tumors independent of their  
tumor surface antigens. Among the surface markers that closely follow the degree of 
inflammation, we have chosen ICAM-1, a molecule that is rapidly upregulated in response to 
inflammation. With a targeting moiety against ICAM-1 incorporated into our nanoparticles, 
UAN was found to be internalized into not only ICAM-1-positive tumors but also the tumor-
associated vasculature (CD31+) and macrophages (CD68+). The ability of ICAM-1-targeted 
nanoparticles to deliver paclitaxel into CD31/CD68-positive cells resulted in suppression of 
ICAM-1-negative 293T tumors. 
Nanoparticle-based drug carriers that are devoid of molecular targeting rely heavily on 
leaky tumor vessels. However, tumor vessels available to many drug carriers of ~100 nm in size 
are sparsely distributed, particularly near high-level expression of vascular endothelial growth 
factor receptors[31]. Though nonleaky tumor microvasculature may still be permeable to 
molecules much smaller (less than ~12 nm), the large size of most drug carriers renders them 
inadequate for delivery in this route[32]. In order to address this problem, substantial research 
has been dedicated to identifying molecular markers in tumor-associated vasculature, also 
called the ‘vascular zip codes’[10]. The luminal side of tumor-associated vessels is available to 
blood-borne particles and, once bound, the drug carriers can easily access the tumor 
interior[33]. Several molecules have been reported to be over- or uniquely expressed in tumor-
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associated vessels and used as therapy targets (e.g., v integrin[10, 34, 35]; ED-B domain of 
fibronectin[11], and VCAM-1[36]). Recently, it has been demonstrated that VCAM-1, a cell 
adhesion molecule that interacts with 41 integrin, was induced in the cerebral vasculature in 
the vicinity of brain metastases[36, 37]. Similarly, we have found overexpression of ICAM-1 in 
the vascular endothelium associated with tumors[13, 38-40]. Multimeric binding and clustering 
of ICAM-1 triggers cellular internalization of bound particles, and it has been shown that ICAM-
1 can be recycled back to the cell surface after endocytosis[41], providing a mechanism to 
deliver drug agents in repeated doses. We have also found that ICAM-1 is induced in other 
tumor microenvironment mediators besides tumor-associated endothelium, such as 
macrophages and the tumors themselves[38, 41-43]. Hence, using a targeting probe with 
tumor-homing properties for a molecular signature shared between tumor stroma and tumor 
cells can provide synergistic advantages. 
The majority of drug carriers are designed to either induce nonspecific cellular uptake or 
rapidly release drugs outside of cells after extravasation into or in the vicinity of tumors to 
achieve maximum therapeutic effect. However, nanoparticles possessing such properties would 
inevitably cause systemic toxicity as they would be prone to release cytotoxic drugs to 
phagocytic and parenchyma cells in major organs[2]. UAN nanoparticles used in this study 
were, however, designed to encapsulate and stably retain hydrophobic molecules. Without 
internalization into the cells, the release rate of cancer drugs from UAN would be too slow to 
produce significant cytotoxicity[29]. Polyethylene moiety forming the outer layer of UAN was 
introduced to greatly reduce opsonization and non-specific uptake by parenchyma and 
phagocytic cells. These properties of UAN nanoparticles in the absence of active targeting led to 
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their accumulation mainly into interstitial space within the major organs, resulting in low levels 
of toxicity. The insignificant tumor attenuation by the non-targeted UAN is also ascribed to the 
need for a much higher dose of PTX required to have cytotoxic effects compared to that of 
ICAM-1-selective delivery (EC50 = 1 M with targeted vs. 37.5 M with non-targeted). The 
nickel-NTA moiety present at the terminal hydroxyl group of polyethylene makes UAN particles 
highly versatile for facile conjugation with targeting ligands with a His-tag, obviating highly 
unpredictable chemical conjugations. The ability of drug carriers to actively bind target cells is 
vital to lessen the barriers created by the elevated interstitial fluid pressure[39, 44, 45], which 
retards the penetration of drug carriers deep into tumors and even forces them back into 
circulation. Rapid binding and subsequent receptor-mediated endocytosis, therefore, may 
overcome such limitations of many non-targeted drug carriers. 
 
Conclusions 
 
In this work, we have successfully engineered polymeric drug carriers to target ICAM-1-
expressing tumors as well as inflamed tumor microenvironment. UAN has exhibited its 
advantages as a targeted drug carrier for its ability to evade the mononuclear phagocytic 
system and cause low levels of systemic toxicity. By targeting an inflammatory marker in tumor 
vessels, Id-UAN particles may act as a double-edged sword: Not only will they be able to localize 
drug delivery to the tumor site, they may also inhibit the infiltration of LFA-1-expressing pro-
tumor immune cells by occupying ICAM-1 on endothelium or by promoting internalization of 
the receptors. As demonstrated with ICAM-1-negative 293T tumor, the upregulation of ICAM-1 
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in the tumor environment can be utilized to deliver chemotherapeutics to tumors lacking 
unique markers. UAN’s ability to encapsulate and deliver a cocktail of hydrophobic drugs may 
also aid in addressing the problems of drug-resistance. 
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CHAPTER 4 
Affinity-tuned leukocyte integrin chimeric antigen receptor T cells for increased therapeutic 
index against tumors in mice 
Summary 
 
Due to the lack of tumor-specific antigens that demarcate tumor from normal tissue, on-
target off-tumor toxicity has become a significant hurdle encountered in the development of 
chimeric antigen receptor (CAR) T cells for solid tumors. The target antigen recognition site 
within the CAR design is often a single chain variable fragment (scFv) derived from antibodies 
that exhibit affinities that are sufficiently high to bind physiologic levels of target antigens. In 
this study, we have replaced the scFv region with a natural ligand recognizing an adhesion 
molecule that is highly inducible in inflammatory settings, such as tumor microenvironment. By 
tuning the affinities of CAR, we engineered T cells to have a wide range of binding capabilities 
against target. A panel of CAR T cells with affinities varying over six orders of magnitude was 
generated to functionally screen for CAR T cells that can discriminate tumors and stromal cells 
overexpressing target from normal tissues that express it at physiologic levels. High-affinity CAR 
T cells recognized the target antigen at all levels of expression, consistently leading to fatalities 
in hosts. Affinity-tuning, however, allowed us to isolate CAR T cells displaying robust antitumor 
efficacy while sparing normal cells expressing low target density. The proposed affinity-tuning 
methodology endows the potent CAR T cell technology a strategy to selectively target antigens 
overexpressed on solid tumors with improved therapeutic index. 
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Introduction 
  
 Chimeric antigen receptor (CAR) T cells are composed of synthetic binding moieties that 
direct T cells to target antigens for subsequent eradication. Using this technology, adoptive 
immune therapy has achieved extraordinary success in eradicating blood-borne cancers, 
prominently, the CD19 CAR T cells in B cell leukemias and lymphomas[1-4]. However, the 
application of this powerful technology in solid tumors has been limited due to the scarcity of 
tumor antigens that are deemed safe for targeting. As such, in spite of the increasing clinical 
trials focusing on solid tumor target antigens[5, 6], the clinical results have not been promising 
and ways to improve the performance are being actively investigated. 
 Ideally, a target tumor antigen is highly expressed on the surface of tumor cells but not 
on healthy normal tissues. However, many commonly targeted tumor antigens, such as human 
epidermal growth factor receptor 2 (ErbB2), epidermal growth factor receptor (EGFR), mucine 1 
(MUC1), prostate-specific membrane antigen (PSMA), and diganglioside (GD2)[5] are also 
expressed by non-tumor tissues. This means with sufficiently high affinity to such antigens, 
healthy cells can also be recognized by CAR T cells. Toxicities arising from this, known as on-
target, off-tumor toxicity, has therefore become the major limiting factor in the progress of CAR 
technology. Though in the case of CD19 CAR T cells, the expression of CD19 on all B cells has not 
been a critical factor since depletion of B cells is manageable, recent reports on severe adverse 
toxicities associated with CAR T cells[7-9] illustrate the importance of ligand/receptor pair 
selection for safe and efficient therapy.  
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 The single chain variable fragment (scFv) domain of the CAR design against target 
antigen is derived from antibodies selected for high affinity to target. Though this trait allows 
CAR T cells to bind efficiently to target tumor cells, it also renders it difficult for CAR T cells to 
distinguish between tumor cells and normal tissues expressing lower levels of antigen. Such 
methods for generating CARs by selecting high affinity scFvs have shown to exhibit lower 
activation thresholds compared to low affinity scFvs[10]. In addition, others have found that 
there is an optimum range of recognition affinity for T cell activation, and further increasing the 
affinity only decreases selectivity[11, 12].  
 In this study, we have equipped T cells with affinity-tuned CARs that specifically target 
intercellular adhesion molecule (ICAM)-1, a molecule that has been shown to be dynamically 
upregulated in many carcinomas compared to normal tissues. The recognition domain of this 
CAR design is composed of the inserted (I) domain of a leukocyte integrin called lymphocyte 
function-associated antigen (LFA)-1. Previously, the I domain has been engineered using 
directed evolution to isolate variants exhibiting affinities to ICAM-1 that spanned six orders of 
magnitude (KD ~1 nM to 1 mM)[13]. We found that increasing the affinity of I domain to the 
natural TCR/pMHC affinity range could significantly increase the therapeutic index of CARs, 
while increasing the affinity further caused unbiased reactivity against all ICAM-1-expressing 
cells. After arming CAR T cells with the various I domain mutants, we sought to determine 
whether the ability of T cells to discriminate tumors from normal tissues could be recovered at 
lower affinities. Since human LFA-1 I domain exhibits the unique quality of cross reacting with 
both murine and human ICAM-1 with comparable affinities[14], it allowed for simultaneous 
comparison of performance against high density of human ICAM-1 expressed on tumors and 
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low density murine ICAM-1 expressed on normal tissue. To our knowledge, this study presents 
the first robust examination of on-target, off-tumor toxicity to host in a preclinical setting.  
 
Experimental Procedures 
 
Cell lines and primary human lymphocytes 
Human dermal microvascular endothelial cells (HMEC-1) were obtained from the Center 
for Disease Control. HMEC-1 was cultured in MCDB 131 medium (Invitrogen) supplemented 
with 10% (v/v) fetal bovine serum (FBS; Atlanta Biologicals), 10 mM L-alanyl-L-glutamine 
dipeptide (Gibco), Penicillin-Streptomycin (Pen-strep; 100 units/ml), 1 ug/ml hydrocortisome 
(MP Biomedicals), and 10 ng/ml recombinant human epidermal growth factors (Invitrogen). 
Mouse brain microvascular endothelial cells (bEnd.3, ATCC) were maintained in Advanced 
Dulbecco’s Modified Eagle Medium (DMEM) medium supplemented with 4 mM L-glutamine, 
Pen-strep, and 10% FBS. HeLa cells (ATCC) were cultured in Advanced DMEM medium 
(Invitrogen) containing 10% FBS, 2 mM L-glutamine, and Pen-strep. 8505c cells (DSMZ) were 
cultured in RPMI-1640 medium (Invitrogen) containing 10% FBS, 2 mM L-glutamine, and Pen-
strep. HMEC-1, bEnd.3, HeLa, and 8505c cells were transduced with lentivirus encoding Firefly 
Luciferase-F2A-GFP (Biosettia) followed by fluorescence activated cell sorting (FACS) to purify 
GFP expressing cells.  
Human peripheral blood was obtained from healthy volunteer donors by venipuncture. 
Peripheral blood mononuclear cells (PBMC) were isolated over Ficoll-Paque PLUS (GE 
Healthcare) and cultured in GIBCO Optimizer CTS T-cell Expansion SFM (Thermo) supplemented 
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with 5% human AB serum (Sigma), 2 mM L-alanyl-L-glutamine dipeptide, Pen-Strep, and 30 
IU/ml human IL-2 (Cell Sciences). Non-adherent cells were removed after 24hr and magnetically 
enriched for T cells with Dynabeads CD3/CD28 T cell expander (Thermo) at a 2:1 bead:T cell 
ratio. Dynabead-bound T cells were subsequently cultured in IL-2 containing media at a density 
of 1 - 2 x 106 cells/ml. All cells were incubated at 37°C in a 5% CO2 humidified incubator. 
 
Construction of I domain mutant CAR genes  
The genes for LFA-1 I domain exhibiting varying affinities to ICAM-1 were derived from 
the a previous study[13]. I domain variants were then fused with the transmembrane and 
cytoplasmic domains of CD28, CD137, and CD3 of an independent third generation CAR gene 
(a kind gift from Dr. Carl June at University of Pennsylvania[15]). The complete CAR inserts were 
then subcloned into a pLenti backbone.  
 
Lentivirus production and transduction of T cells  
Lentivirus was produced by transiently transfecting HEK 293 cells using calcium 
phosphate. Briefly, 10 µg of transfer gene, 7.5 µg of pCMV-dR8.2 (Addgene) and 5 µg of pCMV-
VSVG (Addgene) were mixed and incubated with 2 M CaCl2 followed by 2x HBSS. Resulting 
solutions were added dropwise to 10 cm2 cell culture dishes seeded with 3.2 x 106 HEK 293 in 
10 ml DMEM 24hr previously. Transfection media was replaced after 6 hr.  Media containing 
lentivirus was harvested at 48 and 72hr post transfection, filtered through 0.45 µm filters, and 
concentrated by ultracentrifugation at 75,000x g for 2hr at 4°C. Lentivirus was then 
resuspended in serum containing media at an approximate titer of 108/ml and frozen at -80°C. 
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Human T cells were transduced 24 - 72hr post activation with anti-CD3/CD28 Dynabeads either 
by spinfection at 1,000x g for 1hr at 32°C or by overnight incubation of lentivirus in the 
presence of Synperonic F108 (Sigma)[16]. T cells were transduced once more 24hr after initial 
transduction. During and following transduction, media containing IL-2 was replaced with 
media containing human IL-7 (10 ng/ml) and IL-15 (5 ng/ml) (Peprotech). Jurkat T cells were 
transduced by a single incubation with lentivirus overnight in the presence of Synperonic F108. 
 
Luciferase-based cytolytic T cell assay 
2 x 105 target cells (HMEC-1, bEnd.3, HeLa, and 8505c) stably transduced to express GFP 
and firefly luciferase were co-cultured with either non-transduced or I domain CAR T cells at 
varying E:T ratios as indicated. In additional conditions, the ICAM-1 gene was deleted from 
8505c using CRISPR (Santa Cruz, #sc-400098; denoted as 8505c-) or 8505c was exposed to 
lipopolysaccharide (LPS) for 12 hours and washed prior to the assay to induce the expression 
level of ICAM-1 (denoted as 8505c+). Co-cultures were carried out in T cell culture medium 
containing 150 µg/ml D-Luciferin (Gold Biotechnology) with no cytokine supplementation.  
Luminesence was measured with a plate reader (TECAN infinite M1000 PRO) with readings in 
each E:T condition normalized to the non-transduced T cell:target co-culture controls.  
 
8505C mouse model, measurement of ex vivo organs and whole-body tumor growth  
7.5 x 105 8505c cells were injected into NSG mice via tail vein. 3 x 106 T cells were 
injected via tail vein 10 days after tumor cell injection. Luminescence imaging of tumor 
xenografts in live mice was performed using a whole body optical imager (In-Vivo Extreme, 
- 89 - 
 
Bruker). Mice were anesthetized first with 3% isoflurane in 2 L/min O2 and subsequent to this, 
maintained at 2% isoflurane in 2 L/min O2. Tumor burden was estimated by integration of 
luminescence over chest cavity and the entire mouse body.  
  
Flow cytometry  
Tumor xenografts were resected from mice at appropriate time points. Resected tumors 
were diced and flushed through an 80 µm cell strainer to yield single cell suspensions. Red 
blood cells were lysed by incubating with 1x RBC lysis buffer (eBiosciences). Remaining cells 
were washed, re-suspended in 1x HBSS containing 2% normal goat serum, and then blocked 
with mouse IgG at 2 µg/ml for 10 min. This was followed by staining with 1 µg/ml Propidium 
Iodide (Invitrogen) in combination with 2 µg/ml murine anti-human CD3-Alexa Fluor 647 
(Biolegend) or 2 µg/ml rabbit anti-c-myc-Alexa Fluor 647 (Biolegend). Flow cytometry gates 
were determined based on live cell gating (Propidium Iodide negative). ICAM-1 expression on 
tumor cell lines was determined using a murine anti-human R6.5 monoclonal antibody (10 
µg/ml) obtained from hybridoma (ATCC). I domain-CAR expression on T cells was detected 
using 2 µg/ml rabbit anti-c-myc-Alexa Fluor 647 (Biolegend).  
 
ICAM-1 binding assay 
I domain Jurkat T cell variants were incubated with 10 ug/ml recombinant human ICAM-
1 fused to human Fc (R&D Systems). The cells were then washed and resuspended in 1 ug/ml 
rabbit anti-human PE (Santa Cruz Biotechnology) prior to FACS analysis.  
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ELISA assays 
Target cells were washed and suspended at 1 × 106 cells/ml in T cell culture medium 
without cytokines. 100 μl each target cell type was added in triplicate to a 96-well round 
bottom plate (Corning). Effector T cells were washed and resuspended at 5 × 106 cells/ml in T 
cell culture medium without cytokines and then 100 μl of T cells were combined with target 
cells in the indicated wells. The plates were incubated at 37°C for 24 - 48 hours. After the 
incubation, supernatant was harvested and subjected to an ELISA assay (Biolegend). 
 
CD25 staining 
Cells were plated at an effector to target ratio of 1:1 (1 × 105 effectors: 1 × 105 targets) 
in 150 μl of Jurkat cell culture medium in a 96-well plate. The plate was incubated at 37°C for 6 
hours. After incubation, the cells were washed with PBS containing 0.1% bovine serum albumin 
(BSA) (FACS buffer) prior to being labeled with 2 ug/ml anti-human CD25-allophycocyanin (APC; 
Biolegend) for 30 minutes on ice. After incubation, samples were washed with the FACS buffer 
and analyzed by flow cytometry. 
 
Statistical analysis  
One-way ANOVA and unpaired Student’s t-test were performed using Prism (GraphPad) 
on data indicated. 
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Results 
 
Altering the affinity of I domains against ICAM-1 
Monovalent affinities of the LFA-1 I domain variants for ICAM-1 span six orders of 
magnitude (KD ~1 nM to 1 mM) as measured by surface plasmon resonance (SPR) or flow 
cytometry (Fig. 4.1A)[13]. Various I domain mutations in the region known as the metal-ion 
dependent adhesion site (MIDAS; F265S) and the C-terminal 7-helix (F292A, F292G), whose 
downward shift has been shown to cause allosteric changes in the conformation of MIDAS, led 
to step-wise increases in the affinity against ICAM-1 (Fig. 4.1B). A combination of mutations 
(F265S/F292G) coupled with an insertion of a disulfide bond to stabilize the MIDAS in its high-
affinity conformation (G311C), has led to a remarkable increase in the affinity, dubbed triple-
mutant (TM). Together, the affinity of wild-type I domain to ICAM-1 was increased from 1500 
mM to 1 nM (Table 1), to allow a rigorous study on the effect of protein binding affinity in CAR 
T cell therapy. An additional advantage of using human I domain is its ability to bind murine 
ICAM-1 with comparable affinity (KD ~2 nM vs. 6 nM respectively), which helps us to examine 
the way various I domain CAR T cells interact with host’s ICAM-1 expressed on healthy cells in 
preclinical mouse models (Fig. 4.1C). In essence, it helps us determine the on-target, off-tumor 
toxicity in mouse tumor models to project how the CAR T cells may behave in human patients.  
The R6.5 scFv (adopted from the mouse hybridoma clone, R6.5) only binds human 
ICAM-1 (KD ~10 nM) (Table 1) and therefore is used in this study as a model system 
representing CAR T cells that only cause on-target, on-tumor toxicity. This is useful to help us  
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Figure 4.1: ICAM-1 interaction with monovalent LFA-1 I domain variants and I domain-CAR T 
cells.  
(A) SPR measurements of I domain variants to human ICAM-1. (B) Structural model of LFA-1 I 
domain and ICAM-1. (C) SPR measurement of F265S/F292G I domain to murine ICAM-1. (D) 
Soluble human ICAM-1 binding to I domain-CAR T cells of varying affinities. (E) ICAM-1 
expression on various cell lines. (F) FACS histograms of latex beads coated with 103 – 106 R6.5 
antibody per bead. (G) Induction of activation (CD25) in Jurkat T cells stably expressing I 
domain-CARs of varying affinities to ICAM-1 after stimulation by cell lines expressing different 
levels of ICAM-1. 
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interpret the degree of toxicity to host caused by off-tumor activity from I domain CAR T cells 
attacking the basal ICAM-1 expression in normal mouse tissues. 
 
Careful interplay between CAR affinity and target antigen density influences T cell activation 
and the therapeutic index of I domain CAR T cells in vitro 
Theoretically, the binding capabilities of the different I domain CAR T cells should 
adhere to the pattern exhibited by monovalent I domain mutants. When Jurkat T cells (JC) 
stably expressing I domain-CARs of varying affinities were exposed to soluble ICAM-1, affinity-
dependent increase in binding was observed (Fig. 4.1D). The expected affinity-dependent 
behavioral pattern of I domain-CAR T cells allowed the subsequent systematic evaluation of 
affinity and avidity thresholds for activation of T cells. To accomplish this, we assembled a 
collection of target cells, characterized by a wide range of ICAM-1 expression as measured by 
flow cytometry (Fig. 4.1E). The expression levels of ICAM-1 in the target cells were estimated by 
utilizing latex beads coated with known densities of human ICAM-1 as reference (Fig. 4.1F). 
HMEC-1 represents human non-tumor cells expressing a physiologic level of human ICAM-1 
(<105 per cell). Anaplastic thyroid carcinoma (8505c) and cervical cancer (HeLa) cell lines 
expressed intermediate (105 - 106 per cell) and high human ICAM-1 (>106 per cell). In 8505c-, 
ICAM-1 gene is deleted by CRISPR, while 8505c+ is treated with lipopolysaccharides (LPS) to 
upregulate the expression of ICAM-1. 
Different I domain CAR-JCs were stimulated with the target cells and cell activation was 
assessed by upregulation of CD25, which demonstrated activation correlating with ICAM-1 
affinity (Fig. 4.1G). Lowest-affinity WT I domain (IdWT) CARs were activated only in the 
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presence of high density of ICAM-1 on 8505c+, but could not discriminate among the cells 
expressing lower levels. Highest-affinity I domain CAR (IdTM), on the other hand, were non-
selectively activated to all levels of ICAM-1. Another high-affinity I domain CAR (IdG) also 
behaved in a promiscuous manner, recognizing moderate to high levels of human ICAM-1 and 
low levels of murine ICAM-1. However, IdA-CAR T cells successfully recognized only 8505c as 
well as 8505c+, becoming activated against the tumor cell lines but not the normal cells 
expressing basal levels of ICAM-1. 
Then, primary human T cells transduced with different I domain CAR designs (IdWT, IdA, 
IdG, and IdTM) were tested against the same panel of target cells to determine the cytotoxic 
capabilities (Fig. 4.2A). Our results indicate that for all the I domain CAR T cells, the rate of 
target killing correlated with increasing levels of ICAM-1 expression, with higher ICAM-1 
expressing cells being more sensitive to CAR T cell lysis. The rate of killing also correlated well 
with ICAM-1 affinity. Cytokine release during target cell lysis, measured by IFN-, exhibited a 
similar pattern (Fig. 4.2B). To quantitatively compare the efficacy of killing by affinity variant 
CAR T cells, values for the time required to achieve 50% killing (t_50%) were obtained from a 
best fit variable slope sigmoidal curve (%live = 100/[1+10( t_50%-t)* Slope]) (Fig. 4.2C). Our analyses 
demonstrate, in addition to the previously observed patterns, that high affinity CAR T cells (IdG 
and IdTM) are less sensitive to variations in target antigen density, and that low-affinity I 
domain CAR T cells were insensitive to low levels of target antigen density.  
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Figure 4.2: Control of target recognition density via affinity-tuning.   
(A) Luminescence-based cytolytic activity measurement against different expression densities 
of ICAM-1 (solid lines are fitted sigmoidal curves). E:T ratio used was 5:1. (B) IFN secretion by 
the panel of I domain-CAR T cells stimulated by different cell lines (ELISA). (C) Values for time 
required to achieve 50% target lysis obtained from fitted sigmoidal curves as a function of CAR 
affinity.  
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Affinity-tuned I domain CAR T cells eliminate tumor in vivo and significantly reduce on-target, 
off-tumor toxicity against physiologic levels of ICAM-1 
To extend the above in vitro results, the efficacy of affinity-tuned CAR T cells was 
examined in both systemic and subcutaneous tumor xenograft models in vivo. NSG mice were 
xenografted systemically with 8505c followed by treatment with the I domain variant CAR T  
cells (IdWT, IdA, IdS, and IdTM), R6.5-CAR T cells, mock-transduced T cells (Mock), control non-
transduced T cells (NT), and no T cells (NoT) 10 days after xenoplantation. Tumor burden was 
evaluated by whole-body luminescence imaging of firefly luciferase activity. Primary tumors 
localized to the lungs and liver with distant metastatic foci evident throughout the body[18]. 
8505c, which expresses ICAM-1 at a level only moderately higher than normal cells, was used as 
the model tumor cell line to highlight the applicability and potential of the affinity-tuning 
method we present here.  
Independent 8505c tumor growth, observed in mice receiving no treatment or NT cells, 
resulted in approximately 100-fold increase in luminescence over a three-week period (Fig. 
4.3A). In contrast, human ICAM-1-specific R6.5 CAR T cells began to show decrease in tumor 
burden 6 days after T cell infusion (Fig. 4.3B). Similarly, IdA, IdS and IdTM-CAR T cells displayed 
patterns of rapid tumor lysis (Fig. 4.3B, C). However, after approximately 7-10 days after 
receiving T cell infusion, all of the IdTM-CAR T-treated mice began to show symptoms of 
systemic toxicity (Fig. 4.3D) and eventually succumbed to death by day 14 after treatment. 
Subsequent autopsy and flow cytometry revealed drastic expansion of IdTM-CAR T cells in the 
lungs (~55% human CD3 T cells as a percentage of total lung cells) and spleen combined with 
severe lung tissue hemorrhaging, suggesting the occurrence of on-target, off-tumor toxicity  
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Figure 4.3: Affinity-tuned I domain CAR T cells and regression of advanced tumors in mice. 
Treatment administered 10 days after systemic 8505c xenotransplantation. Lung and whole-
body luminescence of 8505c tumors after treatment with (A) IdWT-CAR T cells, NT cells, NoT 
cells, (B, C) IdA-CAR T cells, IdS-CAR T cells, IdTM-CAR T cells, mock transduced T cells, and R6.5-
CAR T cells. (D) Percent body weight change in mice treated with IdA, IdS, and IdTM-CAR T cells 
compared to non-transduced T cells (control). (E) FACS and (F, G) histological validation of 
tumor growth and T cell expansion in the lungs. Red ‘X’: death, green ‘O’: imaging discontinued. 
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mediated by IdTM-CAR T cells cross-reacting with murine ICAM-1 in lung tissue (Fig. 4.3E). 
Substantial accumulation of IdTM-T cells in lungs was confirmed by histology, which showed T 
cell localization to tumor lesions as well as wide-spread presence within normal alveoli (Fig. 
4.3F). 
Despite a slower in vitro tumor lysis by IdA and IdS-CAR T cells, they displayed similar 
rate of tumor eradication as IdTM-CAR T cells in vivo. Complete eradication of tumor cells from  
the lungs as well as the normalization of the alveoli structures were observed in histology (Fig. 
4.3G). In addition, no physical signs of systemic or local toxicity was observed in these mice (Fig. 
4.3D). IdWT-CAR T cells, on the other hand, failed to induce tumor eradication (Fig. 4.3A). Based 
on the in vitro data, it can be postulated that the rate of killing by IdWT-CAR T cells was too 
slow to overtake tumor growth rate.  
In order to further evaluate the efficacy of the affinity-tuned CAR T cells in vivo, a NSG 
mouse model was designed to harbor subcutaneous 8505c tumors. The tumors were created 
bilaterally in the lower flanks by injecting 1.5 x 106 8505c cells in 150 ul of matrigel. Different I 
domain CAR T cells (3 x 106) were injected when tumor size reached approximately 100 mm3 
and serial bioluminescence imaging and tumor size assessments were conducted. 
Unfortunately, the efficacy of CAR T cells was much less drastic (Fig. 4.4). Only sign of 
tumor reduction was observed 17 days after treatment with IdTM-CAR T cells and as observed 
with the systemic tumor model, these mice showed severe systemic toxicity. IdA and IdS-CAR T 
cells, which accomplished near-complete lung tumor eradication previously, were unable to 
limit the subcutaneous tumor growth. 
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Figure 4.4: Insufficient I domain-CAR T cell efficacy against subcutaneous 8505c xenograft 
mouse model. Treatment with various CAR T cells administered 10 days after subcutaneous 
bilateral 8505c xenografts. Whole-body bioluminescence images taken on indicated days post-
xenograft. 
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Discussion 
 
 The compelling accomplishment by CAR T cell therapy in blood-borne malignancies is 
fueling the development of CARs that can overcome the problems inherent in solid tumor 
landscape. Similar to many other cancer therapies, identifying a target to allow specific 
elimination of tumor while sparing normal tissue is the top priority. Candidate targets may be 
mutated or upregulated on tumor cell surfaces, but even trace amounts on normal tissues can 
lead to serious side effects. The same issue complicates the delicate balance between T cell 
persistence and safety, since greater persistence often leads to better clinical response as well 
as increased chance for damage to normal tissues with low levels of target antigen.  
Though CARs specific for the B-cell lineage antigens CD19 and CD20 displayed potent 
efficacy in B-cell malignancies[19], in solid tumors, with the exception of tumor-specific 
neoantigens such as EGFRviii[20], on-target, off-tumor toxicity is anticipated to be detrimental. 
Our results demonstrate that CARs with possible on-target, off-tumor toxicities can be 
engineered to exhibit higher selectivity and reduced toxicity. For example, in our study, the 
IdTM-CAR caused lethal toxicity in host due to recognition of physiologic levels of ICAM-1 
expressed in normal tissues like the lungs. By reducing the affinity of TM I domain down to the 
physiologically natural affinity (low micromolar KD), a substantial improvement in the 
therapeutic index was achieved.  
Similar to previously reported studies[11], our results showed that the high-affinity I 
domain CAR T cells (KD ranging from 1-100 nM) exhibited little to no discrimination between 
high and low target antigen density. In addition to the decreased selectivity in target 
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identification, our high-affinity I domain CAR T cells were strongly reactive to model endothelial 
cells in vitro as well as to all the hosts in aggressive mouse tumor models. However, the IdA-
CAR that exhibits “natural” affinity (1-100 uM)[21] displayed higher selectivity by better 
mimicking the binding half-life of natural TCR/pMHC interaction, which may have aided in 
improved serial engagement.  
The success in systemic 8505c tumor treatment was not extrapolated to the 
subcutaneous model. Among the many obstacles faced by T cells in efficient infiltration and 
lysis of solid tumors, hypoxia, low pH, high interstitial pressure, dysregulated blood vessels, and 
dense collagen networks have been presented as major limitations[22]. We hypothesize that 
these factors hamper efficient killing of subcutaneous tumors compared to systemic 
counterparts by CAR T cells. Local administration of TLR agonists in these instances could 
therefore increase ICAM-1 antigen density but also increase T cell localization and diapedesis 
through cytokine signaling and stronger chemokine gradients, which can increase therapeutic 
efficacy with particular regard to the lower affinity CAR T cells. 
On-going studies are exploring other strategies to maximize the therapeutic index of 
CAR T in managing on-target, off-tumor toxicity. Notable endeavors include the inclusion of 
inhibitory CARs or chimeric co-stimulatory receptors[23, 24], which depend on more than one 
target antigen to increase specificity. Other strategies include combining suicide genes with the 
CAR design or transiently expressing CAR molecules using expression systems of mRNA[25-27]. 
Our work on the affinity-tuning strategy presented here has the potential to improve the 
therapeutic index of CAR T cell therapy against many of the validated targets previously 
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considered risky because of on-target, off-tumor toxicities. Developing safer CAR designs would 
also benefit the potential usage of CAR technology in other diseases, such as autoimmunity. 
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Sequencing of the human genome has classified 18 alpha and 8 beta subunits of 
integrins, resulting in 24 currently identified functional integrins in humans. These numerous 
integrins mediate stable adhesion to basement membranes, the formation of and migration on 
extracellular matrices, the formation of platelet aggregates, the establishment of intercellular 
junctions in the immune system, and bacterial and viral entry during infectious diseases. 
Integrin-mediated adhesions, especially, modulates signaling cascades in control of cell motility, 
survival, proliferation, and differentiation.  
In this dissertation, I have demonstrated various applications of such interactions 
involving a leukocyte integrin, LFA-1, for development of therapeutics. One of the major 
breakthroughs that allowed for my thesis work was the directed evolution engineering of the L 
I domain to various affinity states that ranges six orders of magnitude. The specificity and 
affinity of the I domain mutants to their native ligand, ICAM-1, provide ways to specifically 
target therapeutics to many human carcinomas and the associated inflammation therein. I 
demonstrated affinity-dependent targeted delivery of anti-tumor drug compounds as well as 
plasmids, using the engineered LFA-1 I domains. From these studies I have confirmed the 
presence of inflammation in the tumor stroma and demonstrated the possibility of targeting an 
inflammation marker, such as ICAM-1, in delivery of therapeutics targeting even tumors that 
lack the expression of unique tumor antigens. 
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Combining therapy and diagnostics in one dose is a novel idea that will be a key part of 
advancing predictive medicine. This approach allows real-time tracing of the drug-carriers, 
while also tracking the progress of the tumor growth/suppression. I have shown here the ability 
of the UAN platform to encapsulate high concentrations of various different payloads 
simultaneously. Incorporating Zr-89 into drug-carriers would bestow theranostic capabilities, 
allowing concurrent chemotherapy and tumor tracing using PET imaging. Such method will 
facilitate gaining real-time information about the trafficking pathway, kinetics of delivery, and 
therapeutic efficacy. Combining therapeutic and diagnostic capabilities in this fashion has 
potential for effective personalized medicine. 
One of my major goals in developing targeted therapy has been to establish a system 
that can initiate on-target, on-tumor potency while minimizing off-tumor toxicities. Many years 
of engineering and optimizations have led to better understanding for safer drug delivery 
vehicles. Necessary qualifications include longer circulation time using blood proteins or 
molecules like PEG, slow or controlled release of payloads for non-promiscuous uptake by cells, 
optimal range of size to take advantage of the EPR effect, and surface characteristics to 
minimize uptake by phagocytic cells. Our studies utilized such safety mechanisms to counteract 
the possible problems that arising from targeting a protein that is widely expressed in healthy 
tissues. Ultimately, the transient presence of our drug-carriers in hosts has led to insignificant 
increase in systemic toxicity.  
However, in the field of targeted immunotherapy, especially those utilizing the CAR-T 
technology, this achievement has been more elusive. Once engineered T cells encounter the 
target antigen with sufficient avidity and affinity, they become activated, proliferate, and 
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secrete toxic substances to lyse cells presenting the target antigen. We observed that their 
ability to kill serially, proliferate, and persist triggers a chronic response leading to host fatalities 
if the target recognition becomes sensitive enough to react against physiologic levels of target 
density. As described in Chapter 4, the strategy to fine tune the affinity of LFA-1 I domain has 
allowed us to identify a variant that can endow much improved therapeutic index against a 
target antigen that was previously considered too risky due to the prevalence in healthy tissues. 
I envision that such methods for safe immunotherapy will become the major tool for 
development of targeted immunotherapy technologies against debilitating diseases, and will 
greatly aid the translation into the clinic. 
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APPENDIX A 
 
VIRUS-MIMETIC POLYPLEX PARTICLES FOR SYSTEMIC AND INFLAMMATION-SPECIFIC TARGETED 
DELIVERY OF LARGE GENETIC CONTENTS 
This chapter was originally published in Gene Therapy (Kang, S., Lu, K., Leelawattanachai, J., Hu, X., Park, S., Park, T., Min, I.M., 
Jin, M.M. Gene Therapy. 2013;20(11):1042-52.), and is reprinted with permission. Park S contributed to the validation of virus-
mimetic particles in vitro. This included the experiments related to Figures 4, 7, and 10. 
 
Summary 
 
Systemic and target-specific delivery of large genetic contents has been difficult to 
achieve. Although viruses effortlessly deliver kilobase-long genome into cells, its clinical use has 
been hindered by serious safety concerns and the mismatch between native tropisms and 
desired targets. Nonviral vectors, in contrast, are limited by low gene transfer efficiency and 
inherent cytotoxicity. Here we devised virus-mimetic polyplex particles (VMPs) based on 
electrostatic self-assembly among polyanionic peptide (PAP), cationic polymer 
polyethyleneimine (PEI) and nucleic acids. We fused PAP to the engineered ligand-binding 
domain of integrin αLβ2 to target intercellular adhesion molecule-1 (ICAM-1), an inducible 
marker of inflammation. Fully assembled VMPs packaged large genetic contents, bound 
specifically to target molecules, elicited receptor-mediated endocytosis and escaped 
endosomal pathway, resembling intracellular delivery processes of viruses. Unlike conventional 
PEI-mediated transfection, molecular interaction-dependent gene delivery of VMPs was 
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unaffected by the presence of serum and achieved higher efficiency without toxicity. By 
targeting overexpressed ICAM-1, VMPs delivered genes specifically to inflamed endothelial cells 
and macrophages both in vitro and in vivo. Simplicity and versatility of the platform and 
inflammation-specific delivery may open up opportunities for multifaceted gene therapy that 
can be translated into the clinic and treat a broad range of debilitating immune and 
inflammatory diseases. 
 
Introduction 
 
Viruses have evolved ways to efficiently deliver their genetic materials into cells that can 
be as large as multiples of kilobase-long nucleic acids. The use of viral gene delivery vectors for 
clinical applications[1-5] however, poses serious safety issues, including pathogenicity by 
insertional mutagenesis[6] and anaphylactic response to the virus[7, 8]. On the other hand, 
synthetic nonviral vectors suffer from inherent cytotoxicity and are severely limited due to low 
gene transfer efficiency in systemic parenteral applications. Particularly, cationic nonviral 
vectors, which can disrupt the integrity of plasma membrane during entry into cells[9, 10], are 
easily inactivated by negatively charged molecules such as glycosaminoglycans in 
circulation[11-13]. 
To achieve cell type- or cell state-specific targeted systemic delivery, it often requires 
the use of complex molecules such as antibodies and proteins that specifically bind to target 
molecules.  
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However, systemic site-directed delivery of large nucleic acid molecules has met limited 
success. In fact, studies have been mostly constrained to the delivery of small nucleic acids, 
such as siRNA[14-17]. Although viruses possess the ability to overcome many barriers of gene 
delivery such as cell entry through the membrane and escape from lysosomal nuclease 
degradation, engineering the tropism of viral vectors for site-directed delivery to a range of 
different targets[18-20] has been challenging. Nonviral vectors are capable of delivering large 
content of nucleic acids such as plasmids, but modifications to confer specific targeting have 
been mostly confined within chemical/covalent attachments of small 
molecules[21], peptides[22] and several types of proteins[23, 24], which would inevitably affect 
the original physicochemical properties of the vectors. 
In this study, we devised a polyanionic peptide (PAP) comprised of 18 randomly ordered 
glutamic and aspartic acids that can be expressed as a fusion to proteins to mediate 
electrostatic attachment to cationic transfection agents. Polyethyleneimine (PEI) was used as a 
scaffold to hold both a large content of nucleic acid and PAP-fused targeting moieties. PEI has 
been extensively studied as a cationic polymer-mediated gene delivery agent and has been 
considered to have relatively high gene transfer efficiency[25-29] PEI has all primary, secondary 
and tertiary amines, providing buffering capacity at low pH of late endosomes[30]. This 
promotes an influx of counter-ions such as chloride[31], raising osmotic pressure that 
eventually bursts the vesicles and releases nucleic acid payload, which has been termed as the 
proton sponge effect[32]. 
To achieve targeted gene delivery to inflammatory diseases, we fused the PAP to the 
major ligand-binding domain (I domain) of integrin lymphocyte function-associated antigen-1 
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(LFA-1; αLβ2) as a targeting moiety. The physiological counter receptor for LFA-1 is the 
intercellular adhesion molecule-1 (ICAM-1), which is highly expressed on inflamed cell 
surfaces[33, 34] that often colocalizes at various disease sites[35]. ICAM-1 is also subverted as a 
receptor for the major human rhinoviruses (HRVs)[36], which gain cell entry by multivalent 
interaction with ICAM-1 that promotes rapid endocytosis[37, 38]. We have previously 
engineered the I domain into a high-affinity (HA) mutant to ICAM-1 by directed 
evolution[39]. The I domain is a globular Rossmann fold protein of approximately the size of a 
single-chain variable-fragment antibody. We previously used the HA I domain as a targeting 
moiety for various types of carriers to deliver drugs[40, 41] and imaging contrast agents[42] 
specifically to inflamed endothelial cells and immune cells, and to cancer cells and their stroma. 
Here we show that, by fusing the PAP to the I domain (PAP-Id) and using a cationic 
nonviral vector PEI, we were able to establish a molecular interaction-dependent gene delivery 
platform based on their stepwise electrostatic self-assembly, which creates virus-mimetic 
polyplex particles (VMPs) that mimic the processes involved in virus infection. Similarly as to 
how cell entry is gained by HRVs, our VMPs were also able to mediate cellular endocytosis by 
clustering ICAM-1 via multivalent binding of the I domains. Because the attachment of targeting 
moieties is a self-assembling process, we were able to precisely control the moiety density or 
avidity, optimal for efficient endocytosis and gene transfer. Not only did the association of DNA 
and PEI particles with PAP-Id reduce the inherent cytotoxicity of PEI, it also enabled the delivery 
to be unaffected by the presence of serum. Similarly as acid-catalyzed conformational change in 
HRV capsid leads to penetration of the membrane, VMPs escaped endosomal degradation and 
- 113 - 
 
led to efficient gene expression. Moreover, by targeting ICAM-1, we were able to deliver genes 
specifically to inflamed endothelial cells and immune cells both in vitro and systemically in vivo. 
 
Experimental Procedures 
 
Cell culture conditions 
HeLa, bEnd.3, RAW 264.7 (ATCC, Manassas, VA, USA) and primary mouse lung cells were 
cultured in Advanced Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA, USA) 
containing 2 mM L-glutamine, Pen-step (100 units/ml penicillin and 100 μg/ml streptomycin) 
and 10% fetal bovine serum (FBS; endotoxin free, PAA Laboratories, Piscataway, NJ, USA). 
Primary mouse lung cells were harvested from fetus lungs of mouse strain 
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo(Jackson Laboratory, Bar Harbor, ME, USA). Lungs were 
aseptically minced and digested in 1 mg/ml collagenase A (Roche, Basel, Germany) for 3 h at 
37 °C, which were then filtered through 70-μm nylon mesh cell strainer and washed twice in 
complete media for culture. HMEC-1 (Center for Disease Control, Atlanta, GA, USA) was 
propagated in MCDB 131 medium (Invitrogen) supplemented with 10% FBS, 10 mM L-
glutamine, Pen-strep, 1 μg/ml hydrocortisone (MP Biomedicals, Solon, OH, USA) and 
10 ng ml−1 human epidermal growth factor (Invitrogen). THP-1 cells (ATCC) were cultured in 
RPMI 1640 medium (Invitrogen) with 10% FBS and Pen-strep. Endothelial cells and primary 
mouse lung cells were trypsinized at confluency and washed to remove residual trypsin before 
plating. All mammalian cells were maintained at 37 °C in a 5% CO2 humidified incubator. 
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Protein construction, design, and purification 
Wild-type LFA-1 I domain sequence (Asn-129 to Tyr-307) followed by a stop codon was 
subcloned into pET28a vector (Novagen, Madison, WI, USA) between BamH1 and Xho1. 
QuickChange (Stratagene, La Jolla, CA, USA) site-directed mutagenesis was used to create 
F265S/F292G and D137A mutants. For GFP-Id, a superfolder GFP[43] was inserted between 
Nhe1 and BamH1. To construct PAP-Id, complementary primers encoding 5′-
ctagcgaggatgaagatgaggaagacgaagaagatgaagaggacgaagaggacgaggatg-3′ and 5′-
gatccatcctcgtcctcttcgtcctcttcatcttcttcgtcttcctcatcttcatcctcg-3′ were annealed and directly 
ligated between Nhe1 and BamH1. Constructs were transformed into Escherichia coli, BL21 
(DE3) cells (Novagen) for production of the fusion proteins. Overnight starter culture was used 
to inoculate a larger Luria Bertani medium at 1:40 volume ratio and was grown at 37 °C to 
OD600 of 0.4–0.5 (~2 h). Then cells were induced with freshly prepared 1 mM isopropyl-β-D-
thiogalactopyranoside at 25 °C overnight (~15 h). Cells were recovered by centrifugation and 
sonicated in buffer A (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, protease inhibitor 
cocktail (ProteCEASE-EDTA free, G-Biosciences, St. Louis, MO, USA)) with pH adjusted to 8.0 for 
GFP-Id and 6.0 for PAP-Id. Soluble fraction of GFP-Id was purified by passage over a Ni-NTA 
column (Pierce, Rockford, IL, USA). Insoluble fraction of PAP-Id was washed in buffer A with 
four cycles of sonication and super-centrifugation at 20 000 g for 30 min. Protein pellet was 
then solubilized in buffer B (buffer A plus 6 M guanidine HCl, pH 8.0) and purified by Ni-NTA. 
GFP-Id and PAP-Id were washed in buffer C (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 
pH 8.0) and then eluted in buffer D (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 8.0). 
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Eluted proteins were then subjected to gel filtration chromatography using Superdex S200 
column in phosphate-buffered saline (PBS) connected to AKTA Purifier (GE Healthcare, 
Pittsburgh, PA, USA). 
 
Electrostatic self-assembly of VMPs 
For any given mass ratios, plasmid and PEI (branched, MW 25 000, Sigma-Aldrich, St. 
Louis, MO, USA) were each diluted in one volume of PBS (pH 7.4) and PAP-Id in two volumes of 
PBS. Solutions containing plasmid and PEI were first vortex mixed and incubated at room 
temperature for 40 min. Plasmid/PEI mixture was then gently mixed with PAP-Id solution and 
incubated at room temperature for 40 min. Vector for GFP expression (pGFP) was constructed 
by subcloning a complete Kozak consensus sequence and enhanced GFP sequence followed by 
a stop codon between EcoRI and BglII of pAAV-MCS vector (AAV Helper-Free System, Agilent 
Technologies, Santa Clara, CA, USA). Vectors for expression of diphtheria toxin A (pDTA) and Cre 
recombinase (pCRE) were obtained from Addgene (Cambridge, MA, USA), originally named as 
PGK-DTA-bpA[44] (plasmid 13440) and pLOX-CW-CRE[45] (plasmid 12238), respectively. All 
components used for assembly of VMPs, including plasmids, PAP-Id, PEI and PBS, were filter 
sterilized through 0.2-μm centrifugal or syringe filters before assembly. 
 
Dynamic light scattering and zeta-potential measurements of VMPs 
The size distribution and zeta-potential of VMPs were determined using Zetasizer Nano 
ZS (Malvern Instruments (Malvern, Worcestershire, UK)). VMPs prepared with 1 μg of plasmid 
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and the relative mass of PEI and/or PAP-Id were each diluted in 750 μl of PBS (pH 7.4). The 
solution was added to the cell and the measurements were carried out at 25 °C. 
 
In vitro delivery of VMPs 
Cells were grown in 24-well plates to confluence and pretreated with complete media 
containing 1 μg/ml of LPS (E. coli, 026:B6, Sigma) to induce inflammation. Each well received 
VMPs prepared with 0.4 μg of plasmid and the relative mass and volumes of PEI and PAP-Id. 
Final VMPs were then mixed with an equal volume of FBS and incubated at room temperature 
for 40 min before delivery to cells. After delivery, cells were washed twice with media, followed 
by addition of fresh complete media. 
 
In vivo delivery of polyplex particles 
Eight-to-ten-week-old female BALB/c mice (Jackson Laboratory) were used. All 
administrations performed in this study were given intravenously, using 29G × 0.5′′ insulin 
syringes via lateral tail vein route injections. To induce systemic inflammation, 20 μg per mouse 
of LPS (E. coli, 026:B6, Sigma) in PBS (pH 7.4) was injected. VMPs bearing 5 μg of plasmid was 
formed in a mass ratio of the components (plasmid:PEI:PAP-Id) fixed to 1:6:16 in a final volume 
of 200 μl. All animal procedures were approved by the Cornell University IACUC and were 
conducted in accordance with recommendations in the Guide for the Care and Use of 
Laboratory Animals published by the National Institutes of Health. 
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Immunofluorescence for imaging and flow cytometric analysis 
Mean fluorescence intensity and percentage of GFP-positive cells were quantified by 
flow cytometry (Beckman Coulter EPICS XL-MC, Brea, CA, USA). After in vitro delivery of VMPs 
for GFP expression, cells were trypsinized, washed with washing buffer (PBS, 0.5% bovine 
serum albumin, pH 7.4) and subjected to flow cytometer. Total fluorescence was quantified by 
lysing cells with 1% (v/v) Triton X-100 in PBS and measuring with a fluorescence plate reader 
Infinite M1000, TECAN (Männedorf, Switzerland). Confocal microscopy (Zeiss LSM 710, Zeiss 
(Oberkochen, Germany)) was used to assess endocytosis of VMPs and protein expression in 
HeLa cells. PAP-Id was conjugated to Alexa Fluor 555 (succinimidyl ester, Invitrogen) and pGFP 
was labeled with Cy5 (Label IT Nucleic Acid Labeling Kit, Mirus Bio (Madison, WI, USA)). HeLa 
cells were grown in 35 mm glass bottom dishes (0.16–0.19 mm cover glass, In Vitro Scientific 
(San Jose, CA, USA)) and fixed in 3.7% formaldehyde for 1 h at different time points after 
delivery of fluorescently labeled VMPs. Expression of ICAM-1 in mouse lungs were assessed by 
GFP-Id. Lungs were collected at different time points after systemic LPS treatment (20 μg per 
mouse, E. coli, 026:B6, Sigma) and were minced and digested in 1 mg ml−1 collagenase A 
(Roche) for 3 h at 37 °C. Singlet lung cells were prepared by passage through 70-μm nylon mesh 
cell strainer and incubation with red blood cell lysis buffer (eBiosciences, San Diego, CA, USA) 
for 5 min on ice. Cells were then washed and labeled for ICAM-1 with 10 μg/ml GFP-Id in ice-
cold labeling buffer (PBS, 0.5% bovine serum albumin, 10 mM MgCl2, pH 7.4) for 1 h. Cells were 
then labeled with either rat IgG anti-mouse CD31 (1:20, BD Pharmingen, San Diego, CA, USA) or 
rat IgG anti-mouse F4/80 (1:50, Abcam, Cambridge, UK) for 1 h, followed by goat anti-rat IgG-PE 
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(Santa Cruz, Santa Cruz, CA, USA) as secondary antibody for 1 h. For detection of GFP 
expression after delivery of VMPs bearing pGFP, singlet lung cells were fixed with 
3.7% formaldehyde for 1 h and permeabilized with 1% (v/v) Triton X-100 for 30 min. 
Permeabilized cells were then labeled with rabbit IgG anti-GFP antibody (1:20, Invitrogen) for 
1 h, followed by goat anti-rabbit IgG-PE (1:100, Santa Cruz) for 1 h. Cells were then labeled for 
CD31 and F4/80 similarly as described, followed by goat anti-rat IgG-FITC (1:100, Santa Cruz) for 
1 h. 
 
Real-time quantitative PCR 
Total RNAs from harvested lungs were extracted using TRI Reagent (Ambion, Austin, TX, 
USA). Briefly, mouse lung tissue (~150 mg) was homogenized in 1 ml of TRI Reagent solution 
followed by brief sonication. Homogenized lysates were mixed with 200 μl chloroform and 
centrifuged at 12 000 g for 15 min. In all, 400 μl of colorless upper aqueous phase was collected 
and mixed with 500 μl isopropanol and loaded to spin columns (Zymo-Spin II, Zymo Research, 
Irvine, CA, USA). Eluted RNA (1 μg) was converted to cDNA using a reverse transcription kit 
(High Capacity cDNA RT kits, Applied Biosystems, Foster City, CA, USA) in a thermal cycler 
(GeneAmp PCR System 2700, Applied Biosystems). Real-time gene amplification analysis (MyiQ 
iCycler, Bio-Rad) was performed using a quantitative PCR kit (Sybr Green 2 × Master Mix, Bio-
Rad, Hercules, CA, USA) to measure gene expression of GFP relative to CYC1 housekeeping 
gene. Primers for GFP were previously reported[46] and for CYC1 (NM_025567) were obtained 
from Mouse qPrimerDepot of the National Cancer Institute. 
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Quantification of cell viability 
Cell viability of HeLa cells treated with VMPs bearing pDTA was analyzed by trypan blue 
exclusion test. Cells were incubated with 0.2% trypan blue for 5 min, and microscopic images 
were taken at random places of culture wells. Viable cells that excluded trypan blue and 
nonviable cells with blue cytoplasm were counted per given image field for analysis. Viability 
measurements presented in Figures 3, 4, 5 were quantified by MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) assay. Cells were incubated with basal media containing 
0.5 mg/ml MTT for 4 h at 37 °C. Blue formazan products were solubilized in dimethyl sulfoxide 
and quantified by absorbance at 570 nm. 
 
Statistical analysis 
Data were expressed as mean ± s.d. of at least quadruplicate samples. Statistical analysis 
of data was carried out using GraphPad Prism 5; GraphPad Software Inc. (La Jolla, CA, USA). 
Unpaired Student’s t-test was used to determine statistical significance in comparison to 
matching controls. One-way analysis of variance was used to compare mean responses among 
the different groups, followed by Tukey’s post-hoc test to determine statistical significance. 
 
Results 
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Molecular interaction-specific VMPs for targeted gene delivery 
VMPs were designed to mimic the components of non-enveloped viruses (for example, 
HRVs) and their entry into a specific range of host cells (Fig. A1a). VMPs were assembled in a 
sequential manner: first PEI and DNA plasmids were mixed together, to which proteins were 
added. The ratio of protein, DNA, and PEI was adjusted so that unsaturated positive charges in 
PEI would assemble with the negatively charged residues (PAP) and DNA (Fig. A1b). When 
added to cells with ICAM-1 expression, VMPs that were assembled with integrin LFA-1 I domain 
would cluster ICAM-1 and trigger the cells for endocytosis. A decrease in pH in late endosomes 
would increase the degree of protonation in PEI, whereby it attracts counter-ions and bursts 
the vesicle by proton sponge effect[31, 32]. Escaped plasmid payloads are then transported 
into the nucleus and leads to the expression of encoding genes. 
To visualize VMPs throughout the processes of cell entry, endosomal escape and gene 
expression, we fluorescently labeled plasmids and PAP-Id to track the particles by confocal 
microscopy. We used the I domain engineered for HA with double mutations 
F265S/F292G[39] (denoted as PAP-Id(HA)). We used a plasmid encoding enhanced green 
fluorescent protein (GFP) under cytomegalovirus promoter (denoted as pGFP). VMPs were 
constructed using Cy5-labeled pGFP and Alexa Fluor 555-conjugated PAP-Id(HA) at a mass ratio 
determined to be within an optimal range for delivery (1:6:16 for pGFP:PEI:PAP-Id(HA); see Fig. 
A2). We then delivered the fluorescently labeled VMPs in the presence of serum to HeLa cells, 
which express a high level of ICAM-1. Cells were fixed at 3, 24 and 48 h after delivery. At 3 h 
post delivery, VMPs were found mostly inside cells, confirmed by confocal microscopy (Fig A1c,  
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Figure A1: Cell entry, endosomal escape and gene expression of polyplex particles. (a) HRV 
gains cell entry by binding and clustering ICAM-1, which is overexpressed on inflamed cell 
surfaces. Acid-catalyzed conformational change in the viral capsid (violet) penetrates the 
membrane of late endosomes, through which it releases the RNA genome that leads to the 
synthesis of more viruses (green). (b) Self-assembly of VMPs is mediated by stepwise 
electrostatic interactions among negatively charged nucleic acids, positively charged PEI and 
PAP-Id. VMPs similarly gain cell entry by multivalent ICAM-1 clustering-mediated endocytosis. A 
decrease in pH in late endosomes protonates PEI, attracting counterions (Cl-) and exerting 
osmotic pressure and eventually bursting the vesicle. Plasmid payloads that escaped endosomal 
nuclease degradation are then transported into the nucleus through the nuclear pore complex 
(NPC), leading to the expression of encoding genes. (c–e) Confocal microscopy was used to 
track intracellular localization of PAP-Id(HA) (high affinity) conjugated to Alexa Fluor 555 (red), 
pGFP labeled with Cy5 (blue) and GFP expression (green) in HeLa cells. (c) VMPs were self-
assembled at its optimal mass ratio of pGFP:PEI:PAP-Id(HA) adjusted to 1:6:16. Cells received 
VMPs in the presence of serum, which then were fixed at time points of 3, 24 and 48 h after 
delivery. Colocalization of red and blue appears in magenta in merged image. Focal plane was 
set through the middle of cells to capture VMPs inside cells. Dotted lines mark the cell 
boundaries. Bar = 20 m. (d) Z-stack confocal images also show localization of VMPs inside HeLa 
cells at 3, 24 and 48 h after delivery. Dotted lines indicate the top surface of cells. Bar = 10 m. 
(e) Similarly, confocal images were taken at 3 h post delivery to assess the uptake of control 
particles (formed with PEI and PAP-Id(HA), PAP-Id(HA) and pGFP or PEI and pGFP). Note that 
focal plane for imaging was set through the middle of cells to visualize only the particles 
internalized into cells. Bar = 50 m. (f) Fluorescence microscope images (top view) of HeLa cells 
at 3 h post delivery are shown (imaged without fixation). PAP-Id(HA), conjugated to Alexa Fluor 
555 for fluorescent detection, was either assembled with only plasmid or with PEI and plasmid. 
The particles were incubated with HeLa cells in the presence of serum. Bar = 50 m. 
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d). PAP-Id(HA) (red) and pGFP (blue) appeared to be in complex with each other, evidenced by 
colocalization of the two in the merged image. At 24 h post delivery, some cells began to 
express GFP, which coincided with the observation that the components of VMPs appeared to 
be dissociated from each other. At 48 h, most cells expressed GFP, while much of the 
components of VMPs were no longer detectable. PEI/DNA plasmids polyplex without the I 
domain (PEI:pGFP=6:1 w/w) exhibited a size of 169 nm and a zeta potential of +26 mV. With the 
addition of the I domain (PEI:eGFP:I domain=6:1:12), VMPs increased in size (245.5 nm) but 
displayed a reduced zeta potential (+20 mV), presumably due to the presence of negatively 
charged peptides (PAP) fused to the I domains. 
To show that all three components are necessary for gene delivery by VMPs, we 
assembled fluorescently labeled particles with one component omitted (that is, PAP-Id(HA)/PEI, 
PEI/pGFP and PAP-Id(HA)/pGFP) and delivered to HeLa cells in the presence of serum (Fig. A1e). 
At 3 h post-delivery, the particles that were formed without pGFP (that is, PAP-Id(HA)/PEI) were 
found as small vesicles inside the cells but to a lesser extent than fully assembled VMPs. 
Particles that were assembled without PAP-Id(HA) (that is, PEI/pGFP) were sparsely found 
inside the cells. The mixture without PEI (that is, PAP-Id(HA)/pGFP), where PAP-Id(HA) would 
not associate with pGFP and remain as monomers, were not found inside the cells (Fig. A1e). In 
order to show that clustering of ICAM-1 is necessary for internalization of particles by the cells, 
we imaged cells without fixation under conventional fluorescence microscopy (Fig. A1f). The 
mixture of PAP-Id(HA)/plasmid was indeed smoothly distributed over the cell surfaces, which 
was in contrast to fully assembled VMPs appearing as endocytosed intracellular speckles (Fig. 
A1f). As a negative control for the HA I domain, we used the PAP-fused I domain containing a 
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loss-of-function mutation D137A[47] (denoted as PAP-Id(D137A)). Particles that were 
assembled with Id(D137A) were neither observed on the cell surface nor inside the cells, 
proving that it is ICAM-1-mediated internalization by which our VMPs were delivered inside the 
cells (images and functional data shown throughout Fig. 2, 3, 4, 5, 6). 
 
Determining optimal ratios of protein, DNA and PEI for efficient gene delivery 
In an effort to assemble VMPs for the highest gene transfer efficiency, we varied the 
mass ratios of individual components and examined the efficiency of gene expression (Figure 
2). With a fixed amount of pGFP, we varied the amount of PEI ranging from 3 to 8 mass ratios of 
PEI to plasmids. To the mixture of pGFP/PEI particles, PAP-Id(HA) or PAP-Id(D137A) were added 
at mass ratios varying from 2 to 32 of proteins to plasmids (Fig. A2a). Assembled VMPs were 
delivered to HeLa cells in the presence of serum. As additional controls and for comparison to 
conventional transfection methods, pGFP/PEI particles were used without proteins, both with 
or without serum (Fig. A2a). Gene transfer efficiency was assessed by two different assays, that 
is, total fluorescence measured from cell lysates, and mean fluorescence intensity and the 
percentage of GFP-positive cells measured by flow cytometry. Overall, VMPs formulated with 
the mass ratios of 8–16-fold excess of PAP-Id(HA) and 5–7-fold excess of PEI over pGFP led to 
the highest readouts of total fluorescence and a percentage of GFP-positive cells (Figure 2a). 
Higher than optimal ratios of I domains mixed with pGFP/PEI resulted in a decrease in delivery 
efficiency due to the inhibition of VMP binding to cells by free I domains occupying available 
ICAM-1 on cell surface. Although VMPs assembled with PAP-Id(HA) produced over 80% GFP-
positive cells and total fluorescence as high as 20-fold over the mixture of PAP-Id(HA)/pGFP,  
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Figure A2: Molecular interaction-specific gene delivery of VMPs.  
(a, b) VMPs were assembled with varying mass ratios among the three components: pGFP, PEI 
and PAP-Id. The mass ratio of plasmid to PEI was titrated from 1:3 to 1:8, which were then 
assembled with various mass ratios of PAP-Id(HA) to probe optimal gene transfer efficiency. 
PAP-Id(D137A) (no affinity) was used as a negative control as the loss-of-function point 
mutation abrogates the interaction with ICAM-1. (a) Heat map in green shows the total 
fluorescence measured by a fluorescence microplate reader after cell lysis (n = 4), in yellow 
shows the mean fluorescence intensity measured by flow cytometry (n = 4) and in white is the 
percentage of GFP-positive cells as compared with non-transfected control cells (n = 4). 
Fluorescence values are shown in relative fold difference compared with the negative control, 
of which the particles were assembled without PEI. (b) VMPs bearing pDTA (diphtheria toxin 
subunit A) were delivered to HeLa cells in a similar manner. Heat map in cyan shows the 
percentage of viable cells counted per image field (n = 4) relative to untreated normal HeLa 
cells. Trypan blue exclusion assay was used to stain nonviable cells and exclude those from the 
counts. 
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VMPs assembled with PAP-Id(D137A) did not show any sign of GFP expression. Particles 
assembled without the I domains, a formulation identical to conventional PEI-based 
transfection method, overall resulted in much lower GFP expression compared with VMPs. 
Furthermore, the addition of serum almost completely abolished GFP expression induced by 
conventional PEI-based transfection (Fig. A2a). 
To demonstrate ICAM-1-specific delivery of functional genes, we assembled the 
particles with a plasmid encoding a catalytic domain (subunit A) of diphtheria toxin without the 
other two domains responsible for receptor-binding and endosomal escape[48] (pDTA). This 
would limit a potent cell killing only to the transfected cells but not to the neighboring non-
transfected cells. Cell death mediated by pDTA-encapsulating VMPs would thus indicate that 
our delivery system was able to compensate for the functions provided by the other two 
missing domains: cell binding/entry and endosomal escape. Potent cytotoxicity in HeLa cells 
was evident at similar mass ratios found to be optimal for the delivery of pGFP (Fig. A2b). In 
contrast to highly efficient and ICAM-1-dependent cell killing by PAP-Id(HA)-mediated delivery, 
pDTA/PEI particles in the presence of serum and the VMPs assembled with PAP-Id(D137A) were 
completely ineffective in causing cell death. Altogether, these assays provided evidence that 
Id(HA), but not PEI, was responsible for specific targeting of ICAM-1 and cell entry of VMPs. 
 
Inflammation-specific gene delivery to endothelial cells and monocytes/macrophages 
Major cellular culprits of inflammatory diseases[49, 50] are endothelial cells that line the 
luminal surface of blood vessels and immune cells that actively elicit immune responses. Cell-
surface expression of ICAM-1 is highly upregulated in the course of acute and chronic 
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inflammation, which makes ICAM-1 a target for inflammatory diseases. We chose human 
dermal microvascular endothelial cells (HMEC-1) and human acute monocytic leukemia cells 
(THP-1) as representative in vitro cellular models. As a model of inflammation, HMEC-1 and 
THP-1 were treated with endotoxin lipopolysaccharides (LPS) (Fig. A3a) that would initiate 
nuclear factor-kappa B transcription factor-dependent inflammatory response[51]. VMPs 
formulated with a fixed mass ratio of pGFP to PEI at 1:6 and varying amounts of targeting 
moiety were delivered to either normal or LPS-treated HMEC-1 (Fig. A3b, c) and THP-1 cells (Fig. 
A3d, e). Overall, LPS- or inflammation-dependent delivery of GFP gene was observed only with 
VMPs assembled with PAP-Id(HA), with >80% of cells being GFP-positive. Particles formed 
without the I domain showed a much lower efficiency of transfection independent of LPS 
treatment, which was largely abolished by the addition of serum. Notably, pGFP/PEI 
transfection caused cell death reaching as high as 90%, whereas VMPs with PAP-Id(HA) 
preserved the viability of both HMEC-1 and THP-1. 
One of the major advantages of using the I domain for targeted delivery is that it cross-
reacts with murine ICAM-1[41, 42], allowing the same targeting moiety to be used for 
preclinical animal studies. Similarly, we chose two types of cells, mouse brain microvascular 
endothelial cells (bEnd.3) and mouse leukemic monocyte macrophage cells (RAW 264.7), to 
study inflammation-specific delivery of VMPs bearing pGFP. Overall, the induction of ICAM-1 in 
murine cells in response to LPS was slower than in human cells (data not shown); accordingly, 
we delivered VMPs at 48 h post-LPS treatment (Fig. A4a). Similar to the effects of VMPs on 
human cells, mean fluorescence intensity and the percentage of GFP-positive cells for both 
bEnd.3 and RAW 264.7 were significantly higher in the group that were treated with LPS and  
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Figure A.3: Inflammation-specific targeted gene delivery to human endothelial cells and 
monocyte/macrophages.  
(a) Timeline shows the sequence of LPS treatment, virus-particle delivery and measurements 
for human cell lines. Twenty-four hours of LPS treatment was required in human cells to trigger 
maximal ICAM-1 expression level for optimal delivery. (b–e) VMPs were formed with varying 
mass ratios of the components, pGFP, PEI and PAP-Id, and were delivered to either normal or 
LPS-treated HMEC-1 and human acute monocytic leukemia cells (THP-1). A fixed mass ratio of 
1:6 between pGFP and PEI was used for all cases. Mass ratios of PAP-Id(HA) was titrated to 
assess the effect of avidity on the efficiency of ICAM-1-mediated endocytosis and gene delivery 
in human cell lines. PAP-Id(D137A) was used as a negative control. (b, d) Cells were analyzed for 
mean fluorescence intensity and percentage of GFP-positive cells by flow cytometry (n = 4). (b, 
d) Cell viability was measured by MTT assay (n = 4). Data represent mean ± s.d. (c, e) 
Representative fluorescence and light microscopic images of the optimal mass ratio 
(pGFP:PEI:PAP-Id adjusted to 1:6:16) are shown. Bar = 50 m. 
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received VMPs formed with PAP-Id(HA) (Fig. A4b–e). pGFP/PEI without added serum resulted in 
up to 90% GFP-positive in bEnd.3, irrespective of LPS treatment (Fig. A4b, c). RAW 264.7 after 
treatment with LPS became enlarged and autofluorescent, resulted in an increase in 
fluorescence intensity across all conditions (Fig. A4d, e). Nonetheless, PAP-Id(HA)-mediated 
delivery resulted in a significant increase in fluorescence and as much as 20% cells were 
determined GFP-positive (Fig. A4d, e). For LPS-treated RAW 264.7cells, pGFP/PEI particles 
delivered without serum resulted in ~15% GFP-positive cells, ascribed to nonspecific phagocytic 
uptake of activated macrophages. PAP-Id(HA)-mediated delivery preserved cell viability, while 
non-specific pGFP/PEI transfection caused significant cell death in both the cell lines. 
 
Inflammation-specific gene delivery to primary mouse lung cells 
We also studied gene delivery to primary mouse lung cells cultured in vitro, harvested 
from a transgenic mouse strain, where exogenous Cre recombinase would excise the loxP-
flanked transcriptional STOP region and turn on GFP expression. We formed VMPs with a 
plasmid encoding Cre recombinase fused to nuclear localization signal under the CMV 
promoter. Similarly, cells were treated with LPS and received VMPs (Fig. A5a), formulated with 
a fixed ratio of pCRE to PEI (1:6) and with varying amounts of PAP-Id (Fig. A5b). PAP-Id(HA)-
mediated delivery was specific to LPS-treated cells, evidenced by increased mean fluorescence 
intensity (Fig. A5b, c). Normal cells treated with VMPs were as high as 40% GFP-positive, 
presumably because even a low copy number of Cre recombinase can excise STOP signal and 
induce GFP expression. PAP-Id(HA)-mediated delivery to LPS-treated cells, however, resulted in 
90% GFP-positive cells. Conventional transfection of pCRE/PEI in serum-free media resulted in a  
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Figure A4: Inflammation-specific targeted gene delivery to mouse endothelial cells and 
monocyte/macrophages.  
(a) Timeline shows the sequence of LPS treatment, virus-particle delivery and measurements 
for mouse cell lines. LPS was treated for 48 h in mouse cells to reach maximal ICAM-1 
expression level for optimal delivery. (b–e) VMPs were formed with varying mass ratios of the 
components, pGFP, PEI and PAP-Id, and were delivered to either normal or LPS-treated bEnd.3 
and RAW 264.7. A fixed mass ratio of 1:6 between pGFP and PEI was used for all cases. Mass 
ratios of PAP-Id(HA) was titrated to assess the effect of avidity on the efficiency of ICAM-1-
mediated endocytosis and gene delivery in mouse cell lines. PAP-Id(D137A) was used as a 
negative control. (b, d) Cells were analyzed for mean fluorescence intensity and percentage of 
GFP-positive cells by flow cytometry (n = 4). (b, d) Cell viability was measured by MTT assay (n = 
4). Data represent mean ± s.d. (c, e) Representative fluorescence and light microscopic images 
of the optimal mass ratio (pGFP:PEI:PAP-Id adjusted to 1:6:16) are shown. Scale bar, 50 m. 
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Figure A5: Inflammation-specific targeted delivery to primary mouse lung cells.  
(a) Timeline shows the sequence of treatments for VMP delivery to primary mouse lung cells in 
culture. Lung cells were harvested from a mouse strain engineered for inducible expression of 
GFP after Cre recombinase-mediated loxP-STOP-loxP excision. (b) VMPs were assembled with 
pCRE (Cre recombinase) and delivered to either normal or LPS treated primary mouse lung 
cells. A fixed mass ratio of 1:6 between pCRE and PEI was used for all cases. Mass ratios of PAP-
Id(HA) was titrated to assess the effect of avidity on the efficiency of ICAM-1-mediated 
endocytosis and gene delivery in primary lung cells. PAP-Id(D137A) was used as a negative 
control. Cells were analyzed for mean fluorescence intensity and percentage of GFP-positive 
cells by flow cytometry (n = 4). Cell viability was measured by MTT assay (n = 4). Data represent 
mean ± s.d. (c) Representative fluorescence and light microscopic images of the optimal mass 
ratio (pCRE:PEI:PAP-Id adjusted to 1:6:16) are shown. Bar = 50 m. 
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significant cytotoxicity of primary cells, whereas no cell death was observed with fully assembled VMPs. 
 
Inflammation-specific targeted gene delivery of VMPs in vivo 
Gene delivery has the potential to treat many diseases, which may benefit much from 
systemic and targeted treatments via intravenous routes. Cationic nonviral gene delivery 
systems without molecular targeting are severely limited due to loss of efficiency in cell entry, 
inhibited by negatively charged molecules (for example, glycosaminoglycans) in blood serum. 
We chose to study the delivery of VMPs to the lung, where endothelial cells comprise a large 
portion of tissue composition. We also confirmed that cell-surface expression of ICAM-1 is 
highly upregulated in the lungs after systemic LPS treatment (data not shown). 
As for specific cell types, upregulation of ICAM-1 was observed in >50% of CD31-positive 
cells (Fig. A6a), which consist of mainly endothelial cells and small percentages of a subset of 
immune cells. We also found a comparable level of ICAM-1 induction in F4/80-positive myeloid 
lineage macrophages, which participate critically in inflammatory diseases, including 
atherosclerosis and cancer (Fig. A6b). We injected VMPs bearing pGFP via the lateral tail vein 
route, either to normal or LPS-treated mice (BALB/c) (Fig. A6c). Relative amount of GFP mRNA 
expression in the lung was analyzed at 48 h post injection of VMPs (Fig. A6d). PAP-Id(HA)-
mediated delivery was specific to LPS-treated group, whereas pGFP/PEI particles had a lower 
gene transfer efficiency irrespective of the induction of inflammation (Fig. A6d). Similarly, gene 
delivery by VMPs formulated with PAP-Id(D137A) was ineffective (Fig. A6d). VMP delivery for 
GFP expression in the lung was also assessed at 72 h post-delivery by immunostaining of 
fixed/permeabilized and collagenase-digested lung cells (Fig. A6e). Gene delivery by VMPs with  
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Figure A6: Systemic and inflammation-specific targeted gene delivery to the mouse lung in vivo. 
(a) Cell-surface expression of ICAM-1 in CD31- positive endothelial cells and (b) F4/80-positive 
monocyte/macrophages in the mouse lung was detected by flow cytometry with I domain 
fused to GFP (GFP-Id(HA)) (n = 4). Lungs were collected 72 h after systemic LPS injection for 
comparison of the level of ICAM-1 expression between normal and inflamed states. Percentage 
of cells in each quadrant is shown. (c–g) VMPs bearing pGFP was systemically applied in vivo to 
target inflamed mouse lung. Mass ratio of the components of VMPs was fixed to 1:6:16 
(pGFP:PEI:PAP-Id). VMPs were injected intravenously via lateral tail vein route into either 
normal or LPS-treated mice (BALB/c). (c) Timeline shows the sequence of treatments, injections 
and data collection. (d) Lungs were collected and analyzed for GFP mRNA expression by 
quantitative PCR. Expression was normalized to a housekeeping gene (CYC1) and presented as 
relative fold difference as compared with PAP-Id(D137A) case (n = 4). PAP-Id(HA)-mediated 
delivery to LPS-treated group was statistically significant among all the groups. Data represent 
mean ± s.d. (*P < 0.05, one-way analysis of variance followed by Tukey’s post-hoc test). (e) Flow 
cytometric histograms show GFP expression assessed by immunostaining of fixed/ 
permeabilized lung cells (n = 4). Lung cells were dual labeled for GFP and for either CD31 or 
F4/80 and were analyzed for the percentage of GFP-positive cells (black dots) within (f) CD31-
positive or (g) F4/80-positive subset (yellow region and dotted box). FSC, forward scatter; NS, 
not significant. 
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PAP-Id(HA) was specific to LPS-treated group, resulting in nearly 15% of the entire cell 
population being GFP-positive, while pGFP/PEI particles produced much less GFP-positive cells 
irrespective of inflammatory condition (Fig. A6e). We further analyzed for the types of cells that 
were targeted by PAP-Id(HA)-mediated delivery (Fig. A6f, g). Specifically, 71% of GFP-positive 
cells were CD31-positive cells (Fig. A6f), whereas only about 14% of GFP-positive cells were 
F4/80-positive (Fig. A6g). This finding demonstrates that intravenous delivery of VMPs was 
mainly against the cellular components that are directly accessible to the agents in circulation 
and express high levels of ICAM-1 in response to LPS treatment. 
 
Discussion 
In this study, we have demonstrated that VMPs can be formulated by functionalizing PEI 
with a PAP for fusion to targeting moieties, allowing systemic and molecular interaction-
dependent gene delivery. With the targeting moiety derived from the integrin LFA-1, our VMPs 
were highly selective to cells with inflammation-induced overexpression of ICAM-1. VMPs 
mimicked some of the essential properties of non-enveloped viruses by possessing the ability to 
(a) package large nucleic acid molecules by PEI-mediated condensation, (b) bind specifically to 
cell-surface receptors, (c) elicit receptor-mediated endocytosis, (d) escape endosomal 
degradation (attributed to the proton sponge effect of PEI) and (e) express the payload gene 
with high efficiency. 
VMPs were far more efficient in delivering genes to cells with overexpressed ICAM-1 
than cells at basal level, which enabled inflammation-specific delivery both in vitro and in vivo. 
This is analogous to HRVs that displayed enhanced infectivity when host cells were treated with 
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inflammatory cytokines and upregulated ICAM-1[52]. The efficiency of gene transfer by VMPs 
was also largely dependent on the coating density or avidity of PAP-Id, as it would influence the 
degree of multimeric interaction with ICAM-1 necessary for receptor-mediated endocytosis. 
Furthermore, in contrast to toxicity-laden conventional transfection by PEI due to plasma 
membrane destabilization associated with non-specific internalization, molecular interaction-
dependent uptake of VMPs produced little cytotoxicity. We speculate that, unlike how 
nonspecific uptake of densely charged cationic particles can damage cell membranes and cause 
cell death,9 viability may have been maintained as receptor-mediated endocytosis is an active 
cellular process that can be regulated by cells. Greatly reduced toxicity with VMPs is also 
ascribed to the presence of PAP that counterbalances positive charges of PEI. 
By targeting ICAM-1, VMPs delivered genes mostly to CD31-positive cells in the lung, 
which are predominantly composed of pulmonary endothelial cells. With the current detection 
method of gene expression, we failed to observe GFP expression in other organs, including the 
liver, despite accumulation of VMPs therein. Although further work is required to finely control 
the size of VMPs and its subsequent effects on biodistribution, clearance rate and other 
pharmacokinetic parameters with the given size of VMPs (150–250 nm in diameter), we expect 
that targeted cells would mainly be the ones that reside in the blood-accessible stroma as 
opposed to the parenchyma. However, endothelial cells as well as immune cells such as 
monocytes/macrophages have been implicated to have critical roles in the pathology of 
inflammatory diseases, especially in the cases of atherosclerosis[50], psoriasis and 
arthritis[53]. The ability to deliver corrective genes specifically to these types of cells under 
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dysregulated inflammation should provide an immense therapeutic opportunity, even without 
the access to the parenchyma. 
Apart from the ability of viruses to efficiently deliver genes into host cells, they also 
have evolved mechanisms to self-replicate their genome, elude the immune system by 
synthesizing viral cytokine homologues and over-ride host cellular component or activity. 
Likewise, the use of more advanced genetic materials (for example, plasmids with promoters 
for improved expression or cell type-specific expression, mechanisms for self-
replication/integration or functions that can be activated under disease-associated cellular 
activities) may further improve VMPs for enhanced gene transfer efficiency, specificity and 
safety. Finally, we anticipate that simplicity and versatility of the system developed in this study 
may facilitate rapid assessments of multifaceted VMPs, formed with a range of different 
targeting moieties and payloads, and contribute to successful translation of nonviral vectors 
into the clinic. 
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APPENDIX B 
 
SSTR2 as a genetic reporter for quantitative imaging of distribution, expansion, and activity of 
adoptively transferred chimeric antigen receptor T cells 
 
Park S contributed to the in vitro and ex vivo validation of various CAR T cell models, including E to T assays and ex vivo flow 
cytometry, as well as in vivo luminescence imaging. This included the experiments related to Figures 1, 5, and 6. 
 
Summary 
 
Adoptive T cell therapy (ATT) has shown promising results for the treatment of certain 
cancers owing to the increased specificity and persistence in targeting and killing tumor cells. 
To date, the efficacy and toxicity of T cell activity in patients have been monitored by peripheral 
T cell counts and serum cytokine measurements - methods which provide a useful but 
incomplete picture of the spatiotemporal dynamics of ATT. Quantitative positron emission 
tomography/computed tomography (PET/CT) imaging techniques have yet to be applied to 
clinical monitoring of ATT; however, it remains to be seen if molecular imaging can provide the 
specificity and sensitivity required to detect initial trafficking to subsequent expansion of 
sparsely distributed, adoptively transferred T cells. To define the detection limit of infiltrating T 
cells in solid tumors, we produced mosaic xenografts of Jurkat T cells with varying expression of 
the reporter marker somatostatin receptor 2 (SSTR2), and performed PET/CT imaging to detect 
the uptake of SSTR2 radiotracer over the course of tumor growth. Using this model, SSTR2 
expressing T cells were detected at a density of as low as 1% within tumors larger than 100 
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mm3 with 95% specificity and 70% sensitivity. To apply SSTR2 as an imaging marker to predict 
ATT activity in vivo, we engineered primary human T cells with a single lentiviral vector to 
express SSTR2 and a chimeric antigen receptor (CAR) specific to intercellular adhesion molecule 
(ICAM-1) that is overexpressed in anaplastic thyroid cancer. Tumor specific CAR T cell 
localization and expansion were visualized in a metastatic tumor model in mice, which 
correlated with T cell killing of tumors. Our study demonstrates the potential for SSTR2-based, 
real-time quantitative imaging of adoptively transferred T cells, enabling the visualization and 
monitoring on-site and off-site T cell activity.  
 
Introduction 
 
ATT is being studied as a potent treatment strategy for cancers that are refractory to 
standard chemotherapy and radiation therapy. Currently, serum cytokine profiles associated 
with T cell activation (interferon-γ, IL-2, IL-6)[1, 2] are used to measure activity of adoptive T 
cells in patients. However, while useful, changes in serum cytokine levels likely reflect a 
broader, systemic immune response within the body, reflecting not only the activation of 
adoptively transferred T cells, but also their effects on neighboring immune cells as well as 
dying tumor cells. The ability to map the distribution of T cells in the body will not only 
significantly improve monitoring T cell activity against tumor and potential toxicity from off-site 
targeting, but could also contribute to exploring adjuvant therapies to enhance adoptive T cell 
efficacy against solid cancers.  
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The current gold-standards for whole-body visualization of cell trafficking are SPECT, 
PET/CT, or PET/MRI techniques for detection of radiolabeled cells in combination with 
anatomical information of the body. Current reporter markers used in preclinical and clinical 
studies are based on both intracellular enzymes e.g., herpes simplex virus type-1 thymidine 
kinase (HSV1-tk)[3, 4] and surface receptors e.g., sodium iodide symporter (NIS)[5] and 
prostate-specific membrane antigen (PSMA)[6]. However, previous clinically-relevant studies 
have not examined T cell detection in a quantitative and statistically rigorous manner to fully 
demonstrate the feasibility of harnessing genetic reporters for detection of adoptively 
transferred T cell distribution[7-15]. We have chosen SSTR2 as a reporter marker in efforts to 
determine the detection limit of T cells infiltrating solid tumors, and also to predict temporal 
kinetics of T cell recruitment and expansion, directly related to T cell activity against tumor. 
SSTR2 belongs to a family of G protein coupled receptor, and its expression is restricted to 
within the brain, gastrointestinal tract, and kidneys.[16] SSTR2 is a potentially ideal reporter 
marker for monitoring ATT for its limited expression in the body and owing to a clinical use of 
radiotracers for SSTR2 (e.g., DOTATOC, DOTATATE) for detection of SSTR2-overexpressing 
neuroendocrine tumors[17]. To determine the limit of detection of T cells within a solid tumor 
mass, we introduced SSTR2 into Jurkat T cells and titrated these with wild type Jurkat cells to 
produce subcutaneous Jurkat tumor xenografts, each with a defined percentage of SSTR2 
expressing cells ranging from 0 – 100 %, with the aim of replicating the varying degrees of T cell 
localization at tumor sites and T cell expansion upon activation. In the course of tumor growth, 
we performed PET/CT imaging using SSTR2 radiotracer (68Ga-DOTATOC) to quantify the 
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detection limit of T cells within a tumor, and to correlate radiotracer uptake with tumor size 
and percentages of SSTR2 expressing cells. 
On-going activity of T cells against both on- and off-tumor sites can be predicted by 
quantitative imaging of T cell distribution and expansion. Observation of T cell activity in the 
body is based on the presumption that adoptively transferred T cells will proliferate upon 
activation by interaction with target antigen-expressing cells, leading to an increase in T cell 
density and uptake of PET radiotracers. Therefore, to further demonstrate the utility of SSTR2 
for imaging T cell distribution and expansion, we designed a single lentivirus vector to modify T 
cells to express both SSTR2 and CAR specific to ICAM-1, which is overexpressed in a range of 
malignant cancers. Whole-body imaging of SSTR2 expressing, ICAM-1 specific CAR T cells by 
PET/CT was then evaluated in mice with systemic growth of poorly differentiated, radioactive 
iodine resistant, anaplastic thyroid tumor[18, 19]. Our study demonstrates the application of 
SSTR2 as a clinically adaptable reporter for detection of adoptively transferred T cell activity 
against tumors and potential off-target sites.  
 
Experimental Procedures 
 
Mammalian cell culture  
Parental HeLa, HEK 293T (ATCC), and 8505c (DSMZ) were transduced with lentivirus 
encoding Firefly Luciferase-F2A-GFP (Biosettia) followed by fluorescence activated cell sorting 
(FACS) to purify GFP expressing cells. HeLa-FLuc+GFP+ cells and HEK 293-FLuc+GFP+ cells were 
cultured in Advanced Dulbecco’s Modified Eagle Medium containing 10% (v/v) fetal bovine 
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serum (FBS), 2 mM L-alanyl-L-glutamine dipeptide (Gibco), and 100 U/ml Penicillin-
Streptomycin (Pen/Strep) (Gibco). 8505c-FLuc+GFP+ cells were cultured in RPMI-1640 
supplemented with 10% (v/v) FBS, 2 mM L-alanyl-L-glutamine dipeptide and 100 U/ml 
Pen/Strep. Human peripheral blood was obtained from healthy volunteer donors by 
venipuncture. Peripheral blood mononuclear cells (PBMC) were isolated over Ficoll-Paque PLUS 
(GE Healthcare) and cultured in GIBCO Optimizer CTS T-cell Expansion SFM (Thermo) 
supplemented with 5% human AB serum (Sigma), 2 mM L-alanyl-L-glutamine dipeptide, 100 
U/ml Pen/Strep and 30 IU/ml human IL-2 (Cell Sciences). Non-adherent cells were removed 
after 24hr and magnetically enriched for T cells with Dynabeads CD3/CD28 T cell expander 
(Thermo) at a 2:1 bead:T cell ratio. Dynabead-bound T cells were subsequently cultured in IL-2 
containing media at a density of 1 – 2 x 106 cells/ml. All cells were incubated at 37°C in a 5 % 
CO2 humidified incubator. 
 
Construction of ICAM-1 CAR and SSTR reporter genes  
The CAR gene specific to ICAM-1 was derived from the single-chain fragment variable 
(scFv) sequence of a murine monoclonal anti-human R6.5 antibody – itself derived from 
hybridoma (ATCC). The R6.5 specific scFcv was then fused with the transmembrane and 
cytoplasmic domains of CD28, CD137, and CD3 of an independent third generation CAR gene 
(a kind gift from Dr. Carl June at University of Pennsylvania[26]). The complete R6.5 CAR was 
then subcloned into a pLenti backbone. A lentivirus vector (derived from CAR vector) encoding 
human SSTR2 (NM_001050) was constructed by synthesizing SSTR2 coding sequencing (IDT) 
and inserting it into the vector using Xba1 and Sal1 sites.  
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Lentivirus production and transduction of T cells  
Lentivirus particles were produced by transiently transfecting HEK 293 cells using 
calcium phosphate. Briefly, 10 µg transfer gene, 7.5 µg CMV-dR8.2 (Addgene) and 5 µg pCMV-
VSVG (Addgene) were mixed and incubated with 2 M CaCl2 followed by 2x HBSS. Resulting 
solutions were added dropwise to 10 cm2 cell culture dishes seeded with 3.2 x 106 HEK 293 in 
10 ml DMEM 24 hr previously. Transfection media was replaced after 6 hr.  Media containing 
lentivirus was harvested at 48 and 72 hr post transfection, filtered through 0.45 µm filters, and 
concentrated by ultracentrifugation at 75,000x g for 2 hr at 4 °C. Lentivirus was then 
resuspended in serum containing media at an approximate titer of 108/ml and frozen at -80 °C. 
Human T cells were transduced 24 - 72 hr post activation with CD3/CD28 Dynabeads either by 
spinfection at 1,000x g for 1 hr at 32°C or by overnight incubation of lentivirus in the presence 
of Synperonic F108 (Sigma)[27]. T cells were also transduced a second time, 24 hr after initial 
transduction. The virus titer was adjusted to give a transduction level of approximately 50%. 
During and following transduction, media containing IL-2 was replaced with media containing 
human IL-7 (10 ng/ml) and IL-15 (5 ng/ml) (Peprotech) which was found to augment T cell 
persistence in-vitro {ref}. Jurkat T cells were transduced by a single incubation with lentivirus 
overnight in the presence of Synperonic F108. 
 
Functional confirmation of SSTR expression and measurement of SSTR2 site density 
SSTR2-transduced Jurkat T cells were incubated with or without octreotide, 1 µM 
(Sigma) for 30 mins at 37 °C. Subsequent internalization of SSTR2 was measured by flow 
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cytometry analysis of SSTR2 expression. The site density of SSTR2 expression on Jurkats was 
determined by incubating non-transduced and SSTR2-transduced Jurkat T cells with DOTATOC 
(250 nM-8 nM) at either 37°C or 4°C for 30 min in PBS/0.1% BSA. After incubation, cells were 
washed three times and DOTATOC uptake was measured by gamma counter (Packard, Coba II 
Auto - Gamma). Values obtained were used for Scatchard analysis to estimate affinity and site 
density. 
 
Subcutaneous Jurkat T cell xenograft  
All animal experiments were performed in strict accordance with the recommendations 
in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. 
The protocol of this study was approved by the Institutional Laboratory Animal Use and Care 
Committee of Weill Cornell Medicine (Permit Number: 2012-0063). SSTR2 expressing Jurkats 
were spiked with increasing numbers of non-transduced Jurkats to derive distinct cultures 
containing defined percentages of SSTR2 expression ranging from 100-0%. For each 
subcutaneous xenograft, 5 x 106 total cells were resuspeneded in 100 µl Matrigel Basement 
Membrane Matrix (Corning) and injected bilaterally into NOD-SCID IL2Rγnull (NSG) mice (Jackson 
Laboratory). Measurements of tumor size were made using an external digital caliper. Tumor 
volume was calculated by use of the modified ellipsoid formula 1/2(Length × Width2). Length 
was measured as longer dimension. Each dimensional measurement was rounded to nearest 
0.5 cm.  
 
PET/CT imaging  
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68Ga-DOTATOC synthesis--Registered CT images was using a micro-PET/CT scanner 
(Inveon, Siemens). Projection data was acquired in a cone-beam geometry approximately 1 s 
steps at 1 degree angular increments. At least 10 million coincidence events were acquired for 
PET per study using a 250 to 750 keV energy window and a 6 ns timing window. Reference was 
included using a tube containing 100 µl of 10 %ID/cm3 for quantification of DOTATOC uptake in 
vivo. The conversion of %ID/cm3, computed relative to the counts in a reference tube, to a 
standard uptake value (SUV) can be made by dividing %ID/cm3 by a value ‘4’, assuming injection 
efficiency of 100% and 25 g of body weight. Visualization and analyses of PET/CT images were 
performed using Amide. 
 
E:T assay 
2 x 105 HeLa-FLuc+GFP+, 8505c-FLuc+GFP+ or HEK 293-FLuc+GFP+ cells were co-cultured 
with either non-transduced or CAR expressing T cells (SSTR2-R6.5 or R6.5) at varying E:T ratios 
as indicated. Co-cultures were carried out in ‘T cell media’ containing 150 µg/ml D-Luciferin 
(Gold Biotechnology) with no cytokine supplementation.  Luminesence was measured with a 
plate reader (TECAN infinite M1000 PRO) with readings in each E:T condition normalized to the 
non-transduced T cell:target co-culture controls.  
 
8505c mouse model, measurement of ex vivo organs and whole-body tumor growth  
5 - 7.5 x 105 8505C cells were injected into NSG mice via tail vein. 2 – 3 x 106 T cells were 
injected via tail vein 4 -14 days after tumor cell injection. Luminescence imaging of tumor 
xenografts in live mice was performed using a whole body optical imager (In-Vivo Extreme, 
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Bruker). Mice were anesthetized first with 3% isoflurane in 2 L/min O2 and subsequent to this, 
maintained at 2% isoflurane in 2 L/min O2. Growth or reduction in tumor burden was estimated 
by integration of luminescence over the entire mouse body. Ex-vivo fluorescence imaging of 
mouse liver, lungs, spleen and resected tumors were performed using a whole body optical 
imager (In-Vivo Extreme, Bruker).  
  
Flow cytometry  
Tumor xenografts were resected from mice following completion of PET/CT imaging. 
Resected tumors were diced and flushed through an 80 µm cell strainer to yield single cell 
suspensions. Red blood cells were lysed by incubating with 1x RBC lysis buffer (eBioscience), 
followed by washing and re-suspension in 1x HBSS containing 2% normal goat serum. Prior to 
staining, cells were blocked with mouse IgG at 2 µg/ml for 10 min. This was followed by live 
staining with 1 µg/ml Propidium Iodide (Invitrogen) in combination with 2 µg/ml murine anti-
human CD3-Alexa Fluor 647 (Biolegend) or 2 µg/ml PE-conjugated murine anti-human SSTR2 
(Clone # 402038, R&D). Flow cytometry gates were determined first based on live cell gating 
(Propidium Iodide negative) and subsequently by parallel staining of SSTR2-transduced and 
wild-type Jurkat cells from culture. ICAM-1 expression on tumor cell lines was determined using 
a murine anti-human R6.5 monoclonal antibody (10 µg/ml) derived from hybridoma (ATCC). 
R6.5-CAR expression on T cells was detected using FITC-conjugated goat anti-mouse F(ab')2 
secondary antibody (Thermo).    
 
Statistical analysis  
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One-way ANOVA and unpaired Student’s t-test were performed using Prism (GraphPad) 
on data indicated. 
 
Results 
 
Expression of SSTR2 in Jurkat T cells  
We constructed a second-generation lentivirus vector for expression of human SSTR2 by 
inserting the SSTR2 gene downstream of the elongation factor-1 promoter. With increasing 
lentivirus titer, 100% of Jurkat T cells were transduced to express SSTR2 as measured by 
antibody binding (Fig. B1A). Consistent with agonist-induced internalization of SSTR2[20], 
incubation of T cells with the synthetic SSTR2 agonist (octreotide) reduced surface expression 
of SSTR2 as indicated by reduced antibody binding (Fig. B1B). Labeling of SSTR2-transduced 
Jurkat T cells with 68Ga-DOTATOC (hereafter referred to as DOTATOC) at 250 nM – 8 nM 
followed a first-order Langmuir isotherm equation, giving a dissociation constant (KD) of 38 nM 
(Fig. B1C). In comparison, DOTATOC uptake by non-transduced T cells was approximately 10-
fold lower. Similar to the KD estimated by Langmuir isotherm, Scatchard analysis estimated the 
KD of DOTATOC to be 32 nM and the site density of SSTR2 to be approximately 3.2 x 106 
molecules per cell (Fig. B1D).  Actual site density is likely to be lower due to recycling of SSTR2 
after internalization of DOTATOC and some level of non-specific binding. Incubation of cells at 
4°C to inhibit SSTR2 recycling resulted in an estimated site density of 1.8 x 106 molecules per 
cell; however, the affinity of DOTATOC for SSTR2 was also determined to be substantially lower 
(KD = 170 nM) at this temperature (Fig. B1D).  
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Figure B1: Expression of SSTR2 by lentivirus vector in T cells.  
(A) A schematic of a lentivirus vector encoding human SSTR2 is shown. Histograms show the 
level of SSTR2-specific antibody binding to wild-type Jurkat T cells and Jurkat T cells transduced 
with increasing virus titers (1, 5, 15 µl). Percentages of SSTR2 positive cells are indicated. (B) 
Level of SSTR2-specific antibody binding to SSTR2-transduced Jurkat T cells with and without 
pre-incubation with 1 µM octreotide (37oC, 30 min). (C) DOTATOC uptake by SSTR2-transduced 
and wild-type Jurkat T cells versus DOTATOC concentration is shown. A first-order Langmuir 
isotherm equation was used to fit the data to find an equilibrium dissociation constant (Kd). 
Confidence interval of Kd is shown in parenthesis. (D) DOTATOC uptake of SSTR2-transduced 
and wild-type Jurkat T cells is shown in Scatchard plot. Estimates of Kd are shown. 
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Growth of mosaic Jurkat T cell xenografts  
To examine the utility of SSTR2 for detection of sparsely distributed T cells in tumors, we 
produced subcutaneous Jurkat T cell xenografts in NSG mice with a mixture of SSTR2 
transduced (referred to as SSTR2+) and non-transduced (wild-type) in order to titrate levels of 
SSTR2 expressing cells ranging from 0 % to approximately 100 %. Xenografted Jurkat T cell 
tumors began to show palpable growth 30 days after xenograft, and exhibited continuous 
growth for the next 30 days, reaching approximately 1 cm3 (Fig. B2A). The level of SSTR2 
expression did not affect Jurkat T cell tumor growth (Fig. B2B). SSTR2+ T cells in culture were 90 
- 95% SSTR2 positive by antibody staining (Fig. B2C). However, later resection of 100 % SSTR2+ 
tumor followed by staining for SSTR2 by flow cytometry revealed that the level of SSTR2 
expression was reduced to 70 - 80 %, with the15 - 20 % reduction accounted for by the 
presence of mouse stroma cells within tumors (Fig. B2C). The reduction of SSTR2 expression 
was not caused by the loss of SSTR2 expression during tumor growth as a similar level of 
reduction was seen by CD3 staining: 70% positive in cells harvested from tumors, reduced from 
80 - 85 % CD3 positive in culture.   
 
PET imaging of DOTATOC uptake in Jurkat T cell xenografts   
We wanted to ascertain our ability to detect SSTR2 expressing T cells within tumors 
when both their number density (assuming a volume of single cell to be ~1 pl within tissue) and 
absolute numbers ranged from low to high in both respects. Thus to cover this range, we  
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Figure B2.  Growth of mosaic Jurkat SSTR2+ and SSTR2- subcutaneous tumors.  
(A-B) Tumor size measurement is shown along the days of post xenografts and percentages of 
SSTR2+ cells. No significance (n.s.) by one-way ANOVA was found among SSTR2+ groups. (C) 
CD3- and SSTR2-specific antibody binding to Jurkat SSTR2+ and wild-type T cells in culture and 
to T cells harvested from tumors is shown in histograms. Percentages of CD3 and SSTR2 positive 
cells are indicated. 
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Figure B3: Quantitative PET/CT for measuring DOTATOC uptake by Jurkat tumors.  
(A) DOTATOC uptake is shown in %ID/cm3 for Jurkat tumors (100%-0% SSTR2+) in the course of 
tumor growth. (B) Representative PET/CT images of mice xenografted with Jurkat SSTR2+ T cells 
at 0% and 100%. Images are maximum intensity projection (MIP) of entire mouse body (10-20 
mm thick plane). PET intensity is pseudo-colored in the range of 0-10% ID/cm3. 
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initiated PET/CT imaging at 12 days post xenograft, before we could detect palpable tumor 
growth and continued imaging until tumors reached approximately 1 cm3 in volume (Fig. B3A). 
The level of DOTATOC uptake by tumors was quantified as percent injection dose per volume 
(%ID/cm3) based on the region of interest (ROI) enclosing tumors. The ROIs were defined by 
tumor-size measurements and anatomical information from CT images. Overall, over the course 
of tumor growth, DOTATOC uptake was higher in tumors with increasing percentages of SSTR2 
expressing cells (Fig. B3A). PET/CT images showed DOTATOC uptake by tumors and uniformly 
higher uptake by the kidneys and bladder - consistent with its known biodistribution and renal 
clearance (Fig. B3B). DOTATOC uptake values, as measured by %ID/cm3, agreed with visual 
assessment of PET/CT images over the course of tumor growth and correlated with increasing 
SSTR2 expressing Jurkat T cells within the tumor burden (Fig. B3). We also noted a minor 
increase in DOTATOC uptake during growth of 0 % SSTR2+ tumors, which we speculate to be 
caused by the increasing leaky vasculature and stagnant blood pooling within tumors (Fig. B3A).     
 
Defining detection limit, specificity, and sensitivity  
We next analyzed DOTATOC uptake values to determine the detection sensitivity and 
specificity of SSTR2 expressing T cell density within tumors. At tumor sizes below 100 mm3, 
DOTATOC uptake was significant only in tumors with SSTR2+ T cell densities of 10 % or 100 % 
(Fig. B4A, B). However, a detection limit at 10% SSTR2+ tumors <~100 mm3 (approximating 
detection of T cell density ~10%) was deemed unreliable as the area under the receiver 
operating characteristic (ROC) curve (AUC) was 0.75, which is below a clinically acceptable 
cutoff (>0.85) (Fig. B4C). In contrast, DOTATOC uptake for SSTR2+ tumors larger than 100 mm3  
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Figure B4: Statistical analysis of DOTATOC uptake by tumors.  
DOTATOC uptake (%ID/cm3) for Jurkat tumors (A&D), simulated Gaussian distribution as a 
function of the measured mean and standard deviation of uptake for each %SSTR2+ (B&E), and 
ROC curves of sensitivity and 100%-specificity% (C&F) are shown for tumors smaller than 100 
mm3 (A-C) and larger than 100 mm3 (D-F). *** vs. 0%, p<0.001, ** vs. 0%, p<0.01 by Student’s t-
test. 
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was significantly higher at 100, 10, and 1% SSTR2+ (7.1 ± 2.3, 2.8 ± 1.1, and 2 ± 0.77 %ID/cm3, 
respectively) when compared to 0% SSTR2+ uptake (0.8 ± 0.35 %ID/cm3), and was detectable, 
although not significant even at 0.1% SSTR2+ (1.1 ± 0.51 %ID/cm3, p = 0.12) (Fig. B4D, E) A 
threshold of DOTATOC uptake at 1.45 %ID/cm3 gives 95% specificity (5% false positives) and 
71% sensitivity (29% false negatives) for 1% SSTR2+ (approximately 0.7 - 0.8 % density of SSTR2 
expressing T cells accounting for the presence of stroma cells) within our Jurkat tumor model 
(Fig. B4F). With the same threshold, one achieves >95% sensitivity for tumors where the SSTR2 
expressing T cell density is at or above 10%.  
 
In vitro efficacy of ICAM-1 specific CAR T cells against thyroid tumors  
We then examined application of SSTR2 imaging to CAR T cells to acquire visual mapping 
of T cells that have been engineered to target tumors overexpressing ICAM-1. Anaplastic 
thyroid cancer is a particularly aggressive cancer with high mortality and has been found to 
overexpress ICAM-1 at levels correlating with tumor malignancy and metastatic potential[21]. 
The anaplastic thyroid cancer cell line 8505c was found to be 40% - 100 % positive for ICAM-1, 
the level of which varied due to culture conditions, exposure to cytokines, and growth in vivo 
(Fig. B5A). The cervical cancer cell line, HeLa, exhibiting naturally high levels of ICAM-1 and the 
ICAM-1 negative cell line, HEK 293, served as positive and negative controls respectively to test 
selectivity of CAR T cell mediated killing. The CAR is 3rd generation and is comprised of an ICAM-
1-specific scFv (derived from mAb R6.5[22]), the transmembrane and cytoplasmic domains of 
CD28 followed by CD137, and CD3. A lentiviral vector encoding both SSTR2 and R6.5 CAR was  
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Figure B5: CAR T cell efficacy against thyroid tumor cells in vitro and in vivo.  
(A) Histograms show the level of anti-ICAM-1 antibody binding to ICAM-1 negative 293T, ICAM-
1 positive HeLa, and 8505C with the level of ICAM-1 expression influenced by culture conditions 
(passage number, confluency) and growth in vivo. (B) A schematic of a lentivirus vector of 
SSTR2-R6.5 CAR is shown. Anti-SSTR2 and anti-CAR antibody binding to transduced (filled) and 
non-transduced (open) primary T cells are shown in histograms. (C) Anti-SSTR2 antibody 
binding to SSTR2-transduced (filled) and non-transduced (open) primary T cells is shown in 
histograms. (D) Effector to target assay to measure lysis of target cells by CAR T cells. The ratios 
of T cells to target were 5:1, 2.5:1, and 1.25:1. Percentages of live cells were measured by the 
intensity of luminescence normalized to the levels of target cells incubated with non-
transduced T cells as 100%. (E) Total luminescence counts (photons per second, P/s) of whole 
body imaging were plotted for each mouse to estimate a tumor burden of a group of mice right 
after injection of tumor cells (X0), a group of 18-22 days of xenograft (X18-22), a group of 22 
days after xenograft and 8 days after injection of non-transduced T cells (X22/NT-T8), a group of 
20 days after xenograft and 16 days after injection of CAR T cells (X20/CAR-T16), and a group of 
22 days after xenograft and 8 days after injection of CAR T cells (X22/CAR-T8). (F) Whole body 
luminescence imaging of a group of 4-5 mice after 22 days of xenograft with or without 
injection of NT-T cells or CAR-T cells. *** p<0.001, * p<0.05 by Student’s t-test. 
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constructed by linking SSTR2 to CAR with a ‘ribosome skipping’ porcine teschovirus-1 2A 
(P2A)[23] sequence (Fig. B5B). Primary T cells were transduced to express SSTR2 and R6.5-CAR 
at approximately 50% (65% and 52% for SSTR2 and R6.5-CAR, respectively as shown in Fig. 
B5B). SSTR2 and R6.5-CAR expression levels by the SSTR2-R6.5 CAR vector were comparable to 
what could be attained by two separate SSTR2 and R6.5-CAR vectors at similar virus titers (Fig. 
B5C). Incubation of CAR T cells (either SSTR2- R6.5 CAR or R6.5-CAR T cells) with targets of 
varying ICAM-1 expression showed that CAR T cell killing of target was dependent upon ICAM-1 
expression. After 24 hours, 100% of both 8505c and HeLa cells were lysed at effector to target 
(E:T) ratios of 5:1 and 2.5:1, and ~90% lysis of target cells obtained at an E:T of 1.25:1 (Fig. B5D). 
Although there was minor yet gradual killing of ICAM-1-negative 293 cells with higher E:T ratios, 
specificity of CAR T cells against ICAM-1 was apparent.  
 
In vivo efficacy of ICAM-1 specific CAR T cells against thyroid tumors  
In order to test our ability to image CAR T cells and their anti-tumor efficacy in-vivo, NSG 
mice were xenografted by systemic i.v. injection of 0.75 x 106 8505c-FLuc+GFP+ cells followed by 
treatment with SSTR2-R6.5 CAR T cells. Tumor growth or lysis was evaluated by whole body 
luminescence imaging of firefly luciferase activity. Tumors that received either no T cells by day 
18 - 22 (denoted as X18 - 22) or non-transduced parental T cells (X22/NT-T8) expanded by 
approximately 50-fold (Fig. B5E). In contrast, mice treated with CAR T cells either day 4 or 14 
post-tumor xenograft (X20/CAR-T16 or X22/CAR-T8) showed a dramatic 25-fold reduction in 
tumor burden compared to non-treated mice (p<0.05 vs. X18 - 22) or mice that received non-
transduced T cells (p<0.05 vs X22/NT-T8). Bioluminescence imaging of the tumors revealed 
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localization mainly in the lungs and liver with distant metastatic foci evident throughout the 
body (Fig. B5F), consistent with a prior observation of 8505c tumor growth characteristics in 
mice.  
 
PET imaging of CAR T cells in vivo  
Tumor bearing mice injected with T cells were randomly chosen for PET/CT to detect 
DOTATOC uptake and to image T cell distribution and expansion. Transverse CT images showed 
the heart and tumor-free alveolar air space in lungs in mice without tumors (Fig. B6). When 
these mice were injected with SSTR2 transduced T cells, only the background intensity of 
DOTATOC (0.7 %ID/cm3) could be observed, which is indicative of the absence of T cells in the 
lungs (Fig. B6A). 8505C tumor xenografted mice with or without T cell infusion had alveolar air 
space replaced by the growth of tumor cells, which produced tissue density in CT images (Fig. 
B6B-G). Non-CAR, SSTR2-transduced T cells were unreactive to 8505c tumors growing in lungs 
as demonstrated by low DOTATOC uptake (0.9%ID/cm3) (Fig. B6B) - likely corresponding to less 
than 1% T cell density. Alloreactive killing of tumors by SSTR2 transduced T cells was often 
observed, as illustrated by occasional instances of mice displaying reduced tumor burdens (Fig. 
B5E). This was associated with increased uptake of DOTATOC within lungs (2.1%ID/cm3, 
corresponding to ~1% in T cell density approximated from Fig. B4D) (Fig. B6C). In comparison, 
SSTR2-R6.5 CAR T cells exhibited markedly higher uptake of DOTATOC (5.4 %ID/cm3) localized 
to the area of tumor growth (Fig. B6D). Ex vivo organ imaging revealed the lungs and the liver  
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Figure B6: Quantitative PET for detection of CAR T cell distribution and expansion.  
PET/CT images (transverse view of 1 mm thick plane MIP and coronal view of 15 mm thick 
plane MIP) of a mouse with no tumor and 10 days after injection of SSTR2-transduced T cells 
(A), mice of 20 days after xenograft and 10 days after injection of SSTR2-transduced T cells (B-
C), and a mouse of 20 days after xenograft and 10 days after injection of SSTR2-R6.5 CAR T cells 
(D). (E) A longitudinal PET/CT images of a mouse, 19 days after xenograft and 4 days after 
infusion of SSTR2-R6.5 CAR T cells (left panel) and 26 days after xenograft and 11 days after 
infusion of SSTR2-R6.5 CAR T cells (right panel). PET/CT images of a mouse of 26 days after 
xenograft and no T cells (F) and a mouse of 29 days after xenograft and 14 days after infusion of 
R6.5-CAR T cells (G). Ex vivo fluorescence images of lungs, liver, and spleen are shown (D-G). 
Flow cytometry measurement of percentages of CAR T cells (identified by anti-CD3 antibody 
staining) and 8505C tumor cells (GFP) harvested from lungs are shown as dot plots (D-G). 
Transverse views are shown for CT only, CT/PET superimposed, and PET only. 
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were tumor free (absence of GFP intensity). Total cells were also harvested from lung tissues 
and were analyzed for the presence of tumor (GFP) and T cells by flow cytometry. CD3+ T cells 
accounted for ~38% of live cells in the lungs whereas tumor cells were almost undetectable 
(~0.1%).  
To demonstrate the ability to monitor T cell expansion more directly, we imaged same 
mice on different days after SSTR2-R6.5 CAR T cell injection. A significant increase in DOTATOC  
uptake in lungs was found (1.3 %ID/cm3 to 3.4 %ID/cm3 during the span of seven days, Fig. 
B6E). Compared to higher burden of tumor growth in the lungs and liver of mice without CAR T 
cell treatment (shown as ex vivo imaging of organs and GFP in Fig. B6F), much reduced tumor 
growth was found in lungs and liver (Fig. B6E). By flow cytometry, percentages of T cells and 
8505c tumor cells were estimated to be ~18% and ~5%, respectively. Overall, we observed 
quantitative agreement between in vivo DOTATOC uptake in the lungs and flow cytometry-
based estimates of T cell percentage (3.4 %ID/cm3 vs. 18% T cell density and 5.4 %ID/cm3 vs. 
38% T cell density). Elevated DOTATOC levels in both lungs and heart was frequently observed 
in mice with high burden of tumors and particularly in mice exhibiting difficulties with 
breathing, likely due to slower clearance of DOTATOC from circulation (~1.5 %ID/cm3 in Fig. 
B6F, G). Uptake of DOTATOC was specific to SSTR2 expression, demonstrated by a lack of lung-
specific uptake in mice treated with R6.5-CAR T cells despite CAR T cell density reaching 20 - 
40% of total live cells in lungs (Fig. B6G). 
 
Discussion 
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The ability to detect adoptively transferred T cells in the human body is a potentially 
powerful tool for monitoring T cell activity against target tumor sites as well as potential toxicity 
from off-site reactivity. It may also aid our understanding of the underlying causes behind the 
patchy success of T cell therapy in clinical cases. Our study utilizes mosaic tumor xenografts of 
Jurkat T cells transduced with the genetic reporter SSTR2 to correlate PET intensity to T cell 
density and to visualize T cell distribution in vivo. With the lentivirus developed in this study, 
the site density of SSTR2 in transduced Jurkat T cells was in the range of several million per cell, 
a density significantly higher than previously published[24]. To demonstrate the feasibility of 
SSTR2 reporter-based imaging to predict T cell activity against tumor, we chose ICAM-1 positive 
anaplastic thyroid cancer cells as a target model and engineered T cells to express both ICAM-1 
specific CAR and SSTR2 by a single lentiviral vector. Although the correlation between T cell 
imaging and a change in tumor burden needs to be examined in a larger set of mice for 
statistical analysis, the current study presents a convincing validation for the use of SSTR2 to 
monitor T cell activity against tumors in vivo.   
Quantitative PET imaging is increasingly used for disease diagnosis and to gauge therapy 
response in a more accurate and objective manner. From an ATT standpoint, the T cells to be 
imaged will distribute throughout tissues rather than form solid mass. Therefore, the utility of 
any T cell imaging technique will depend upon a limit-of-detection threshold low enough to 
enable monitoring of meaningful T cell activity. In the context of T cell killing of solid tumors, T 
cell density needs to be at least 1% within tumor lesions for substantial elimination of tumor 
mass[25]. To gauge detection limit, specificity, and sensitivity of T cell imaging in our system, 
we produced mosaic xenografts consisting of lentivirally transduced SSTR2 and wild type Jurkat 
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T cells. By titrating SSTR-transduced cells against wild type, we produced xenografts with SSTR2 
levels varying from 0% to approximately 100%. We observed that with a known threshold of 
radiotracer uptake, one can detect T cell density at 1% with 95% specificity and 71% sensitivity. 
Extrapolating a change of radiotracer uptake at between 1% and 10% T cell density, a gradual 
increase in T cell density would increase sensitivity to >90% levels.  
We chose SSTR2 as a generic reporter for a number of reasons. One was to take 
advantage of the FDA-approved radiotracer DOTATOC, which is currently in use in clinics to 
probe for overexpressed SSTR2 in neuroendocrine tumors. SSTR2 also displays relatively low 
basal expression in major organs except the kidneys as well as in tissues thus making it ideal for 
detection of adoptively transferred T cells targeting a multitude of solid tumors. Another 
surfaced expressed reporter gene, PSMA has been shown to be superior to more widely tested 
receptors such as HSV1-tk and NIS. Compared to our SSTR2 system, we also found that 
reporter-specific radio-ligand uptake in Jurkat T cells transduced with PSMA gave 5 - 10 fold 
higher uptake compared to that of non-transduced cells (data not shown). Therefore, with the 
myriad of available genetic reporters, choosing the most suitable agent for imaging adoptively 
transferred T cells will depend foremost on the tumor being targeted. For example, PSMA 
would not be a suitable imaging marker for CAR T cells designed to treat PSMA positive 
prostate cancer. Likewise, SSTR2 will be inappropriate if T cells are engineered to target SSTR2 
positive neuroendocrine cancers. Therefore, at least two different genetic reporters are 
required to avoid a situation where a potential T cell genetic reporter is already overexpressed 
in the target tumor or in proximal tissues leading to specific yet non-T cell uptake of 
radiotracers. Interestingly, the simultaneous use of two distinct genetic reporters could 
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potentially create new opportunities for live T cell imaging. For example, CD4 and CD8 T 
positive cells could be transduced separately with SSTR2 and PSMA and sequential, time-
delayed injection of cognate radiotracers followed by PET imaging could reveal underexplored 
dynamics of, and interactions between, adoptively transferred CD4/CD8 T cells in pre-clinical 
models. 
Upon administration to patients, the bulk of adoptively transferred T cells undergo rapid 
elimination followed by expansion upon target recognition within the tumor. Indeed, it has 
been noted that greater expansion of T cells against target correlates with better disease 
remission rates[25]. Using luminescence as a measure of tumor burden, we have observed that 
an initial tumor burden of approximately 1 x 106 cells can increase more than 50-fold to an 
estimated 50 x 106 cells over 14 days. This is consistent with our flow cytometry estimate of the 
percentage of GFP expressing tumor cells, which was in the range of 10 - 20% (20 to 60 x 106 
cells) of live cells harvested from lungs (which contain 200 - 300 million cells assuming 1 pl 
volume per cell and 200 - 300 µl of lung tissue volume). When tumor bearing mice were 
injected with 2 - 3 million CAR T cells 1 - 2 weeks post-xenograft, the T cell to tumor ratio will be 
lower than 0.1. Although it is not yet fully appreciated how many target cells can be killed by 
single T cells before experiencing activation-induced cell death, an increase in T cell number or 
expansion would be necessary to produce effective tumor elimination. Therefore, a change in T 
cell density over the course of tumor killing may span from 1% (2 – 3 x 106 cells; assuming 100% 
of injected T cells reside in lungs right after injection) to more than 10% when T cell expansion 
is at its peak. Our PET imaging was able to detect such a span of change, longitudinally and 
across different mice, by either allogeneic reaction or CAR mediated killing. 
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Although numerous efforts have been made to pre-label cells with radiotracer in vitro 
followed by in vivo imaging post-injection, such direct labeling methods do not allow for 
monitoring T cell expansion over the course of the immune response - a critical drawback when 
trying to predict T cell activity at on- and off-target sites as well as subsequent therapy 
outcomes. One drawback of T cell imaging by a genetic reporter marker for adoptive transfer of 
T cells is that primary T cells need to be modified with two different genes. The introduction of 
an extra reporter gene to CAR or T cell receptor-modified primary T cells is technically 
demanding and can substantially reduce the percentage of T cells co-expressing both genes. 
However, with the use of a self-cleaving ‘2A’ sequence, we demonstrated that both genes can 
be successfully expressed on the same T cell without compromising the level of expression 
otherwise achievable using two independent vectors. 
The conversion of DOTATOC uptake by SSTR2-R6.5 CAR T cells into T cell density using 
Jurkat T cell xenografts as reference needs to be examined more thoroughly with a larger set of 
in vivo data.  Besides the number of T cells within tumors, the site density of SSTR2 on T cells, 
and the degree of perfusion within tumors and radiotracer diffusion will all influence DOTATOC 
uptake within tumors in vivo. Although we aim to transduce T cells at approximately 50% to 
avoid overexpressed CAR-mediated T cell exhaustion (unpublished observation), as anticipated 
we observed an increase in the percentage of CAR expressing T cells, presumably due to 
positive selection following recognition of target-positive tumors in vivo (data not shown). 
Under an in vitro setting, SSTR2 expressing T cells can be labeled with DOTATOC to saturation 
to have the level of SSTR2 expression to linearly affect DOTATOC uptake. Such a proportional 
relationship is unlikely to hold in vivo if radiotracers do not fully diffuse into and permeate 
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tumors to saturate every single cells expressing SSTR2. This should explain to a great extent 
why DOTATOC uptake was not linearly proportional to SSTR2+ percentages in Jurkat xenografts. 
Despite the variability in SSTR2 expression and heterogeneity in tumor growth, however, our 
study provides evidence for the feasibility of monitoring multiple phases of T cell distribution 
and activity at on- and off-target sites including initial recruitment, expansion, and gradual 
killing of tumors.  
Our study is the first example of a clinically adaptable, quantitative imaging technique 
capable of specifically detecting adoptively transferred CAR T cells in combination with their 
target-specific or alloreactive expansion at the tumor site. We have also demonstrated a simple 
method of estimating CAR T cell density infiltrating solid tumors by comparing radiotracer 
uptake by SSTR2-CAR T cells to that of titrated SSTR2 expressing Jurkat T cell tumor xenografts. 
We posit that SSTR2/DOTATOC-based T cell imaging should be able to detect T cells with 
clinically acceptable sensitivity and specificity at a T cell density of 1% and higher. We anticipate 
that the imaging technique developed in this study can contribute to improving T cell 
immunotherapy in cancer by facilitating efforts to explore adjuvant therapies, increasing our 
understanding of parameters that mediate successful adoptive therapy and also to aid in the 
investigation of the underlying causes of systemic toxicities that impede adoptive T cell-based 
therapies. 
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